

Note: Page numbers followed by *b* indicate boxes; *f*, figures; *t*, tables.

- A**
- A bands, of skeletal muscle, 71, 72*f*
- A fibers, 563–564, 563*f*
- A δ cold fibers, 592
- A δ fast pain fibers, 584, 585, 587
- A α motor fibers, 656, 659
- A γ motor fibers, 656, 659
- Abdominal compression reflex, 209
- Abdominal muscles
- in expiration, 465, 466*f*
- in labor, 1013
- spasm of, in peritonitis, 665
- Absence syndrome, 726
- Absolute refractory period, 69
- Absorbing colon, 797, 798
- Absorption. *See* Kidney(s), reabsorption by;
- Large intestine, absorption in; Small intestine, absorption in.
- Acceleration of head
- angular, 677, 677*f*
- linear, 676–677
- Acceleratory forces, in aviation and spacecraft, 531–533, 531*f*, 532*f*
- Acclimatization to altitude, 510
- alveolar Po₂ and, 527, 528–530
- work capacity and, 530, 530*t*
- Acclimatization to cold, chemical thermogenesis and, 873
- Acclimatization to heat, 877
- sweating and, 871, 877
- Accommodation
- of eye, 601, 601*f*
- autonomic control of, 631–632, 735
- pupillary reaction to, 632
- of mechanoreceptors, 562
- ACE (angiotensin-converting enzyme) inhibitors
- adverse effects of, 320–321
- antihypertensive effects of, 374
- Acetate, vasodilation caused by, 200
- Acetazolamide, 398, 503
- Acetoacetic acid, 823–824, 839
- in diabetes mellitus, 393, 953
- insulin lack and, 944
- Acetone, 823
- on breath, 953–954
- ketosis and, 823, 824
- Acetyl coenzyme A (acetyl-CoA), 22
- acetoacetic acid produced from, 823
- in acetylcholine synthesis, 732
- amino acids converted to, 825
- cholesterol synthesis from, 827
- in citric acid cycle, 813–814, 813*f*
- after fatty acid oxidation, 822–823
- from fatty acid beta-oxidation, 822, 822*f*, 823
- fatty acid synthesis from, 824, 824*f*, 825
- Acetyl coenzyme A (acetyl-CoA) (*Continued*)
- pantothenic acid and, 855
- pyruvic acid conversion to, 812–813
- steroid synthesis from, 992
- Acetylcholine
- in basal ganglia, 692–693, 692*f*
- of brain stem reticular neurons, 711
- sleep and, 722
- cardiac effects of, 119, 120
- bradycardia as, 144
- as central nervous system transmitter, 551
- of cholinergic nerve endings, 731–732
- drugs with potentiating effect on, 740
- coronary blood flow and, 247
- gastric secretions and, 778, 779
- gastrointestinal smooth muscle and, 755, 756
- Huntington's disease and, 694
- molecular structure of, 731
- at neuromuscular junction
- secretion of, 73, 83–86, 84*f*
- synthesis of, 83, 86
- pancreatic secretions and, 782
- pharmacologic actions of, 740
- as smooth muscle neurotransmitter, 95, 96
- synthesis of, 732
- Acetylcholine receptors. *See also*
- Acetylcholine-gated ion channels.
- in myasthenia gravis, 86
- principal types of, 733
- Acetylcholine system, in brain, 712, 713, 713*f*
- Acetylcholine-gated ion channels, 48,
- 73–74, 83–84, 84*f*, 85, 85*f*. *See also*
- Acetylcholine receptors.
- Acetylcholinesterase
- at neuromuscular junction, 83, 84*f*, 85, 86
- at parasympathetic nerve endings, 732
- Acholinesterase inhibitors, 86, 740
- for myasthenia gravis, 86–87
- Acetyl-CoA. *See* Acetyl coenzyme A (acetyl-CoA).
- Acetyl-CoA carboxylase, 825
- Acetylsalicylic acid. *See* Aspirin (acetylsalicylic acid).
- Achalasia, 765, 799
- Achlorhydria, 778, 800
- Acid(s)
- definition of, 379
- nonvolatile, 385, 387, 388, 390
- anion gap and, 395
- sour taste of, 645, 646*t*
- strong and weak, 379–380
- Acid hydrolases, of lysosomes, 19, 20
- Acid-base disorders. *See also* Acidosis; Alkalosis.
- clinical causes of, 392–393
- diagnosis of, 393–395, 394*f*
- mixed, 394–395, 394*f*
- treatment of, 393
- Acid-base nomogram, 394–395, 394*f*
- Acid-base regulation. *See also* Hydrogen ions.
- buffer systems in, 380–381
- ammonia, 388–389, 389*f*
- bicarbonate, 381–383, 382*f*
- gastrointestinal mucus and, 775
- isohydric principle and, 383–384
- phosphate, 383, 388, 388*f*
- protein, 383–384, 413
- respiratory, 385
- fundamental definitions for, 379–380
- kidneys in, 380, 385–388, 386*f*, 387*f*
- correction of acidosis by, 387, 391
- correction of alkalosis by, 387, 391–392
- phosphate and ammonia buffers in, 388–389, 388*f*, 389*f*
- quantification of, 389–391, 390*t*
- overview of, 379, 380
- precision of, 379, 380
- respiratory system in, 380, 384–385, 384*f*
- Acidophil cells, 896*f*, 897
- Acidophilic tumors, 897, 903–904
- Acidosis. *See also* Acid-base disorders.
- bicarbonate reabsorption in, 386, 387, 390
- calcium and
- protein-bound, 367
- reabsorption of, 369
- characteristics of, 391*t*
- chronic, ammonium excretion in, 389, 391
- definition of, 379, 380
- metabolic, 391, 391*t*
- anion gap in, 395, 395*t*
- clinical causes of, 392–393
- definition of, 382
- in diabetes mellitus, 951
- diagnosis of, 394
- hydrogen ion secretion in, 390
- hyperchloremic, 395, 395*t*
- potassium homeostasis and, 362
- renal correction of, 391
- in neonate, 1024
- neuronal depression in, 557
- potassium homeostasis and, 364, 367
- renal correction of, 391
- in renal failure, 406
- respiratory, 382, 385, 391, 391*t*
- clinical causes of, 392
- diagnosis of, 393–394
- hydrogen ion secretion in, 390
- renal correction of, 391
- in shock, 278
- treatment of, 393
- Acini
- of pancreas, 773, 780–781, 939, 939*f*
- of salivary glands, 773, 774*f*, 775, 776

- Acquired (adaptive) immunity, 433–442.
See also Antibodies; Antigen(s); Lymphocytes.
 basic types of, 433, 434
 passive, 442
 tolerance to own tissues in, 442
- Acquired immunodeficiency syndrome (AIDS)
 helper T cells in, 440–441
 wasting syndrome in, 852
- Acromegaly, 903–904, 903f
 diabetes mellitus in, 952
- Acrosome, 975, 975f, 977
- Acrosome reaction, 977
- ACTH. *See* Adrenocorticotropic hormone (ACTH; corticotropin).
- Actin
 in ameiboid movement, 23
 of cardiac muscle, 101, 103
 Frank-Starling mechanism and, 110
 ventricular volume and, 108
 in cell membrane support, 16
 coated pits and, 18–19, 18f
 in intestinal microvilli, 794
 in mitosis, 39
 in phagocytosis, 19
 of platelets, 451, 454
 of skeletal muscle
 contraction mechanism and, 74, 74f, 75–76, 75f, 76f
 hypertrophy and, 81
 muscle tension and, 77, 77f
 structural features of, 71, 72f, 73f, 74f, 75, 75f
 of smooth muscle, 92, 92f, 93–94
- Action potential(s). *See also* Membrane potential(s).
 calcium ions in, 64
 in gastrointestinal smooth muscle, 754–755
 cardiac, 102–104, 102f
 atrial, 117
 duration of contraction and, 104
 electrocardiogram and, 122, 122f
 excitation-contraction coupling and, 103, 104
 plateau in, 66, 66f
 prolonged ventricular, 147, 148f
 in Purkinje fibers, 102f, 103, 117
 sinus nodal, 115–116, 116f, 117
 spontaneous rhythmicity in, 66–67, 66f
 ventricular, 102, 102f, 122, 122f
- nerve, 60–63, 61f
 anions and, 64
 energy expenditure by, 65, 66f, 68
 energy of ATP for, 860
 excitation of, 68–69, 68f
 initiation of, 64
 inspiratory, 505
 on motor nerve, 73
 olfactory, 649, 650
 as positive feedback, 8–9, 64
 propagation of, 64–65, 65f
 re-establishing ionic gradients after, 65
 refractory period after, 69
 stages of, 61
 summary of, 63, 63f
 threshold for, 64–65, 68–69, 68f
 velocity of, 68
- neuronal
 of brain stem reticular area, 711
 in cerebellum, 684, 685
 facilitation and, 708
 generation in axon, 553–554
 postganglionic, 732
 at presynaptic terminal, 547–548
 of retinal ganglion cells, 617, 619
- Action potential(s), neuronal (*Continued*)
 summation and, 554f, 555
 threshold for, 555, 556–557, 556f
 plateau in
 with cardiac muscle, 66, 66f
 with smooth muscle, 95f, 96
 receptor potentials and, 561–562, 561f
 recording with oscilloscope, 69, 69f
 rhythmic, 66–67, 66f
 skeletal muscle, 74, 83, 87, 88, 88f, 89f
 end plate potential and, 84, 85, 85f
 energy for, 78
 smooth muscle, 95–96, 95f
 of bladder, 306–308
 excited by stretch, 96
 gastrointestinal, 754–755, 754f
 plateau in, 95f, 96
 slow wave, 95f, 96
 of stomach, 766
- Action tremor, 687–688, 689
- Active hyperemia, 194
- Active transport, 14, 18, 52–56
 of amino acids into cells, 832–833
 through cellular sheets, 55–56, 55f
 vs. diffusion, 45–46, 46f
 energy from ATP for, 859
 primary, 52–54, 53f
 in renal tubular reabsorption, 324–328, 325f, 326f, 327f
 in salivary ducts, 775
 secondary, 52–53, 54–55, 55f. *See also* Co-transport.
 thyroid hormones and, 912
- Acupuncture, 588
- Acute local potentials, 68, 69
- Acute subthreshold potentials, 68, 68f
- Acute tubular necrosis, 400–401
- Adaptation
 of olfactory sensations, 650
 of sensory receptors, 562–563, 562f
 of taste, 648
- Adaptive control systems, 9
- Adaptive immunity. *See* Acquired (adaptive) immunity.
- Addison disease, 934–935
 hyperkalemia in, 361, 365
 hyponatremia in, 294–295, 360
 salt appetite and, 360
 volume depletion in, 375
- Addisonian crisis, 935
- Adenine, 27, 28, 28f, 30, 31t
- Adenohypophysis. *See* Pituitary gland, anterior.
- Adenosine
 blood flow control and, 192–193
 in cardiac muscle, 247
 in gut wall, 761
 in skeletal muscle, 243–244
 coronary ischemia and, 248
 irreversible shock and, 278–279
- Adenosine diphosphate (ADP)
 control of glycolysis by, 815
 conversion to ATP, 809–810
 in mitochondria, 814f, 815
 metabolic rate and, 862
 oxygen usage and, 500, 501, 501f
 platelet aggregation and, 452
- Adenosine monophosphate (AMP), 809–810. *See also* Cyclic adenosine monophosphate (cAMP).
- Adenosine triphosphate (ATP), 21–23
 in active transport, 52–53
 by calcium pump, 54
 renal tubular, 324–325, 325f, 326, 326f
 by sodium-potassium pump, 53, 53f
 in cardiac muscle, 248
 chemical structure of, 809, 810f
 ciliary movement and, 25
- Adenosine triphosphate (ATP) (*Continued*)
 control of glycolysis by, 815
 conversion into cAMP, 889
 depleted in irreversible shock, 278–279
 as energy currency, 809–810, 809f, 859–861
 anaerobic vs. aerobic, 860–861
 functions energized by, 859, 860
 nutrients degraded for, 859
 phosphocreatine buffer of, 860
 summary of, 861, 861f
 energy released per mole of, 809–810
 from fatty acid oxidation, 823
 flagellar movement and, 975
 gastrointestinal secretions and, 774
 glycogen-lactic acid system and, 1033, 1033f
 high-energy bonds of, 21, 809, 859
 mitochondrial synthesis of, 16, 22, 22f
 nerve fiber ionic gradients and, 65
 in olfactory cilium, 649, 649f
 phosphocreatine and, 1033, 1033f
 in postganglionic nerve endings, 732
 production of, 812
 acetyl-CoA and, 812–813
 citric acid cycle and, 813–814, 813f
 glycolysis and, 812, 812f
 oxidative phosphorylation and, 814–815, 814f
 summary of, 815
 in protein synthesis, 34, 34f
 in RNA synthesis, 30
 in skeletal muscle, 73, 74, 75, 76, 78–79
 of athletes, 1032–1034, 1033f, 1033t
 in smooth muscle, 93, 94
 structure of, 21
 uses of, 22–23, 22f
 as vasodilator, in skeletal muscle, 243–244
- Adenylyl cyclase. *See also* Cyclic adenosine monophosphate (cAMP).
 ACTH and, 932
 adrenergic or cholinergic receptors and, 733
 antidiuretic hormone and, 905
 glucagon and, 948
 growth hormone secretion and, 902
 hormonal activity and, 889–890, 889b, 890f
 hormone receptors and, 888
 memory and, 707–708
 in olfactory cilium, 649, 649f
 in smooth muscle, 97
 thyroid hormone secretion and, 914
- ADH. *See* Antidiuretic hormone (ADH; vasopressin).
- Adhesion molecules
 in inflammation, 428, 429f
 in T-cell activation, 440, 440f
- Adipocytes (fat cells), 12, 821
 cytokine hormones produced by, 881
 deficiency of, 822
 obesity and, 850
- Adipokines, 881
- Adipose tissue, 821
 fatty acid diffusion into, 820, 820f
 fatty acid mobilization from, 823, 825
 cortisol and, 929
 fatty acid storage in, 825
 insulin and, 943
 food intake and feedback from, 849
 lipase in, 821, 826
 triglyceride storage in, 824, 825
 triglyceride synthesis in, 824, 825
- Adiposogenital syndrome, 985, 985f
- ADP. *See* Adenosine diphosphate (ADP).
- Adrenal cortex. *See also* Adrenocortical hormones.
 anatomy of, 921, 921f
 cholesterol used by, 827
 fetal, 1008
 neonatal hypofunction of, 1026

- Adrenal diabetes, 928
- Adrenal glands
adenoma of, 935
anatomy of, 921, 921*f*
- Adrenal insufficiency. *See* Addison disease.
- Adrenal medulla. *See also* Epinephrine; Norepinephrine.
anatomy of, 921, 921*f*
exercise and, fat utilization in, 825
function of, 736
basal secretion in, 737
duration of action in, 732, 736
receptors and, 733
hypovolemic shock and, 275
sympathetic nerve fibers and, 730
sympathetic vasoconstrictor system and, 204
- Adrenergic drugs, 739–740
- Adrenergic fibers, 731–732
- Adrenergic receptors, 733, 733*t*. *See also* Alpha adrenergic receptors; Beta adrenergic receptors.
drugs causing block of, 740
- Adrenocortical hormones, 921–937. *See also* Androgens, adrenal; Glucocorticoids; Mineralocorticoids.
abnormalities of, 934–936, 935*f*, 936*f*
classification of, 921
excretion of, 924
metabolism of, in liver, 924
plasma protein binding of, 923–924
pregnancy and, 1009
properties of, 922–923, 924*t*
synthesis and secretion of, 921–924, 921*f*, 923*f*, 924*t*
- Adrenocorticotrophic hormone (ACTH; corticotropin), 896, 896*t*
adrenocortical hormone synthesis and, 922
aldosterone secretion and, 927, 928
chemistry of, 931
cortisol secretion and, 931–934, 932*f*
deficiency of, 934
excess of, 935, 936
gluconeogenesis and, 817
ketogenic effect of, 825
pregnancy and, 1009
regulation of, by hypothalamus, 931–932
synthesis and secretion of, 933–934
thyroid hormones and, 913–914
- Adrenogenital syndrome, 936, 936*f*
- Aerobic energy, 860. *See also* Oxidative metabolism.
for exercise, 1033, 1033*f*, 1033*t*, 1034*b*
recovery after, 1034, 1034*f*, 1035*f*
- Afferent arteriole(s), renal, 304–305, 305*f*, 307*f*, 311*f*
glomerular filtration rate and, 315, 316, 316*f*
myogenic mechanism and, 321
physiologic control of, 317–318, 319
reabsorption rate and, 336
tubuloglomerular feedback and, 320, 320*f*
- Affinity constant, 438
- Afterdischarge, 567–568
crossed extensor reflex and, 663, 663*f*
flexor reflex and, 662, 662*f*
- Afterload, 109
- Agglutination
by antibodies, 438
by complement system, 439
of red blood cells, 446
in blood typing, 447, 447*t*
- Agglutinins, 446, 446*f*, 446*t*
anti-Rh, 447
in blood typing, 447, 447*t*
- Agglutinogens, 445, 446*t*, 447
- Agonist and antagonist muscles, 81
neuronal circuits and, 566
- Agouti-related protein, 846, 847, 847*f*, 849
- AIDS. *See* Acquired immunodeficiency syndrome (AIDS).
- Air hunger, 522
- Airflow resistance, in bronchial tree, 473
- Airplane. *See* Aviation.
- Airway obstruction
atelectasis secondary to, 519, 519*f*
in emphysema, 517, 518
forced expiratory volume in 1 second and, 517, 517*f*
maximum expiratory flow and, 516–517, 516*f*
sleep apnea caused by, 513
- Airway resistance
in asthma, 520
hypoxia and, 520
- Akinesia, 693
- Alactacid oxygen debt, 1034, 1034*f*
- Alarm reaction
arterial pressure elevation in, 205
sympathetic nervous system in, 738–739
- Albinos, visual acuity of, 611
- Albumin, 833. *See also* Plasma proteins.
bilirubin transport by, 840, 842
cortisol bound to, 923
fatty acid transport by, 820, 821
glomerular filtration of, 313–314, 313*t*
plasma colloid osmotic pressure and, 184, 184*t*, 833
for plasma volume measurement, 290
thyroid hormones bound to, 909–910
- Alcohol
cirrhosis and, 838
gastric absorption of, 793
gastritis caused by, 799
pancreatitis caused by, 801
peptic ulcer and, 801
- Alcoholic headache, 591
- Aldosterone, 924–928
angiotensin II and, 221–222
arterial pressure control and, 221–222, 227*f*, 228
in cardiac failure, 260
chemical formula of, 922, 923*f*
circulatory effects of, 925–926, 925*f*
concentration of, in blood, 924
cortisol and, 924–925
deficiency of, 924, 934
excess of, 925–926, 925*f*
alkalosis caused by, 390
hyponatremia caused by, 296
hypertension caused by, 407
metabolic alkalosis caused by, 393
extracellular fluid osmolarity and, 359–360
extracellular fluid sodium and, 359–360, 359*f*
intestinal sodium absorption and, 795, 797, 926
mechanism of action, 891, 926–927, 926*f*
nongenomic actions of, 927
obesity and, 225
plasma protein binding of, 923
potassium homeostasis and, 361
renal secretion in, 337–338, 364–366, 364*f*, 365*f*, 366*f*, 925
pregnancy and, 1009
properties of, 922, 924*t*
regulation of secretion of, 927–928, 927*f*
renal effects of, 925–926, 925*f*
salivary glands and, 926
sodium reabsorption and, 328, 337–338, 375, 925
sweat glands and, 926
sweating and, acclimatization of, 871, 877
synthesis of, 921–922, 923*f*
tubular reabsorption and, 328, 337–338, 338*t*
- Aldosterone antagonists, 332, 333*f*, 398*t*, 399
- Aldosterone escape, 925
- Aldosteronism, primary, 936
alkalosis in, 390
hypertension caused by, 219–220
hypokalemia in, 361, 365
- Alimentary tract. *See* Gastrointestinal tract.
- Alkali, definition of, 379
- Alkaline phosphatase, in hyperparathyroidism, 968
- Alkalosis. *See also* Acid-base disorders.
in aldosterone excess, 390
bicarbonate excretion in, 385, 390
calcium and
protein-bound, 367
reabsorption of, 369
characteristics of, 391*t*
definition of, 379, 380
grand mal attack and, 726
metabolic, 391*t*, 392
aldosterone excess with, 926
bicarbonate excretion in, 387
clinical causes of, 393
definition of, 382
diagnosis of, 394
hydrogen ion secretion and, 390
potassium homeostasis and, 362
vomiting as cause of, 393, 804
neuronal excitability in, 557
renal correction of, 391–392
respiratory, 391*t*, 392
clinical causes of, 392
diagnosis of, 394
at high altitude, 529
hydrogen ion secretion and, 390
treatment of, 393
- Allergic reactions
in asthma, 520
cortisol and, 931
eosinophils in, 430
mast cells and basophils in, 431
- Allergy, 443–444
in infant, 1026
- Allografts, 449
- All-or-nothing principle, of action potential, 65
- Alpha adrenergic receptors, 733, 733*t*
in coronary vessels, 248
drugs acting on, 739
drugs blocking, 740
of vascular smooth muscle, norepinephrine and, 204
- Alpha waves, 723*f*, 724–725, 724*f*, 725*f*
- Altitude. *See* High altitude.
- Alveolar air, 487–489, 487*t*
expired air and, 487*t*, 489, 489*f*
rate of replacement of, 487–488, 488*f*
- Alveolar ducts, 489, 489*f*
- Alveolar macrophages, 427, 428, 474
- Alveolar membrane, 5. *See also* Respiratory membrane.
- Alveolar pressure, 466–467, 466*f*
- Alveolar ventilation, 471–472
acid-base balance and, 384–385, 384*f*
carbon dioxide partial pressure and alveolar, 488–489, 489*f*
blood, 508, 508*f*, 510, 510*f*
during exercise, 510–511, 511*f*
at high altitude, 529
oxygen partial pressure and alveolar, 488, 488*f*
blood, 509, 509*f*, 510, 510*f*
pH of blood and, 508, 508*f*, 510, 510*f*
ventilation-perfusion ratio and, 492–494
- Alveolus(i), pulmonary, 489, 489*f*, 490*f*
fluid balance with interstitium, 482, 482*f*
- Alzheimer's disease, 727–728

- Amacrine cells, 610*f*, 617, 617*f*
 action potentials of, 617
 functions of, 618–619
 neurotransmitters released by, 617
 visual contrast and, 618
 visual pathway and, 617, 617*f*
- Ameboid movement, 23–24, 23*f*, 425
- Ameloblasts, 969, 970
- Amiloride, 332, 333*f*, 399
 Liddle's syndrome and, 408–409
- Amino acids
 active transport into cells, 832–833
 in blood, 831–833
 equilibrium between proteins and, 833–834, 834*f*
 glucagon secretion and, 948
 glucocorticoids and, 835, 929
 regulation of levels of, 833
 deamination of, 834–835, 839
 as energy source, 834–835
 in starvation, 835
 essential, 832*f*, 834
 deficiency of, 843
 facilitated diffusion of, 50
 glucose synthesis from, 817
 cortisol and, 928
 growth hormone and, 899, 900
 insulin and metabolism of, 944–945
 insulin secretion and, 946–947
 nonessential, 832*f*
 synthesis of, 834, 834*f*, 840
 plasma proteins as source of, 833
 as protein digestion products, 791
 in protein synthesis
 RNA codons for, 29*f*, 30, 31–32, 31*t*, 32*f*
 transfer RNA and, 31, 32, 32*f*, 34, 34*f*
 renal reabsorption of, 311–312, 325, 326*f*
 upper limit of, 833
 sodium co-transport of, 54–55, 794–795, 795*f*, 797
 storage of, 833
 structures of, 831, 832*f*
 tyrosine, hormones derived from, 882–884
- Aminoaciduria, 408
- Aminopolypeptidase, 791
- Aminostatic theory of hunger and feeding, 849
- Aminotransferases, 834
- Amitriptyline, 727
- Ammonia
 from amino acid deamination, 834, 835
 hepatic coma and, 835
 urea derived from, 835, 839–840, 859
- Ammonia buffer system, 388–389, 389*f*
- Ammonium chloride, for alkalosis, 393
- Ammonium ion
 buffering by, 388–389, 389*f*
 excretion of, 389, 389*f*, 390, 391
- Amnesia
 anterograde, 709, 719
 retrograde, 709
- Amniotic fluid, 1011
 fetal urine in, 1020
 ingestion of, 1020
- Amorphosynthesis, 577
- AMP (adenosine monophosphate), 809–810. *See also* Cyclic adenosine monophosphate (cAMP).
- Amphetamines
 athletic performance and, 1040
 for weight loss, 851
- Ampulla, of semicircular duct, 675*f*, 676, 676*f*
- Amygdala, 719–720
 anterior commissure and, 705
 feeding and, 848
- α -Amylase(s)
 pancreatic, 781, 790
 in neonate, 1025
 salivary. *See* Ptyalin.
- Amylin, 939
- Amyloid plaques, in Alzheimer's disease, 728
- Amyloidosis, nephrotic syndrome associated with, 404
- Anaerobic energy, 860–861
- Anaerobic glycolysis, 815–816, 860–861
 in muscle, 1033
- Anaerobic metabolism, brain's lack of, 749
- Anal sphincters, 771, 771*f*, 772
- Analgesia system of brain and spinal cord, 586–588, 587*f*
- Anaphase, 38*f*, 39
- Anaphylactic shock, 280, 443
 sympathomimetic drugs for, 281
- Anaphylaxis, 443
- Anchoring filaments, of lymphatic capillaries, 187, 187*f*, 188
- Androgens. *See also* Testosterone.
 adrenal, 921, 934, 980
 excess of, tumor-produced, 936
 in pregnancy, 1008
 synthesis of, 922, 923*f*
 athletic performance and, 1040
 ovarian production of, 980, 991, 992, 992*f*, 993*f*
 testicular production of, 979–980, 980*f*
- Androstenedione
 adrenal synthesis of, 922, 923*f*
 ovarian synthesis of, 991
 testicular synthesis of, 979
- Androsterone, 980
- Anemia, 420–421
 aplastic, 420
 in chronic renal failure, 406
 circulatory effects of, 233, 420–421
 cyanosis and, 521–522
 hematocrit in, 287
 hemolytic, 420
 hypoxia in, 420–421, 521
 macrocytic, in folic acid deficiency, 854
 megaloblastic, 415*f*, 420
 microcytic, hypochromic, 415*f*, 420
 in neonate, 1025
 pernicious, 417, 420, 778, 800, 854
 in pregnancy, 1010
 red blood cell characteristics in, 415*f*
- Anesthesia
 cardiac arrest during, 153
 general
 cardiac arrest caused by, 279, 281
 neurogenic shock caused by, 279
 paralysis of swallowing in, 799
 respiratory depression caused by, 512
 spinal
 cardiac output and, 239, 239*f*
 neurogenic shock caused by, 279
- Anesthetics
 local, as membrane stabilizers, 69
 synaptic transmission and, 557
- Angina pectoris, 252. *See also* Myocardial ischemia.
 bypass surgery for, 252
 cardiac hypertrophy leading to, 272
 current of injury in, 141
 drug treatment for, 252
 nitrates in, 196
- Angiogenesis, 197, 198
 cancer growth and, 41
 at high altitude, 529
 inhibitors of, 198
- Angiogenin, 198
- Angioplasty, coronary artery, 253
- Angiostatin, 198
- Angiotensin I, 220–221
- Angiotensin II, 220–221, 220*f*
 aldosterone secretion and, 921–922, 927–928
 endothelial cell receptors for, nitric oxide and, 196
 extracellular fluid osmolarity and, 359–360
 extracellular fluid sodium and, 359–360
 glomerular filtration rate and, 318, 320–321
 hypertension involving, 223–224, 223*f*
 in hypovolemic shock, 275
 obesity and, 225
 renal effects of, 221–222, 222*f*
 renal reabsorption and, 337, 338–339, 338*f*, 338*t*, 376
 renal sodium and water excretion and, 374–375, 374*f*
 thirst and, 358
 as vasoconstrictor, 199
 limited long-term effect of, 200
 nitric oxide and, 196
- Angiotensin II receptor antagonists, 374
- Angiotensinases, 221
- Angiotensin-converting enzyme (ACE) inhibitors
 adverse effects of, 320–321
 antihypertensive effects of, 374
- Angiotensinogen, 220
- Angular acceleration, of head, 677, 677*f*
- Angular gyrus area, 700, 701, 702, 704*f*, 705
- Anion gap, 395, 395*t*
- Anorexia, 851–852
- Anorexia nervosa, 851–852
- Anorexigenic substances, 846–847, 847*t*, 851
- Anovulatory cycles, 998, 1001
- ANP. *See* Atrial natriuretic peptide (ANP).
- Anterior commissure, 705
- Anterior motor neurons. *See* Motor neurons, anterior.
- Anterograde amnesia, 709, 719
- Anterolateral system, 573, 580–581, 581*f*
 thermal signals in, 593
 types of sensations in, 573
- Antibodies, 437–438, 437*f*. *See also* Immunoglobulin(s).
 autoantibodies, hyperthyroidism caused by, 916
 classes of, 438
 infusion of, 442
 mechanisms of action of, 438, 438*f*, 439*f*
 in milk, 1016
 in neonate, 1025–1026
 opsonization and, 425
 in saliva, 776
- Anticholinesterases. *See* Acetylcholinesterase inhibitors.
- Anticoagulants
 in blood, 457
 for clinical use, 459–460
 in tissues, 453
- Anticodons, 32
- Antidiuretic hormone (ADH; vasopressin), 896, 904–905. *See also* Diabetes insipidus.
 arterial blood pressure and, 357, 905
 atrial stretch reflex and, 208
 blood volume and, 357, 357*f*, 905
 in cardiac failure, 260
 chemical structure of, 904
 disorders associated with, 354–355
 extracellular fluid osmolarity and, 905
 extracellular fluid volume and, 375–376
 factors affecting level of, 357, 357*t*
 hyponatremia caused by deficit of, 295
 hyponatremia caused by excess of, 295
 hypothalamus and, 356, 356*f*, 716, 904
 in hypovolemic shock, 275, 279

- Antidiuretic hormone (ADH; vasopressin)
(*Continued*)
osmoreceptor feedback and, 355–357, 355f, 356f, 357f, 905
salt intake and, 217
synthesis and release of, 355, 356, 356f
urine concentration and, 345, 346, 346f, 347–348, 348t, 350, 350f
urea and, 350–351, 353
as vasoconstrictor, 199, 905
water reabsorption and, 339, 339f, 904–905
- Antigen(s), 434
antibody binding of, 438
in blood cells, 445
released by macrophages, 436, 437
self-antigens, 434–435
- Antigen-presenting cells, 440, 440f
- Antioncogenes, 40
- Antiperistalsis, 803, 804
- Antipyretics, 876
- Antipyrine, 289
- Antithrombin III, 457
heparin and, 457
- Antithyroid substances, 915
in foods, 917
- Antral follicles, 989–990
- Antrum, gastric, 766, 766f
- Anuria, 399, 401
- Aortic baroreceptors, 205–206, 206f
- Aortic bodies, 208, 507, 508, 508f, 509
high altitude and, 529
- Aortic coarctation, 224, 269
- Aortic pressure, 158, 159f
cardiac cycle and, 105, 105f, 107
cardiac output and, 112, 112f
pulsations in, 168, 169f
abnormal contours of, 169, 169f
transmission to peripheral arteries, 169–170, 169f, 170f
- Aortic regurgitation
circulatory dynamics in, 268
murmur of, 267, 267f, 268
pressure pulse associated with, 169, 169f
- Aortic stenosis
aortic pressure pulse in, 169, 169f
circulatory dynamics in, 268
congenital, 269
murmur of, 267, 267f, 268
work output associated with, 108
- Aortic valve, 105f, 106–107, 107f
aortic pressure curve and, 107
second heart sound and, 107, 266, 266f
- Aphasia, 703–704
- Aplastic anemia, 420
- Aplysia*, 707, 707f, 708
- Apocrine glands, autonomic control of, 735
- Apo ferritin, 840
- Apolipoprotein(a), 829
- Apolipoprotein B, mutations of, 827
- Apolipoprotein E
Alzheimer's disease and, 728
chylomicron removal from blood and, 820, 820f
- Apoprotein B, 819
- Apoptosis, 40
- Apparent mineralocorticoid excess syndrome, 924–925
- Appendix, pain pathways from, 589–590, 589f
- Appetite, 845. *See also* Hunger.
diminished level of, 851–852
gastric secretion and, 779
higher brain centers and, 848
hypothalamus and, 846–847
- Appetite area of brain, 776
- Aquaporins, 47, 905
aquaporin-2, antidiuretic hormone and, 339, 339f
- Aqueous humor, 606, 606f
formation of, 606, 606f
outflow of, 607, 607f
- Aqueous veins, 607, 607f
- Arachidonic acid, 890
- Arachnoidal villi, 746f, 747
cerebrospinal fluid pressure and, 747–748
- Arcuate fasciculus, 704–705, 704f
- Arcuate nuclei
food intake and, 846–847, 847f, 847t
leptin and, 849
gonadotropin-releasing hormone and, 997
- Area postrema, blood-brain barrier and, 748–749
- Arginine, nitric oxide synthesis from, 195, 196f
- Argyll Robertson pupil, 632
- Aromatase, 991, 992, 992f, 993f
- Arousal, pain signals and, 586
- Arrhythmias, cardiac, 143–153
atrial fibrillation, 151–152, 152f
in mitral valvular disease, 269
atrial flutter, 152–153, 152f, 153f
atrioventricular block, 144–145, 144f, 145f
cardiac arrest, 153
circulatory arrest and, 281
cardiac hypertrophy leading to, 272
causes of, 143
hyperkalemia and, 926
in long QT syndromes, 147, 148f
paroxysmal tachycardia, 148–149
atrial, 148, 148f
ventricular, 148–149, 149f
partial intraventricular block, 145–146, 145f
as premature contractions. *See* Premature contractions.
sinoatrial block, 144, 144f
sinus rhythm abnormalities, 143–144, 143f, 144f. *See also* Bradycardia; Tachycardia(s).
supraventricular tachycardias, 148
torsades de pointes, 147, 148f
ventricular fibrillation as. *See* Ventricular fibrillation.
- Arterial blood pressure. *See also* Blood pressure.
acceleratory forces and, 531, 531f
age-related increase in, 171, 171f
blood flow and, 165–166, 165f, 166f
autoregulation of, 165–166, 165f, 194–195, 194f, 200, 217, 744–745, 745f
cerebral, 744–745, 745f
cardiac output and, 112, 112f, 216f, 217, 217f
in cardiogenic shock, 259
in different parts of circulation, 158, 159f
exercise-related increase in, 244–245
extracellular fluid volume and, 217, 217f
gravitational effect on, 173, 174
mean value of, 171, 171f
measurement of, clinical, 170–171, 170f
of neonate, 1024
reference level for, 174–175, 174f
regulation of. *See* Arterial blood pressure control.
renal blood flow and, 319, 319f, 320, 321
renal reabsorption rate and, 336
respiratory waves in, 210
shock and, 273
hypovolemic, 274–275, 274f
thyroid hormones and, 913
urine output and, 337
vascular resistance and, 165
- Arterial blood pressure control, 159
aldosterone and, 925, 925f
as homeostatic mechanism, 6, 7–8
integrated system for, 226–228, 227f
nervous, 204–209, 373–374
antidiuretic hormone and, 357
- Arterial blood pressure control, nervous
(*Continued*)
brain stem in, 739
cardiac output and, 232, 232f
in CNS ischemic response, 209, 210–211, 210f
hypothalamus and, 715
parasympathetic, 736
reflex mechanisms in, 205–209, 206f, 207f
respiratory waves and, 210
skeletal nerves and muscles in, 209–210
sympathetic, 735–736
thirst and, 358
vasomotor waves and, 210–211, 210f
by renal–body fluid system, 213–220, 227–228, 227f, 371–373, 371f, 372f
chronic hypertension and, 218–220, 218f, 220f
pressure diuresis in, 213–218, 214f, 215f
salt in, 217–218, 376. *See also* Pressure natriuresis.
total peripheral resistance and, 216–217, 216f, 217f
by renin-angiotensin system, 220–222, 220f, 221f, 222f
hypertension and, 223–224, 223f
- Arterial pressure pulses, 168–171. *See also* Pulse pressure.
abnormal contours of, 169, 169f
compliance and, 168, 169–170
damping of, 170
transmission to peripheral arteries, 169–170, 169f, 170f
typical record of, 168, 169f
- Arterial system, volume–pressure curve of, 167–168, 168f
- Arteries
blood volume in, 157
distensibility of, 167–168, 168f
function of, 157
sympathetic innervation of, 201, 202f
- Arterioles, 177, 178f. *See also* Metarterioles.
blood volume in, 157
of brain, 743, 743f, 744, 745
function of, 157
hepatic, 837
in nervous control of arterial pressure, 205
renal. *See* Afferent arteriole(s), renal; Efferent arteriole(s), renal.
resistance of, fourth power of radius and, 164
sympathetic innervation of, 201, 202f
sympathetic tone of, 737
vasodilator agents and, 193
bradykinin as, 199
histamine as, 199–200
- Arteriosclerosis. *See also* Atherosclerosis.
atherosclerosis-induced, 828
calcium deposition in, 958
definition of, 827
diabetes mellitus and, 953
pulse pressure in, 168–169, 169f
stroke associated with, 745
- Arteriovenous anastomoses, cutaneous, 868, 868f
heat conduction and, 868
- Arteriovenous fistula
cardiac failure associated with, 263–264, 264f
cardiac output with, 232, 239, 239f, 240
circulatory changes associated with, 239–240, 239f
- Articulation, of speech, 704
- Artificial kidney. *See* Dialysis, renal.
- Ascites, 298, 300, 838

- Ascorbic acid. *See* Vitamin C.
- Aspirin (acetylsalicylic acid)
acidosis caused by, 393
fever and, 876
gastric absorption of, 793
gastritis caused by, 799
peptic ulcer and, 801
- Association areas, 699–701, 699f
caudate nucleus and, 691, 692
granular neurons in, 697
limbic, 699f, 700
parieto-occipitotemporal, 699–700, 699f, 702
prefrontal, 699f, 700, 702–703
Wernicke area and, 701
- Aster, mitotic, 38–39, 38f
- Astereognosis, 577
- Asthma, 444, 473, 520
airway obstruction in, 517, 520
- Astigmatism, 603, 603f, 604f
- Astrocytes, in cerebral blood flow regulation, 743, 743f, 744
- Astronauts. *See* Spacecraft.
- Ataxia, 689
- Atelectasis, 519, 519f
in oxygen toxicity, 537
- Atheromatous plaques, 827, 828, 828f
- Atherosclerosis, 827–829. *See also* Arteriosclerosis.
Alzheimer's disease and, 728
cholesterol and, 828, 829
coronary, 248
acute occlusion caused by, 248–249
bypass surgery for, 252
collateral circulation and, 249
risk factors for, 829
diabetes mellitus, 953
in hypothyroidism, 918
prevention of, 829
renal artery, 403
risk factors for, 828–829
systolic pressure increase in, 171
- Athetosis, 691
- Athletes, bradycardia in, 143–144. *See also* Sports physiology.
- Atmospheric hypoxia, 520, 521, 522.
See also High altitude.
- Atopic allergies, 443
- ATP. *See* Adenosine triphosphate (ATP).
- ATP synthetase, 22, 815
- ATPase(s). *See also* Calcium ATPase; Hydrogen ATPase; Hydrogen-potassium ATPase pump; Sodium-potassium ATPase pump.
in active transport, 53, 53f, 54
in kidneys, 324–325, 325f
mitochondrial, 814f, 815
of myosin head, 75, 76
- ATP-sensitive potassium channels, of pancreatic beta cells, 945, 945f
- Atria
action potential in, 117
cardiac impulse in, 118, 118f
electrocardiogram and, 133–134, 133f
as primer pumps, 104–106
- Atrial fibrillation, 151–152, 152f
in mitral valvular disease, 269
- Atrial flutter, 152–153, 152f, 153f
- Atrial heart sound, 266, 267f
- Atrial natriuretic peptide (ANP)
blood volume and, 376
in cardiac failure, 260–261
renal reabsorption and, 339
sodium excretion and, 376
- Atrial paroxysmal tachycardia, 148, 148f
- Atrial premature contractions, 146, 146f
- Atrial pressure
cardiac cycle and, 105, 105f, 106
ventricular function curves and, 110–111, 110f
- Atrial stretch receptors, 208–209
antidiuretic hormone and, 905
respiratory waves and, 210
sodium excretion and, 376
- Atrial syncytium, 102
- Atrial T wave, 122
vectorial analysis of, 133–134, 133f
- Atrial tachycardia, paroxysmal, 148, 148f
- Atrioventricular (A-V) block
causes of, 144
ectopic pacemaker associated with, 119
first-degree, 144–145, 144f
second-degree, 145, 145f
third-degree (complete), 145, 145f
- Atrioventricular (A-V) bundle, 102, 115, 116f, 117, 117f
blocking of impulses in, 144. *See also* Atrioventricular (A-V) block.
ectopic pacemaker in, 119–120
ischemia of, 144
one-way conduction through, 117–118
premature contractions originating in, 146
sympathetic effects on, 120
timing of impulse in, 117f, 118
- Atrioventricular (A-V) nodal paroxysmal tachycardia, 148
- Atrioventricular (A-V) nodal premature contractions, 146, 146f
- Atrioventricular (A-V) node, 115, 116f, 117, 117f
as ectopic pacemaker, 119
inflammation of, 144
intrinsic rhythmicity of, 119
ischemia of, 144
parasympathetic effects on, 119–120
blocking of conduction by, 144
premature contractions originating in, 146, 146f
sympathetic effects on, 120
- Atrioventricular (A-V) valves, 105f, 106–107, 107f. *See also* Mitral valve; Tricuspid valve.
first heart sound and, 107, 265
- Atrophy, of skeletal muscle, 81, 82
- Audiogram, 642, 642f
- Audiometer, 642
- Auditory cortex, 639, 639f, 640–641, 640f
speech and, 704–705, 704f
- Auditory receptive aphasia, 703
- Auerbach's plexus. *See* Myenteric plexus.
- Augmented unipolar limb leads. *See* Unipolar limb leads, augmented.
- Auscultation, of heart sounds, 266, 266f
- Auscultatory method, for blood pressure measurement, 170–171, 170f
- Autocrines, 881
- Autograft, 449
- Autoimmune diseases, 442
- Autolysis, 19–20
- Autonomic ganglia
drugs blocking transmission through, 740
nicotinic receptors in, 733
peripheral sympathetic, 729
prevertebral, 729
sympathetic chains of, 729, 730f
- Autonomic nervous system, 729–741. *See also* Parasympathetic nervous system; Sympathetic nervous system.
in arterial pressure control, acute, 205
brain stem control of, 739, 739f
circulatory control by, 201–204, 202f, 204f, 205
eye control by, 631–632, 631f
- Autonomic nervous system (*Continued*)
functional characteristics of, 731–737
cholinergic and adrenergic fibers in, 731–732
excitation and inhibition in, 733–735, 734t
receptors on organs and, 732–733, 733t
specific organs and, 734t, 735–736
stimulus frequency required in, 736
tone in, 737
gastrointestinal tract and. *See* Gastrointestinal tract, autonomic control of.
hypothalamic influence on, 739, 739f
insulin secretion and, 947
organization of, 729–731, 730f, 731f
pharmacology of, 739–740
rapidity and intensity of effects, 729
smooth muscle and, 94–95, 94f
- Autonomic reflexes, 665, 729, 738
bowel activity and, 772
local, 738
- Autoregulation of blood flow, 165–166, 165f, 194–195, 194f, 200, 217
cerebral, 744–745, 745f
renal, 317, 319–321, 319f, 320f
- Autoregulatory escape, gastrointestinal blood flow and, 762
- A-V block. *See* Atrioventricular (A-V) block.
- Aviation. *See also* High altitude; Spacecraft.
acceleratory forces in, 531–533, 531f
acute hypoxia in, 528
breathing air vs. breathing oxygen in, 528
deceleratory forces in parachuting in, 532–533
- Axis deviation, 135–137, 135f, 136f, 137f
- Axon, 543, 544f, 547, 547f
- Axonal streaming, 551
- Axoneme, 25, 975
- Azathioprine, for immunosuppression, in transplantation, 449
- Azotemia. *See* Uremia.
- B**
- B lymphocytes, 433, 434. *See also* Antibodies; Lymphocytes.
as antigen-presenting cells, 440
helper T cells and, 436, 437, 441, 441f
interleukins and, 441
memory cells of, 437
plasma cells formed by. *See* Plasma cells.
preprocessing of, 435, 435f, 442
specificity of, 435–436, 436f
- Bacteria
in colon, 798, 855
dental caries and, 971
evolution of, 17–18, 18f
in feces, 798
fever and, 875–876
lysosomal killing of, 20
phagocytosis of, 19, 20. *See also* Phagocytosis.
- Bainbridge reflex, 208–209, 229–230
- Balance. *See* Equilibrium.
- Baldness, 981
- Ballistic movements, cerebellar control of, 688
- Barometric pressure, at different altitudes, 527, 528t
- Baroreceptor reflexes, 205–209, 206f, 207f, 738
acute neurogenic hypertension and, 224–225
adaptation and, 562
in cardiac failure, acute stage, 255–256, 256f
as homeostatic mechanism, 6, 7–8
in hypovolemic shock, 275
in integrated pressure response, 227, 227f
oscillation of, 210, 210f
renal sodium and water excretion and, 373–374

- Bartholin glands, 1000
 Bartter's syndrome, 408
 Basal ganglia, 689–694
 as accessory motor system, 689
 anatomical relations of, 690, 690f
 clinical syndromes associated with, 693–694
 Huntington's disease, 694
 Parkinson's disease, 691, 693–694
 dopamine system and, 712, 713, 713f
 gamma efferents and, 659
 in integrated motor control, 695
 neglect syndrome and, 692, 692f
 neuronal circuitry of, 690, 690f
 caudate circuit, 690f; 691–692, 691f
 putamen circuit, 690–691, 690f, 691f
 neurotransmitters in, 692–693, 692f
 overall motor control by, 681
 patterns of motor activity and, 690–691, 695
 scaling of movements and, 692
 timing of movements and, 692
 Basal metabolic rate (BMR), 863–864, 864f, 867
 in pregnancy, 1010
 testosterone and, 982
 thyroid hormones and, 907, 911, 912, 913f
 in hyperthyroidism, 916
 in hypothyroidism, 918
 Base(s)
 as components of DNA, 27, 28, 28f, 29
 definition of, 379
 strong and weak, 379–380
 Basement membrane, of capillaries, 177, 178f
 Basilar fibers, of cochlea, 635
 hair cells and, 636f, 637, 637f
 traveling wave and, 635, 636
 Basilar membrane, of cochlea, 634–635,
 634f, 635f
 hair cells and, 637
 loudness and, 638
 sound frequency and, 638
 traveling wave along, 635, 635f, 636f
 Basket cells, 685
 Basophil erythroblasts, 415, 415f
 Basophils, 423, 423t, 424f, 431
 allergies and, 443
 complement fragments and, 439, 439f
 eosinophil chemotactic factor of, 430
 heparin produced by, 431, 439, 457
 Bathorhodopsin, 611–612, 611f
 Bends. *See* Decompression sickness.
 Beriberi, 853, 854
 cardiac failure associated with, 263, 264,
 264f, 853
 cardiac output in, 232
 hypoxia in, 521
 peripheral vasodilation in, 194, 853
 Beta adrenergic receptors, 733, 733t
 of bronchiolar smooth muscle, 473
 of cardiac muscle, sympathetic stimulation
 and, 120
 in coronary vessels, 248
 drugs acting on, 739
 potassium homeostasis and, 361–362
 Beta blockers, 740
 for angina pectoris, 252
 hyperkalemia caused by, 361–362
 Beta waves, 723f; 724–725, 724f, 725f
 Beta-aminoisobutyric aciduria, 408
 Beta-amyloid peptide, in Alzheimer's
 disease, 728
 Beta-oxidation of fatty acids, 822, 822f, 839
 Betz cells, 669–670. *See also* Pyramidal cells.
 Bicarbonate. *See also* Sodium bicarbonate.
 in bile, 784, 785
 carbon dioxide transported as, 502–503,
 502f
 in cerebrospinal fluid, at high altitude, 529
 diarrhea-related loss of, 392
 Bicarbonate (*Continued*)
 gastric acid secretion and, 777–778, 778f
 in gastrointestinal mucus, 775
 duodenal, 786
 intestinal absorption of, 795
 intestinal secretion of
 in large intestine, 787, 795, 797
 in small intestine, 787, 795
 pancreatic secretion of, 780–782, 782f
 mucosal protection and, 800
 regulation of, 782–783, 783f
 in plasma
 carbon dioxide transport and, 413
 measurement of, 393–395, 394f
 renal excretion of, 389, 390
 in alkalosis, 392
 renal reabsorption of, 332–333, 332f, 385,
 386–388, 386f, 387f
 carbonic anhydrase inhibitors and, 398
 factors affecting, 390–391, 390t
 in saliva, 774f, 775
 vomiting-related loss of, 393
 Bicarbonate buffer system, 381–383, 382f
 intracellular fluid and, 383
 Bicarbonate-chloride carrier protein, 502–503
 Bile, 783–786
 composition of, 784–785, 784t
 excretion of calcium in, 840
 excretion of hormones in, 886
 functions of, 783, 785
 release into duodenum, 784f, 785
 secretion of, 783–784, 785
 secretin and, 784, 784f, 785
 storage and concentration of, 784, 784f, 785
 Bile acids. *See also* Bile salts.
 cholesterol and, 827, 829
 functions of, 783
 Bile canaliculi, 783–784, 837, 837f
 Bile ducts, 783–784, 837, 837f
 obstruction of, 841–842
 Bile salts. *See also* Bile acids.
 cholesterol and, 839
 cholic acid for, 827
 concentration in bile, 784, 784t
 enterohepatic circulation of, 785
 in fat digestion and absorption, 785, 792
 Bilirubin, 419–420, 783, 840–842
 concentration in bile, 784, 784t
 concentration in plasma, 841
 conjugated, 840, 841–842, 841f
 fecal color and, 798
 formation and transformations of,
 840–841, 841f
 jaundice and, 841–842
 in neonate, 1024
 in neonate, 1024, 1024f
 from transfusion reactions, 1025
 unconjugated, 840, 841–842, 841f
 Biliverdin, 840
 Binocular vision, 605, 605f. *See also* Stereopsis.
 2,3-Biphosphoglycerate (BPG), 500, 500f
 Bipolar cells, 609, 610f, 616–617, 617f
 transmitters at synapses of, 617
 two types of, 618, 619–620
 visual pathway and, 617, 617f
 Bipolar disorder, 727
 Bipolar limb leads, 124–126, 125f, 126f
 vectorial analysis of potentials in, 131, 131f
 atrial T wave, 133–134, 133f
 axes for, 130, 130f
 increased voltage in, 136f, 137
 mean electrical axis, 134–135, 135f
 P wave, 133, 133f
 QRS complex, 131–132, 132f
 T wave, 133, 133f
 Bitemporal hemianopsia, 627
 Bitter taste, 645–646, 646t, 647
 Bladder. *See also* Micturition; Micturition reflex.
 anatomy of, physiologic, 306–308, 307f
 atonic, 310
 external sphincter of, 308, 308f, 310
 innervation of, 308, 308f
 internal sphincter of. *See* Urethra, posterior.
 irritation of, intestinal activity and, 772
 pressure changes in, 309, 309f
 Blastocyst, 1004, 1004f, 1005f
 progesterone and, 1008–1009
 Bleeding tendencies. *See also* Hemorrhage.
 in factor deficiencies, 457–458
 in thrombocytopenia, 458
 Bleeding time, 460
 Blind spot, 627
 Blindness, in premature infant, 197–198, 1027
 Blood. *See also* Extracellular fluid.
 cleansing of, by spleen, 175
 reservoirs of, 175, 175f
 viscosity of, 161–162, 163, 164
 anemia and, 420–421
 hematocrit and, 165, 165f
 mountain sickness and, 531
 plasma loss and, 279
 in polycythemia, 421
 Blood cells, genesis of, 414–415, 414f. *See also*
 Leukocytes (white blood cells);
 Red blood cells (erythrocytes)
 Blood coagulation. *See also* Clot entries;
 Hemostasis.
 abnormalities of
 with bleeding, 457–458
 with thromboembolism, 459
 clotting factors in, 452t, 453
 hepatic synthesis of, 840
 initiation of, 454–456, 455f, 456f
 mechanism of, 453–454
 in neonate, 1025
 outside the body, 460
 positive feedback in, 8, 9
 prevention of, in normal vascular system,
 456–457
 in ruptured vessel, 452, 452f
 tests of, 460–461, 460f
 Blood flow, 160–162. *See also* Circulation.
 arterial pressure and, 165–166, 165f, 166f
 cardiac output and, 159
 cerebral. *See* Cerebral blood flow.
 definition of, 160
 diameter of vessel and, 163–164, 163f
 in different tissues and organs, 191, 192t
 gastrointestinal. *See* Gastrointestinal tract,
 blood flow in.
 interstitial fluid PCO₂ and, 497, 498f
 interstitial fluid PO₂ and, 496–497, 496f
 laminar, 161, 161f
 in liver, 838
 metabolic oxygen use and, 501
 methods for measuring, 160–161, 160f, 161f
 in muscle. *See* Skeletal muscle, blood
 flow in.
 needs of tissues for, 191, 192–193
 pressure difference and, 159, 160
 pulmonary. *See* Pulmonary circulation.
 regulation of. *See* Blood flow control.
 renal. *See* Renal blood flow.
 resistance to. *See* Vascular resistance.
 in skin, heat loss and, 868, 868f
 in thyroid gland, 907
 thyroid hormones and, 913
 in total circulation, 160
 turbulent, 161–162, 161f
 units of, 160
 velocity of
 cross-sectional area and, 158
 parabolic profile for, 161, 161f
 turbulence and, 161–162

- Blood flow control
 humoral, 199–200
 local, 191
 acute, 191, 192–196, 192*f*, 193*f*
 autoregulation in, 165–166, 165*f*,
 194–195, 194*f*, 200, 217
 cardiac output and, 230–231
 long-term, 191–192, 196–198, 197*f*
 tissue factors affecting, 97
 tissue needs and, 158–159
- Blood gases. *See also* Carbon dioxide partial pressure (P_{CO₂}); Oxygen partial pressure (P_{O₂}).
 during exercise, 1037
 measurement of, 515–516
- Blood glucose
 cortisol and, 928
 in Cushing syndrome, 935–936
 diagnosis of diabetes and, 952–953, 953*f*
 glucagon and, 947–948, 948*f*
 gluconeogenesis and, 839
 hepatic buffering of, 839
 hunger and, 766, 849
 importance of regulation of, 949–950
 insulin secretion and, 946, 946*f*, 947
 in neonate, 1023, 1025
 of diabetic mother, 1026
 premature, 1027
 normal level of, 817
 renal blood flow and, 321
 summary of regulation of, 949–950
 urinary excretion and, 327
- Blood pressure. *See also* Arterial blood pressure; Capillary pressure; Venous pressures.
 definition of, 162
 measurement of, high-fidelity, 162, 162*f*
 in parts of circulation, 158, 159*f*
 standard units of, 162
- Blood transfusion, 280–281. *See also* Transfusion; Transfusion reactions.
 blood types in, 445, 446*t*
- Blood types
 O-A-B, 445–447, 446*f*, 446*t*
 Rh, 447–449
- Blood typing, 446–447, 447*t*
- Blood vessels. *See also* Arteries; Arterioles; Capillaries; Veins.
 autonomic control of, 729–730, 730*f*, 731, 734*t*, 735
 adrenal medullae in, 736
 intrinsic tone of, 737
- Blood volume, 287. *See also* Extracellular fluid volume.
 antidiuretic hormone and, 357, 357*f*, 905
 aortic valve disease and, 268
 atrial natriuretic peptide and, 376
 atrial reflexes and, 208
 cardiac output and, 233, 238, 238*f*
 conditions causing large increases in, 376–377
 vs. extracellular fluid volume, 373, 373*f*
 hemorrhage and. *See also* Hypovolemic shock.
 compensatory mechanisms, 275–276
 at high altitude, 529
 in lungs, 157, 478–479
 mean circulatory filling pressure and, 236, 236*f*
 measurement of, 290
 mitral valve disease and, 269
 of neonate, 1024
 in pregnancy, 1010, 1010*f*
 regulation of, 371–373, 372*f*
 testosterone and, 982
 venous return and, 238, 238*f*
- Blood-brain barrier, 748–749
- Blood–cerebrospinal fluid barrier, 748–749
- Blue weakness, 616
- BMR. *See* Basal metabolic rate (BMR).
- Body mass index (BMI), 850
- Bohr effect, 500, 500*f*
 double, 1006
 fetal blood and, 1006
- Bone, 957–960. *See also* Fractures.
 calcification of, 958
 vitamin D and, 962
 calcium exchange with, 958, 967
 in pregnancy, 1009
 deposition and absorption of, 959–960, 959*f*
 estrogenic effects on, 994
 in fetus, 1020
 growth hormone and, 900
 somatomedins and, 900–901
 growth mechanisms of, 900
 hydroxyapatite in, 957, 958
 organic matrix of, 957
 parathyroid hormone and, 963–964
 phosphate in extracellular fluid and, 958
 radioactive substances in, 957–958
 rickets and, 968
 salts of, 957–958
 strength of, 958, 960
 structure of, 959–960, 960*f*
 testosterone and, 982
 thyroid hormones and, 912
 in cretinism, 918
 vitamin D and, 962
- Bone fluid, 964
- Bone marrow
 B lymphocyte processing in, 435, 442
 leukopenia and, 431
 macrophages of, 427–428
 response of, to inflammation, 429, 430, 430*f*
- Bone marrow aplasia, 420
- Bony labyrinth, 634, 674
- Botulinum toxin, 85
- Bowman's capsule, 305–306, 305*f*, 310–311, 311*f*, 312, 313*f*
 pressure in, 314–315, 314*f*
- Boyle's law, 535
- BPG (2,3-biphosphoglycerate), 500, 500*f*
- Bradycardia, sinus, 143–144, 143*f*
- Bradykinin, 199, 200
 in asthma, 520
 glomerular filtration rate and, 319
 in gut wall, 761
 from mast cells and basophils, 431
 as pain stimulus, 583, 584
 in salivary glands, 776
- Brain. *See also* Basal ganglia; Cerebellum; Cerebral cortex; Nervous system.
 acceleration injury to, 746
 activating systems of, 711–713
 neurohormonal systems, 711, 712–713, 713*f*
 reticular excitatory area, 711–712, 712*f*
 blood flow in. *See* Cerebral blood flow.
 capillaries of, tight junctions of, 178
 carbon dioxide in blood and, 200
 childhood development of, 1027–1028
 glucose for, 949
 insulin and, 942–943
 growth of, thyroid hormones and, 912
 interstitial fluid pressure in, 183
 metabolism of, 749–750
 reticular inhibitory area and, 712, 712*f*
 vegetative functions of, 714, 715–717, 716*f*
- Brain damage
 Cheyne-Stokes breathing in, 512
 circulatory arrest causing, 282
 neurogenic shock caused by, 279–280
- Brain edema, 749
 in acute mountain sickness, 530
 hyponatremia with, 295, 296*f*
 negative acceleratory forces causing, 531–532
 respiratory depression in, 512
 treatment of, 749
- Brain stem. *See also* Medulla; Pons.
 autonomic control centers of, 739, 739*f*
 basal ganglia input from, 692–693, 692*f*
 cerebellar functions and, 686–687, 694
 cerebellar input from, 683, 683*f*
 cerebellar signals to, 684
 cerebral activation by, 711–713
 continuous excitatory signals in, 711–712, 712*f*
 neurohormonal systems in, 711, 712–713, 713*f*
 cerebral inhibition by, 712
 chewing and, 763
 feeding and, 847–848
 functions of, 673
 gastrointestinal reflexes and, 757
 hypothalamus and, 715
 limbic system and, 715
 motor functions and, 673–674, 673*f*, 674*f*
 anencephaly and, 678–679
 gamma efferents in, 659, 660
 stretch reflexes and, 660
 pain pathways to, 586
 salivatory nuclei in, 776, 776*f*
 swallowing and, 764, 765
 vestibular nuclei in, 678, 678*f*
 vomiting center in, 803, 803*f*, 804
- Brain waves. *See* Electroencephalogram (EEG).
- Braxton Hicks contractions, 1012
- Breasts
 anatomy of, 1014*f*
 development of, 1014
 estrogens and, 994, 1014
 of neonate, 1026
 progesterone and, 995, 1014
- Breathing. *See also* Respiration.
 cardiac output curve and, 234, 234*f*
 work of, 468
- Broca's area, 668–669, 669*f*, 699*f*, 700, 704–705
- Brodman's areas, 574–575, 575*f*
- Bronchi, 472–473
- Bronchial circulation, 477
 shunt blood and, 496, 496*f*
- Bronchioles, 472–473
 particles entrapped in, 474
- Bronchospasm
 in anaphylaxis, 443
 in asthma, 444
- Brown fat, 865, 873
- Brown-Séquard syndrome, 590
- Brunner glands, 786, 800
- Brush border, intestinal, 790, 791, 794, 794*f*
- Buccal glands, 775
- Buffer nerves, from baroreceptors, 207
- Buffer systems, 380–381
 ammonia, 388–389, 389*f*
 bicarbonate, 381–383, 382*f*
 intracellular fluid and, 383
 gastrointestinal mucus and, 775
 isohydric principle and, 383–384
 phosphate, 383, 388, 388*f*
 proteins, 383–384
 hemoglobin, 383, 413
 respiratory, 385
- Bulboreticular facilitatory region, 711
 gamma efferents and, 659–660
 stretch reflexes and, 660
- Bulbourethral glands, 307*f*, 973, 973*f*, 979

- Bulk flow
 in artificial kidney, 409
 into peritubular capillary, 323–324, 324f
- Bumetanide, 331, 331f, 397
- Bundle branch block
 axis deviation in, 136–137, 136f, 137f
 QRS prolongation in, 138, 142
 T wave and, 142
- Bundle branches, 115, 116f, 118. *See also* Purkinje fibers.
- Bundle of His. *See* Atrioventricular (A-V) bundle.
- Burns
 plasma loss in, 279
 water loss caused by, 285
- C**
- C cells, thyroid, 966
- C fibers, 563–564, 563f
 analgesia system and, 587
 cold receptors and, 592
 pain sensation and, 584, 585, 586
 visceral, 588
 sympathetic, 729–730
 warmth receptors and, 592
- C peptide, 940, 940f
- Cachexia, 852
- Caffeine, 557
 athletic performance and, 1040
- Caisson disease. *See* Decompression sickness.
- Cajal, interstitial cells of, 754
- Calbindin, 962
- Calcarine fissure, 623, 624, 624f
- Calcitonin, 965f, 966
 renal calcium reabsorption and, 368–369
- Calcitriol, 304
- Calcium, 856
 action potential and, 64
 in gastrointestinal smooth muscle, 754–755
 blood coagulation and, 453, 453f, 454, 455, 455f, 456, 456f
 prevention of, 460
 in bone, 957
 deposition of, 958
 exchange with extracellular fluid, 958, 967
 parathyroid hormone and, 963–964
 in cardiac muscle
 excitation-contraction coupling and, 103–104, 104f
 sympathetic stimulation and, 120
 exchangeable, 958, 967
 excretion of, in bile, 840
 exocytosis and, 21
 of gastrointestinal secretions, 774
 in extracellular fluid and plasma, 955–957, 957f
 calcitonin and, 965f, 966
 cardiac muscle contraction and, 103–104, 104f, 112
 excess or deficiency of, 367, 856, 956, 956f
 forms of, 955, 956f
 as nerve membrane stabilizer, 69
 normal range of, 7, 7t
 parathyroid hormone and, 963–966, 963f, 965f, 967
 regulation of, 367–368, 368f
 in rickets, 968
 of smooth muscle, 97–98
 summary of, 966–967
 vitamin D activation and, 961–962, 961f
 fecal excretion of, 367, 368, 956–957, 957f
 fetal accumulation of, 1020, 1020f
 in gastrointestinal smooth muscle
 action potential and, 754–755
 tonic contraction and, 755
- Calcium (*Continued*)
 intestinal absorption of, 796, 956–957, 957f
 parathyroid hormone and, 796, 964–965
 vitamin D and, 796, 855, 962, 964–965
 neonatal need for, 1025, 1026, 1027
 in nonosseous tissues, 958
 peptide hormone secretion and, 882
 plasma protein binding of, 312
 at postganglionic nerve endings, 732
 renal excretion of, 368, 369t, 957, 957f
 renal reabsorption of, 339, 368–369, 368f
 parathyroid hormone and, 964
 as second messenger, in hormone action, 890, 891
 in skeletal muscle contraction, 75–76, 88–89, 88f, 89f
 in smooth muscle, 93–94, 94f, 97–98
 sodium channels and, 64, 69
 sodium counter-transport of, 55, 55f
 vasoconstriction induced by, 200
- Calcium ATPase, 324–325
 of cardiac muscle, 104, 104f
- Calcium carbonate, of vestibular system, 675
- Calcium ion channels. *See also* Calcium-sodium channels
 of cardiac muscle, 102–103, 104f
 hormone receptors and, 891
 memory system of *Aplysia* and, 707, 708
 of smooth muscle, 97
 voltage-gated, 64
 at neuromuscular junction, 83, 84f, 86
 of pancreatic beta cells, 945, 945f
 at presynaptic terminal, 548
 of smooth muscle, 96
- Calcium pumps, 54
 of cardiac muscle, 104, 104f
 renal, 368–369, 368f
 of skeletal muscle, 74, 88–89, 88f, 89f
 of smooth muscle, 97, 98
- Calcium release channels, 88, 88f, 103
- Calcium-sensing receptor (CaSR), 965
- Calcium-sodium channels.
 in cardiac muscle, 102–103
 in gastrointestinal smooth muscle, 754–755
- Calmodulin, 93–94, 94f
 hormone action and, 891
- Calorie, 862
- Calorimeter, 862, 863
- Calsequestrin, 88, 88f
- cAMP. *See* Cyclic adenosine monophosphate (cAMP).
- cAMP-dependent protein kinase, 889
- Cancer
 anorexia-cachexia in, 852
 genetic mechanisms of, 40–41
- Capacitance, vascular, 167. *See also* Vascular compliance.
 sympathetic control of, 168
- Capillaries
 blood flow in
 average, 179
 intermittent character of, 178–179
 velocity of, 158
 blood volume in, 157
 cerebral, 743, 743f, 745
 barriers at, 748–749
 edema and, 749
 diffusion across walls of, 4–5, 4f, 179–180, 179f
 concentration difference and, 180
 molecular size and, 179–180, 180t
 distance from any single cell, 4–5, 177
 fluid filtration across, 181–186, 181f
 excess, causing edema, 297
 into potential spaces, 300
 function of, 157
 in gastrointestinal tract, pores of, 178
- Capillaries (*Continued*)
 glomerular. *See* Glomerular capillaries.
 increase in number of, 197, 197f
 at high altitude, 529
 intercellular clefts of, 177–178, 178f
 diffusion through, 179–180
 lymphatic, 186f, 187, 187f, 188, 188f
 pumping by, 188–189
 organization of, 177, 178f
 peritubular. *See* Peritubular capillaries
 permeability decrease in, cortisol-induced, 930
 permeability increase in
 bradykinin-induced, 199
 in circulatory shock, 277
 edema caused by, 297
 histamine-induced, 199–200
 pores in, 157, 158, 177–178, 178f
 diffusion through, 4–5, 179–180
 fluid filtration and, 181
 permeabilities for various molecules, 179–180, 180t
 pressures in
 gravity and, 173–174
 hydrostatic. *See* Capillary pressure.
 pulmonary, 158
 systemic, 158
 pulmonary. *See* Pulmonary capillaries.
 of skeletal muscle, blood flow during exercise, 243
 surface area of, 177
 wall structure of, 177, 178f
- Capillary filtration coefficient, 181, 185
- Capillary fluid shift, for arterial pressure regulation, 227, 227f
- Capillary pressure, 181, 181f, 184t, 185t
 edema caused by increased in, 297
 increased blood volume and, 238
 lymph flow and, 188
 measurement of, 181–182, 182f
- Carbachol, 86
- Carbaminohemoglobin, 503
- Carbohydrates
 absence of, fat utilization in, 823, 825
 absorption of, 796
 in athlete's diet, 1034, 1035, 1035f
 in cell, 12, 13
 of cell membrane, 14
 dental caries and, 971
 dietary sources of, 789–790
 digestion of, 789–790, 790f
 pancreatic enzyme for, 781, 790
 as energy source. *See* Glucose, energy production from.
 excess of, fat metabolism and, 825
 in foods
 energy available in, 843–844
 metabolic utilization of, 844–845
 growth hormone and, 899–900
 metabolism of. *See also* Glucose.
 insulin and, 941–943, 942f, 947
 liver's functions in, 839
 thyroid hormones and, 912
 storage of. *See* Glycogen.
 synthesis of, in Golgi apparatus, 20
 triglycerides synthesized from, 824–825, 824f
- Carbon dioxide
 diffusing capacity for, 491–492, 492f
 diffusion coefficient of, 487t
 diffusion of. *See also* Diffusion, of gases.
 through capillary membrane, 179
 from cells to capillaries to alveoli, 497–498, 497f, 498f, 502
 in extracellular fluid
 acid-base balance and, 384
 normal range of, 7t
 regulation of, 6, 7

- Carbon dioxide (*Continued*)
 in large intestine, 804
 lipid solubility of, 46
 from metabolism
 of carbohydrates, 812–813, 813f, 814,
 816–817, 816f
 mitochondrial, 22
 placental diffusion of, 1007
 removal by lungs, 5
 respiratory control by, 507–508, 507f, 508f
 transport in blood, 495, 502–504, 502f,
 503f, 504f
 pH change caused by, 504
 in urea synthesis, 835
 as vasoconstrictor, 200
 as vasodilator, 97, 200
 in skeletal muscle, 243–244
- Carbon dioxide dissociation curve, 503, 503f
- Carbon dioxide partial pressure (P_{CO_2}). *See also* Hypercapnia.
 alveolar, 488–489, 489f
 in deep-sea diving, 537
 ventilation-perfusion ratio and,
 492–494, 493f
- blood
 cerebral blood flow and, 743–744, 744f
 chemoreceptors and, 208, 509
 exercise and, 511, 511f, 1037
 measurement of, 515–516
 respiratory control and, 507–508, 508f,
 510, 510f, 512–513, 512f
 in extracellular fluid, 382, 384, 385
 in acidosis, 390, 391, 392
 in alkalosis, 390, 392
 high levels of, 537
 in interstitial fluid, 497–498, 498f
 oxygen-hemoglobin dissociation curve and,
 500, 500f
 plasma measurement of, 393–395, 394f
 solubility coefficient and, 486
- Carbon monoxide
 diffusing capacity for, 492, 492f
 hemoglobin combination with,
 501–502, 501f
- Carbonate ions, in bone, 957–958
- Carbonic acid
 in bicarbonate buffer system, 32, 381
 cerebral blood flow and, 744
 intestinal bicarbonate absorption and, 795
 pancreatic secretions and, 781,
 782–783, 782f
 in red blood cells, 502–503
- Carbonic anhydrase
 gastric acid secretion and, 777–778
 in kidney, 381
 bicarbonate reabsorption and, 386–387,
 386f, 389f
 pancreatic secretions and, 781, 782f
 in red blood cells, 413, 502, 502f, 503
 zinc in, 856
- Carbonic anhydrase inhibitors, 398, 398t, 503
- Carboxypolypeptidase, 781, 791
- Carcinogens, 41
- Cardiac. *See also* Heart.
- Cardiac arrest, 153
 circulatory arrest and, 281
- Cardiac catheterization, premature
 contractions caused by, 146
- Cardiac cycle, 104–107, 105f
 current flows around heart in, 123–124,
 124f
 volume-pressure diagram during, 108–109,
 108f, 109f
- Cardiac failure, 255–264
 acute, in anemia, 421
 aortic valve lesions with, 268, 269
 blood volume in, 376–377
- Cardiac failure (*Continued*)
 causes of, 255
 chemical energy expended in, 109, 110
 Cheyne-Stokes breathing in, 512
 circulatory dynamics in, 255–258
 acute stage, 255–256, 256f, 262, 262f
 chronic stage, 256–257, 256f
 compensated, 256f, 257, 262, 262f
 decompensated, 257–258, 257f,
 262–263, 263f
 graphical analysis of, 262–264, 262f,
 263f, 264f
 definition of, 255
 edema caused by, 298
 efficiency of heart in, 110
 extracellular fluid volume in, 375, 376–377
 high-output, graphical analysis of,
 263–264, 264f
 hypertrophy and, 218
 hypertrophy leading to, 272
 left-sided
 pulmonary circulation in, 478–479, 481
 pulmonary edema in, 259, 482, 483
 unilateral, 259
 low-output, 259
 peripheral edema in, 259–261, 260f
 pulmonary edema in, 256
 as acute edema, 259, 261
 decompensated, 258
 left-sided, 259
 quantitative graphical analysis of,
 262–264, 262f
 in acute stage, 262, 262f
 during compensation, 262, 262f
 with decompensation, 262–263, 263f
 in high-output failure, 263–264, 264f
 red blood cell production in, 416
 right-sided, emphysema leading to, 518
 in thiamine deficiency, 263, 264, 264f, 853
 unilateral, 259
- Cardiac hypertrophy, 272. *See also* Ventricular hypertrophy.
 athletic training and, 1039
 cardiac output and, 231
 in congenital heart disease, 272
 after myocardial infarction, 256
 in valvular heart disease, 272
- Cardiac index, 229
 age and, 229, 230f
- Cardiac muscle, 101–104
 action potentials in. *See* Action potential(s), cardiac.
 contractile strength of
 body temperature and, 112
 exercise and, 245
 sympathetic stimulation of, 111, 120,
 203, 231
 thyroid hormones and, 913
 vagal stimulation and, 111, 203
 contraction of
 chemical energy for, 109–110
 duration of, 104
 efficiency of, 110
 coronary artery arrangement in, 247, 247f
 coronary blood flow control and, 247
 excitation-contraction coupling in,
 103–104, 104f
 Frank-Starling mechanism and, 110, 111
 histology of, 101, 102f
 hypertrophy of, 272. *See also* Cardiac hypertrophy.
 infarcted, 249–250
 metabolism of, 248
 recording electrical potentials from,
 123–124, 124f
 refractory period of, 103, 103f
 shock-related lesions in, 277–278
- Cardiac muscle (*Continued*)
 vs. skeletal muscle, 102–104
 spiraling layers of, 118
 as syncytium, 101–102, 102f
 three types of, 101
 velocity of signal conduction in, 103
 in atria, 117
 by Purkinje fibers, 117
- Cardiac output, 229
 anemia and, 233, 420–421
 arterial pressure and, 112, 112f, 216f,
 217, 217f
 with arteriovenous fistula, 232, 239,
 239f, 240
 blood volume and, 238, 238f
 definition of, 160
 during exercise, 210, 230, 230f, 232, 244,
 245, 245f
 athletic training and, 1038, 1038f,
 1039, 1039f
 at high altitude, 529
 limits achievable, 231, 231f
 measurement methods for, 240–241,
 240f, 241f
 after myocardial infarction, 250
 of neonate, 1024
 normal values of, 160, 229
 pathologically high, 232–233, 233f
 pathologically low, 232, 233–234, 233f
 in pregnancy, 1010
 regulation of
 by local tissue flows, 159, 230–231, 234
 by nervous system, 111, 111f, 232, 232f
 quantitative analysis of, 234. *See also* Cardiac output curves; Venous return curves.
 by venous return. *See* Venous return, cardiac output and.
 shock and, 273
 hypovolemic, 274–275, 274f
 septic, 280
 skeletal muscle contraction and, 209–210
 sympathetic inhibition and, 239, 239f
 sympathetic stimulation and, 238–239, 239f
 thyroid hormones and, 913
 total peripheral resistance and, 230–231,
 230f
 reduced, 232–233
 volume-loading hypertension and, 219, 220f
- Cardiac output curves, 231, 231f, 234–235
 combinations of patterns of, 235, 235f
 exercise and, 245, 245f
 external pressure on heart and, 234,
 234f, 235
 in heart failure. *See* Cardiac failure, circulatory dynamics in.
 in hypovolemic shock, 276, 276f
 with simultaneous venous return curves,
 238–240, 238f
- Cardiac reserve, 257, 261–262, 261f
 patent ductus arteriosus and, 270
 in valvular disease, 269
- Cardiac surgery, extracorporeal circulation
 during, 271–272
- Cardiogenic shock, 233, 250, 259, 273. *See also* Circulatory shock.
- Cardiopulmonary resuscitation (CPR), 151, 153
- Cardiotachometer, 144
 in sinus arrhythmia, 144, 144f
- Cardiotonic drugs, 258, 261
- Caries, dental, 971
 fluorine and, 971
- Carnitine, 822
- Carotenoids, 853
- Carotid bodies, 208, 507, 508, 508f, 509, 509f
 high altitude and, 529
 rhythmical output signal and, 568, 569f

- Carotid sinus baroreceptors, 205–206, 206f, 207
 Carotid sinus syndrome, 144
 Carrier proteins, 14, 45, 46
 active transport and, 46, 46f, 52–53
 facilitated diffusion and, 46, 46f, 49–50, 49f
 Carrier-mediated diffusion. *See* Facilitated diffusion.
 Cartilage, growth hormone and, 900–901
 Caspases, 40
 CaSR (calcium-sensing receptor), 965
 Catalases, 536–537
 Cataracts, 604
 Catecholamines. *See* Epinephrine; Norepinephrine.
 Catechol-*O*-methyl transferase
 epinephrine degradation by, 732
 norepinephrine degradation by, 732
 Caudate circuit, 690f, 691–692, 691f
 Caudate nucleus, 670, 690, 690f, 691, 691f
 dopamine system and, 713, 713f
 Huntington's disease and, 694
 neurotransmitters in, 692–693, 692f
 Parkinson's disease and, 693
 Caveolae
 of capillary endothelial cells, 178, 178f
 of smooth muscle fibers, 98, 98f
 Caveolins, 178, 178f
 CCK. *See* Cholecystokinin (CCK).
 Cecum, ileocecal sphincter and, 770
 Celiac disease, 801
 Celiac ganglion, 729, 730f, 757
 Cell(s), 3, 11–25, 11f, 12f
 basic characteristics common to, 3
 basic substances of, 11, 12
 compared to precellular life, 17–18, 18f
 cytoplasm of, 11, 11f, 14
 cytoskeleton of, 11, 16–17, 17f
 damaged, lysosomal removal of, 19–20
 functional systems of, 18–23
 for digestion, 19–20, 19f. *See also* Lysosomes.
 for energy extraction, 21–23, 22f
 for ingestion, 18–19, 18f
 for synthesis, 20–21, 20f
 life cycle of, 37
 locomotion of, 23–25, 23f, 24f
 membranous structures of, 13–14, 13f
 nuclear membrane of, 11, 11f, 13, 17, 17f
 nucleoli of, 12f, 17, 17f, 32
 nucleus of, 11, 11f, 17, 17f
 evolution of, 18
 number of, in human body, 3
 organelles of, 12, 12f, 14–17. *See also* Endoplasmic reticulum; Golgi apparatus; Lysosomes; Mitochondria; Peroxisomes.
 overall structure of, 11, 11f, 12, 12f
 secretory vesicles of, 16, 16f, 21
 Cell death, apoptotic, 40
 Cell differentiation, 39–40
 Cell growth, 39
 of cancer cells, 41
 Cell membrane, 11, 11f, 13–14, 13f, 45, 46f
 cholesterol in, 13, 14, 827
 diffusion through. *See* Diffusion through cell membrane.
 oxygen toxicity to, 537
 phospholipids in, 826, 827
 replenishment of, 21
 Cell reproduction, 37–39, 38f
 control of, 39
 Cell volume
 hypernatremia-related changes in, 296
 hyponatremia-related changes in, 295, 296f
 in intracellular edema, 296
 osmotic equilibrium and, 291–292, 292f
 sodium-potassium pump and, 53
 Cell-mediated immunity, 433, 434, 435f, 439–440, 440f. *See also* T lymphocytes.
 Cellulose, 790, 798
 Cementum, 969, 969f, 970
 mineral exchange in, 971
 Central fissure, of cerebral cortex, 575, 575f
 Central nervous system (CNS). *See also* Brain; Spinal cord.
 childhood development of, 1027–1028
 fetal development of, 1020
 major levels of function in, 545–546
 thyroid hormones and, 913
 muscle tremor and, 913
 Central nervous system ischemic response, 209, 210–211, 210f, 227, 227f
 in cardiac failure, acute stage, 255–256, 256f
 in hypovolemic shock, 274, 275
 Central venous catheter, 174
 Central venous pressure, 172. *See also* Right atrial pressure.
 Centrifugal acceleratory forces, 531–532
 Centrioles, 12f, 17, 38–39, 38f
 Centromere, 38, 38f, 39
 Centrosome, 38
 Cephalic phase
 of gastric secretion, 779, 780f
 of pancreatic secretion, 782
 Cephalins
 chemical structure of, 826, 826f
 thromboplastin and, 826
 Cerebellum, 681–689
 anatomical folds of, 682, 682f
 anatomical functional areas of, 681–682, 682f
 auditory pathways and, 639
 ballistic movements and, 688
 basal ganglia and, 690f
 clinical abnormalities of, 689
 smooth progression of movements and, 688
 correction of motor errors by, 686
 damping function of, 687–688, 689
 deep nuclei of, 683–684, 684f, 685
 functional unit of, 684–685, 684f
 gamma efferents and, 659
 inhibitory cells in, 685, 686
 input pathways to, 682–683, 683f
 in integrated motor control, 694
 motor cortex fibers leading to, 670
 output signals from, 683–684, 684f
 overall motor control by, 681, 686–689, 687f
 representation of body in, 682, 682f
 turn-on and turn-off signals from, 685–686, 694
 vestibular system and, 677, 678, 678f
 Cerebral blood flow, 743–746
 autoregulation of, 744–745, 745f
 blockage of, 745–746. *See also* Stroke.
 cessation of, 743
 in hypovolemic shock, 274–275
 local neuronal activity and, 744, 745f
 measurement of, 744
 microcirculation in, 745
 normal rate of, 743
 regulation of, 195, 743–745, 744f, 745f
 vessel architecture for, 743, 743f
 Cerebral cortex, 545–546
 anatomic divisions of, 574–575, 575f
 brain stem excitatory signals and, 711–712, 712f
 connections between hemispheres of, 702, 705
 corticofugal signals from
 from primary visual cortex, 624
 sensory input and, 581–582
 dimensions of, 697
 equilibrium status and, 678
 Cerebral cortex (*Continued*)
 functional areas of, 667, 668f, 698, 698f, 699f.
 See also Association areas.
 for facial recognition, 700–701, 700f
 in nondominant hemisphere, 702
 hearing and. *See* Auditory cortex.
 histologic structure of, 697, 698f
 language and, 699–700, 699f; 703–705, 704f.
 See also Speech.
 layers of, 697
 limbic, 714–715, 714f, 720
 motor control by. *See* Motor cortex.
 pain perception and, 586
 somatosensory. *See* Somatosensory cortex.
 thalamus and, 697–698, 698f
 thought and, 705–706
 vasomotor center controlled by, 204
 vision and. *See* Visual cortex.
 Cerebral ischemia
 arterial pressure response to, 209
 vasomotor paralysis caused by, 279–280
 Cerebrocerebellum, 686, 688–689
 Cerebrospinal fluid (CSF), 746–749
 absorption of, 747
 barrier between blood and, 748–749
 bicarbonate in, at high altitude, 529
 cushioning function of, 746
 flow of, 746, 746f, 747
 formation of, 746, 747
 obstruction to flow of, 748
 osmolarity of, 747
 thirst and, 358
 perivascular spaces and, 746, 747, 747f
 spaces occupied by, 746, 746f
 Cerebrospinal fluid pressure, 747–748
 decreased, headache caused by, 591
 elevated
 blood pressure response to, 209, 210–211, 210f
 papilledema secondary to, 748
 in pathological conditions, 748
 respiratory depression secondary to, 512
 measurement of, 748
 normal level of, 747
 Cerebrovascular disease, dementia in, 728
 CFU (colony-forming unit), 414f, 415
 cGMP. *See* Cyclic guanosine monophosphate (cGMP).
 Channels. *See* Ion channels; Protein channels.
 Chemical gating. *See* Ligand-gated channels.
 Chemical messengers, 881
 Chemical pain stimuli, 583
 tissue damage and, 584
 visceral, 588
 Chemical synapses, 546–547
 Chemical thermogenesis, 873
 Chemiosmotic mechanism, of ATP formation, 22, 814–815, 814f
 starting with fatty acids, 823
 Chemoreceptor reflexes, 208
 in cardiac failure, acute stage, 255–256, 256f
 in integrated pressure response, 227, 227f
 oscillation of, 210
 Chemoreceptor trigger zone, 803f, 804
 Chemoreceptors, 208, 508–510, 508f, 509f, 559, 560b
 at high altitude, 529
 Chemosensitive area, of respiratory center, 507–508, 507f
 Chemotaxis
 ameboid movement and, 24
 complement protein C5a and, 439, 439f
 of eosinophils, 430
 of neutrophils and macrophages, 424f, 425, 428
 Chenodeoxycholic acid, 785

- Chest leads, 126, 126f
- Chewing, 763
- Chewing reflex, 763
- Cheyne-Stokes breathing, 512–513, 512f
- Chief cells
 - gastric. *See* Peptic (chief) cells.
 - parathyroid, 963, 963f
- Child, growth and development of, 1027–1028, 1027f. *See also* Infant.
- Chills, and fever, 876, 876f
- Chloride. *See also* Sodium chloride.
 - absorption of
 - in large intestine, 795, 797
 - in small intestine, 795
 - anion gap and, 395
 - in cerebrospinal fluid, 747
 - diffusion through capillary pores, 179, 180t
 - gastric acid secretion and, 777–778, 778f
 - intestinal absorption of, 794, 795, 795f, 797
 - intestinal water secretion and, 787
 - neuronal somal membrane and, 552, 552f, 553
 - plasma concentration of, with reduced GFR, 404, 405f
 - in red blood cells, 502–503
 - renal reabsorption of, 328
 - in saliva, 774f, 775, 776
 - in sweat gland secretions, 870–871
- Chloride ion channels
 - intestinal, 795
 - diarrhea and, 796
 - of postsynaptic neuronal membrane, 548, 550, 554
 - presynaptic inhibition and, 554
- Chloride shift, 502–503
- Chloride-bicarbonate exchanger, 795
- Chloride-iodide counter-transporter, 908
- Cholecalciferol. *See* Vitamin D.
- Cholecystikinin (CCK), 758, 758t
 - food intake and, 846, 846f, 847f, 848
 - gallbladder emptying and, 768, 785, 784f
 - molecular structure of, 780
 - pancreatic secretions and, 782, 783
 - small intestine peristalsis and, 769
 - stomach emptying and, 768
- Cholera, 796, 802
- Cholesterol, 826–827
 - absorption of, bile salts and, 785
 - adrenocortical hormone synthesis from, 922, 923f
 - in bile, 783, 784, 784t, 786
 - gallstones and, 786, 786f
 - bile salts synthesized from, 785
 - blood level of
 - atherosclerosis and, 828, 829
 - control of, 827
 - insulin and, 944
 - thyroid hormones and, 912, 918
 - of capillary membrane, 178, 178f
 - of cell membranes, 13, 14, 827
 - in chylomicron remnants, 820
 - in chylomicrons, 819
 - dietary, 792
 - endogenous, 826, 827
 - genetic disorders affecting, 827
 - intestinal absorption of, 793
 - as lipid, 819
 - in lipoproteins, 821, 821t
 - in seminiferous tubules, 977
 - steroid hormone synthesis from, 827, 882
 - structure of, 826f, 827
 - synthesis of, 826–827
 - in endoplasmic reticulum, 20
 - in liver, 822, 826, 839
 - uses of, 827
- Cholesterol desmolase, 922, 923f
- Cholesterol ester hydrolase, 792–793
- Cholesterol esterase, 781
- Cholesterol esters, 826
 - dietary, 792
 - digestion of, 792–793
 - steroid synthesis from, 882
- Cholic acid, 785, 827
- Choline, in lecithin synthesis, 826
- Choline acetyltransferase, 551, 732
- Cholinergic drugs, 740
- Cholinergic fibers, 731–732
 - to sweat glands, 870
- Cholinesterase, 551
- Chondroitin sulfate, 20
- Chorda tympani, 647, 648f
- Chordae tendineae, 107, 107f
- Chorea, 691
- Choroid, 611
- Choroid plexus, 746, 747, 747f
 - barriers at, 748–749
- Chromatic aberration, 631
- Chromatids, 38–39
- Chromatin material, 17, 17f
- Chromosomes, 17, 38
 - transcriptional regulation and, 36, 38
- Chronic obstructive pulmonary disease (COPD), ventilation-perfusion abnormalities in, 494
- Chylomicron remnants, 820, 820f
- Chylomicrons
 - formation of, 797, 819
 - pathways involving, 820f
 - removal from blood, 819–820
 - transport of, 819
- Chyme
 - in colon, 770, 797
 - in small intestine, 768, 769, 770, 781, 782
 - cholecystikinin and, 783
 - water absorption and, 794
 - in stomach, 765, 766, 767–768
- Chymotrypsin, 781, 791
- Chymotrypsinogen, 781
- Cilia, 24–25, 24f. *See also* Stereocilia.
 - of fallopian tubes, 993–994, 1003, 1004
 - of respiratory epithelium, 473
 - of vestibular hair cells, 675, 675f, 676
- Ciliary body, aqueous humor formed by, 606, 606f
- Ciliary ganglion, 631, 631f
- Ciliary muscle
 - control of, 601, 631–632, 734t, 735
 - innervation of, 631
- Ciliary processes, 606, 606f
- Circle of Willis, 743
- Circulation. *See also* Blood flow; Systemic circulation.
 - basic principles of, 4, 4f, 158–159
 - fetal, 1022–1023, 1022f
 - microcirculation, 177–178, 178f
 - neonatal
 - readjustments in, 1022–1023
 - special problems in, 1024, 1024f
 - nervous regulation of, 201–204, 202f, 204f. *See also* Arterial blood pressure control, nervous.
 - parts of, 157, 158f
 - cross-sectional areas of, 157, 158, 158t
 - pressures in, 158, 159f
 - volumes of blood in, 157, 158f
- Circulatory arrest, 281–282
 - vasomotor failure in, 277
- Circulatory shock, 234, 273–282. *See also* Cardiogenic shock.
 - in aldosterone deficiency, 925
 - anaphylactic, 280
 - sympathomimetic drugs for, 281
 - arterial pressure in, 273
- Circulatory shock (*Continued*)
 - causes of, 273
 - circulatory arrest and, 281
 - definition of, 273
 - gastrointestinal vasoconstriction during, 762
 - heatstroke with, 876
 - hemorrhagic. *See* Hypovolemic shock.
 - histamine-induced, 280
 - hypovolemic. *See* Hypovolemic shock
 - neurogenic, 279–280
 - sympathomimetic drugs for, 281
 - renal ischemia in, 401
 - septic, 280
 - stages of, 274
 - tissue deterioration in, 273–274, 277–278, 278f
 - treatment of, 280–281
- Circulatory system, 4–5, 4f
- Circus movement, 149–150, 149f, 152
 - after myocardial infarction, 251
- Cirrhosis, 838
 - edema in, 298, 377–378, 833
- Citrate
 - as anticoagulant, 456, 460
 - phosphofructokinase inhibition by, 815
 - vasodilation caused by, 200
- Citric acid, in seminal vesicles, 976
- Citric acid cycle, 22, 813–814, 813f, 815
 - acetoacetic acid and, 823
 - amino acid degradation products in, 835
 - fatty acid oxidation and, 822–823
 - fatty acid synthesis and, 825
 - with excess glucose, 943
- Clathrin, 18–19, 18f
 - at neuromuscular junction, 86
- Clearance methods, renal, 340–343, 340t, 341f, 342f, 343t
- Climacteric, male, 984
- Climbing fibers, 684, 684f, 685, 686
- Clonus, 660, 660f
- Clostridial infections, hyperbaric oxygen therapy for, 540
- Clot dissolution or fibrous organization, 453
- Clot formation, 452, 452f, 454. *See also* Blood coagulation.
 - outside the body, 460
- Clot lysis, 457
- Clot retraction, 452, 452f, 454
 - thrombocytopenia and, 458
- Clotting factors, 452, 452t, 453
 - deficiencies of, 457–458
 - initiation of coagulation and, 454–456, 455f, 456f
- Clotting time, 460
- CNS. *See* Central nervous system (CNS).
- Coagulation. *See* Blood coagulation.
- Coated pits, 18–19, 18f
 - adrenocortical hormone synthesis and, 922
 - at neuromuscular junction, 86
- Cobalamin. *See* Vitamin B₁₂.
- Cocaine- and amphetamine-related transcript, 846, 847f
- Cochlea. *See* Hearing, cochlea in.
- Cochlear nerve, 634f, 636–637, 636f, 638
- Cochlear nuclei, 639, 639f
- Codons, 29f, 30, 31–32, 31t, 32f
- Coenzyme A. *See* Acetyl coenzyme A (acetyl-CoA).
- Colchicine, 39
- Cold environment, 877. *See also* Temperature, body.
 - acclimatization to, 873
 - thyroid-stimulating hormone and, 915
- Cold receptors, 592–593, 592f. *See also* Thermoreceptive senses.
- Cold-sensitive neurons, 871
- Colitis, ulcerative, 771, 802–803

- Collagen
 ascorbic acid and, 855
 of bone, 957, 958
 digestion of, 791
 of lungs, 467
 of sarcolemma, 71
 of teeth, 970
- Collagen fiber bundles, 180, 180f, 181
- Collateral circulation, 198
 in heart, 249, 249f
- Collecting duct, 306, 306f, 307f
 transport properties of, 333–334, 333f
 urine concentration and, 348t, 350, 350f, 352f, 353
- Collecting tubule, 306, 306f, 332–333, 332f, 333f
 aldosterone and, 337
 urine concentration and, 346, 346f, 348t, 352f, 353
- Colloid, of thyroid gland, 907, 907f; 908, 909
- Colloid goiter, 917
- Colloid osmotic pressure. *See also* Osmotic pressure
 interstitial fluid, 181, 181f, 184, 184t, 185t
 in lungs, 481, 482t
 lymph flow and, 188, 189
 plasma, 181, 181f, 184, 184t, 185t
 albumin and, 184, 184t, 833
 lymph flow and, 188
 plasma substitutes and, 281
 reabsorption in kidney and, 335–337, 335f, 336t, 337f
- Colon. *See* Large intestine (colon).
- Colonoileal reflex, 757
- Colony-forming unit (CFU), 414f, 415
- Color blindness, 616, 616f
- Color blobs, 625, 625f
- Color vision, 615–616, 615f, 616f
 dorsal lateral geniculate nucleus and, 624
 ganglion cells in, 619, 620–621
 pigments in, 609, 614, 614f
 visual cortex and, 624f, 625, 625f, 626, 627
 white light and, 616
- Colostrum, 1014
- Coma
 hepatic, 835
 vs. sleep, 721
- Committed stem cells, 414, 415, 423–424
- Compensatory pause, 146
- Complement system, 433, 438–439, 439f
 opsonization and, 425
- Complete atrioventricular block, 145, 145f
- Complete protein, 835
- Complex cells, of visual cortex, 626, 627
- Complex spike, 684
- Compliance, pulmonary
 of lungs, 467, 467f
 of lungs plus thorax, 468
- Compliance, vascular. *See* Vascular compliance.
- Conceptus, 1005
- Concussion, brain edema secondary to, 749
- Conductance of blood vessels, 163
 in parallel circuit, 164
- Conduction system. *See* Heart, excitatory and conductive system of
- Conductive heat loss, 869, 869f
 clothing and, 869–870
 in water, 869
- Cones, 609
 of central fovea, 619
 color blindness and, 616
 dark adaptation by, 614–615
 electrotonic conduction in, 617–618
 neural circuitry and, 616–617, 617f
 pathway to ganglion cells, 617, 617f
 neurotransmitter released by, 617
 number of, 619
- Cones (*Continued*)
 photochemistry of, 611, 613, 613f, 614, 614f
 spectral sensitivities of, 615, 615f
 structure of, 609, 610f
- Congenital heart disease. *See also* Patent ductus arteriosus
 axis deviation in, 135–136, 136f
 cardiac hypertrophy in, 272
 causes of, 271
 circulatory dynamics in, 269–271, 270f, 271f
 valvular, 267
- Conn syndrome. *See* Aldosteronism, primary
- Connecting tubule, 306, 306f
- Consciousness, 706
- Constipation, 802
- Constricted lung diseases, 516, 516f
- Constrictor waves, gastric, 766
- Contact junctions, of smooth muscle, 95
- Contact lenses, 604
- Contraception
 hormonal, 1001
 rhythm method of, 1001
- Contractility, cardiac. *See* Cardiac muscle, contractile strength of.
- Contrecoup injury, 746
- Control systems of body, 6–9. *See also* Feedback; Homeostasis.
 adaptive, 9
 for arterial blood pressure, 6, 7–8. *See also* Arterial blood pressure control.
 for extracellular fluid characteristics, 7
 carbon dioxide concentration, 6, 7
 oxygen concentration, 6
 gain of, 7–8
- Convective heat loss, 869, 869f
 clothing and, 869–870
 in water, 869
 wind and, 869
- Convergence, in neuronal pathways, 566, 566f
- Converting enzyme, 220–221, 220f
- COPD (chronic obstructive pulmonary disease), ventilation-perfusion abnormalities in, 494
- Cord righting reflex, 664
- Cordotomy, 586
- Corona radiata, 989f, 990, 1003, 1004f
- Coronary arteries, 246, 246f
 acute occlusion of, 248–249. *See also* Myocardial infarction.
 causes of death after, 250–251
 collateral circulation and, 249, 251, 256
 arrangement within cardiac muscle, 247, 247f
 collateral circulation involving, 249, 249f
- Coronary artery bypass surgery, 252, 259
- Coronary artery disease, 246, 248–250
 catheter-based treatment of, 253, 259
 pain in, 252. *See also* Angina pectoris.
- Coronary artery spasm, 249
- Coronary blood flow
 control of, 247–248
 adenosine in, 193
 epicardial vs. subendocardial, 247, 247f
 during exercise, 246
 in hypovolemic shock, 274–275, 276
 phasic changes in, 246, 246f
 at rest, 246
- Coronary blood supply, 246, 246f
- Coronary embolus, 248–249
- Coronary steal, 251–252
- Coronary thrombosis, 248–249
 collateral development following, 198
 spasm leading to, 249
- Coronary venous blood flow, 246
- Corpus albicans, 991
- Corpus callosum, 702, 705
- Corpus luteum, 989f, 990–991
 inhibin secreted by, 991, 997
 in pregnancy, 1008
 relaxin secreted by, 1009
- Cortical level of nervous system, 545–546
- Cortical nephrons, 306, 307f
- Corticofugal signals, 581–582
 from primary visual cortex, 624
- Corticopontocerebellar tract, 682, 687
- Corticorubral tract, 670–671, 671f
- Corticospinal (pyramidal) tract, 655f, 656, 669–670, 670f
 cerebellum and, 687, 687f
 corticorubrospinal pathway and, 670–671
 lesions in, 673
- Corticosteroids. *See* Adrenocortical hormones.
- Corticosterone
 activity of, 928
 properties of, 922, 924t
 synthesis of, 922, 923f
- Corticotropes, 896, 896t, 897, 933–934
- Corticotropin. *See* Adrenocorticotrophic hormone (ACTH; corticotropin)
- Corticotropin-releasing factor (CRF). *See* Corticotropin-releasing hormone (CRH).
- Corticotropin-releasing hormone (CRH), 898, 898t, 931–932
 appetite suppression by, 849
- Cortisol, 921
 anti-inflammatory effects of, 930–931
 in allergic reactions, 931
 carbohydrate metabolism and, 928
 chemical formula of, 922, 923f
 circadian rhythm of secretion, 933, 933f
 concentration in blood, 924
 deficiency of, 934
 excess of, 935–936
 fat metabolism and, 929
 gluconeogenesis and, 817
 insulin secretion and, 947
 lymphocytopenia caused by, 931
 mechanism of action, 931
 mineralocorticoid activity of, 924–925
 plasma protein binding of, 923
 properties of, 922, 924t
 protein metabolism and, 928–929
 regulation of, by ACTH, 931–934, 932f
 stress and, 929, 930, 930f
 synthesis of, 922, 923f
- Cortisol-binding globulin, 923
- Cortisone, 922, 924t
- Co-transport, 54–55, 55f. *See also* Sodium co-transport.
 renal tubular, 325–326, 326f
- Cough reflex, 473, 512
- Coumarins, 459–460
- Counter-transport, 54, 55, 55f
 renal tubular, 326, 326f
- Coup injury, 746
- Coupled chemical reactions, 809
- Cowper glands. *See* Bulbourethral glands.
- CPR (cardiopulmonary resuscitation), 151, 153
- Cramp, muscle, 665
- Cramping pain, visceral, 588–589
- Creatine phosphate. *See* Phosphocreatine.
- Creatinine
 chronic renal failure and, 406
 excretion of, 329
 with reduced GFR, 404, 405f
 placental diffusion of, 1007
 plasma concentration of, 341, 341f, 342f
 with reduced GFR, 404, 405f
- Creatinine clearance, 341
- Cretinism, 918, 1026
- CRF (corticotropin-releasing factor). *See* Corticotropin-releasing hormone (CRH).

- CRH (corticotropin-releasing hormone), 898, 898*t*, 931–932
 appetite suppression by, 849
 Cribriform plate, 651
 Crisis, febrile, 876, 876*f*
 Crista ampullaris, 675*f*, 676, 676*f*, 677
 Critical closing pressure, 166, 166*f*
 Crossed extensor reflex, 663, 663*f*
 Crown, of tooth, 969, 969*f*
 Cryptorchidism, 977–978
 Crypts of Lieberkühn, 773, 786–787, 786*f*
 of large intestine, 787
 extreme diarrhea and, 796, 802
 CSF. *See* Cerebrospinal fluid (CSF).
 Cupula, 676, 676*f*, 677
 Curare, 85
 Curariform drugs, 86
 Current of injury, 138–141
 fibrillation tendency and, 250–251
 J point and, 138–140, 139*f*
 myocardial ischemia or infarction and, 138, 140–141, 140*f*, 141*f*
 QRS complex and, 138, 139*f*
 Cushing disease, 935
 Cushing reaction, 209
 Cushing syndrome, 935–936, 935*f*
 diabetes mellitus in, 952
 ketosis in, 825
 osteoporosis in, 969
 Cyanide poisoning, 521
 Cyanosis, 521–522
 Cyclic adenosine monophosphate (cAMP).
See also Adenylyl cyclase.
 ACTH and, 932
 adrenergic or cholinergic receptors
 and, 733
 aldosterone and, 927
 antidiuretic hormone and, 905
 chloride channels and, 796
 glucagon and, 948
 gonadotropic hormones and, 983, 988–989
 growth hormone and, 902
 hormonal activity and, 889–890, 889*b*, 890*f*
 hormone secretion and, 882
 memory and, 707–708
 in olfactory cilium, 649, 649*f*
 parathyroid hormone and, 964–965
 phosphorylase activation and, 36, 812
 in postsynaptic neuron, 549, 549*f*
 as second messenger, 888
 in smooth muscle, 97
 thyroid hormone and, 914
 Cyclic guanosine monophosphate (cGMP)
 nitric oxide and, 195, 196
 penile erection and, 978–979
 phosphodiesterase-5 inhibitors and,
 196, 986
 photoreceptor sodium channels and,
 612–613, 612*f*, 613–614, 613*f*
 in postsynaptic neuron, 549, 549*f*
 in smooth muscle, 97
 Cyclosporine, for immunosuppression, in
 transplantation, 449
 Cystic duct, 783–784
 Cystinuria, essential, 408
 Cystitis, 403–404
 Cystometrogram, 309, 309*f*
 Cytochrome oxidase, 814
 cyanide poisoning and, 521
 Cytochromes, of electron transport chain, 814
 Cytokines, 881
 enzyme-linked receptors for, 888
 fever and, 875–876
 Cytosine, 27, 28, 28*f*, 30, 31*t*
 Cytoskeleton, 11, 16–17, 17*f*
 Cytosol, 14
 Cytotoxic T cells, 440, 441, 441*f*
- D**
 DAG (diacylglycerol), 890
 Dark adaptation curve, 614–615, 614*f*
 Dead space
 anatomical, 471–472
 physiologic, 471–472, 493, 494
 Dead space air, expired air and, 489, 489*f*
 Dead space volume, 471, 471*f*
 Deafness, 642, 642*f*
 Deamination of amino acids, 834–835, 839
 Decarboxylases, 814
 Decerebrate rigidity, 674
 Decibel unit, 638–639, 638*f*
 Decidua, 1005
 Decidual cells, 1005, 1008
 Declarative memory, 706
 Decompression sickness, 537, 538–539, 538*f*
 Decremental conduction, 556, 556*f*
 Deep cerebellar nuclei, 683–684, 684*f*, 685, 688
 lesions of, 689
 Deep nuclear cells, 684–685, 684*f*, 687
 Deep receptors, 560*b*, 580
 Deep sensations, 571
 Deep-sea diving, 535–540
 decompression after, 537–539
 depth of
 gas volume vs., 535
 pressure vs., 535, 536*f*
 high partial pressures in, 535–539
 of carbon dioxide, 537
 of nitrogen, 535
 of oxygen, 499, 535–537, 536*f*
 with SCUBA apparatus, 539, 539*f*
 Defecation, 771–772
 parasympathetic stimulation and, 787
 Defecation reflexes, 771–772, 771*f*, 803
 parasympathetic, 738, 757, 771, 771*f*
 spinal, 757
 Defibrillation
 atrial, 152
 ventricular, 151, 151*f*
 in cardiopulmonary resuscitation, 151
 Deglutition. *See* Swallowing.
 Dehydration
 aldosterone secretion in, 795
 in diabetes mellitus, 950
 diarrhea with, 796
 hyponatremia caused by, 295, 295*t*
 in hyponatremia, 294–295, 295*t*
 hypovolemic shock in, 279
 fluid therapy for, 280
 in neonate, 1024
 Dehydroepiandrosterone (DHEA), 922, 923*f*,
 924*t*, 934, 980
 placental estrogen synthesis from, 1008
 Dehydrogenases, 813, 814, 815
 Deiodinase, 909
 deficiency of, 917
 Delayed compliance of vessels, 168, 168*f*
 Delayed-reaction allergy, 443
 Delta waves, 723*f*, 724–725, 725*f*
 Dementia, 726
 in Alzheimer's disease, 727–728
 cerebrovascular disease and, 728
 in Huntington's disease, 694
 Demyelination
 osmotic-mediated, 295
 in vitamin B₁₂ deficiency, 854
 Dendrites, 543, 544*f*, 547, 547*f*
 excitation and inhibition transmitted by,
 555–556, 556*f*
 Dendritic cells, 440
 Denervation, of skeletal muscle, 82
 Denervation supersensitivity, 737, 737*f*
 Dense bars, of neuromuscular junction, 83, 84*f*
 Dense bodies, of smooth muscle, 92, 92*f*
 Dental lamina, 970–971
 Dentate nucleus, 683, 684, 684*f*, 688
 lesions of, 689
 Dentin, 969, 969*f*, 970
 caries and, 971
 development of, 970, 970*f*
 mineral exchange in, 971
 Dentinal tubules, 970
 Deoxycorticosterone, 922, 923*f*, 924*t*
 Deoxyribonucleic acid. *See* DNA
 (deoxyribonucleic acid).
 Deoxyribose, 27, 28*f*
 Depolarization, of action potential, 61, 61*f*,
 64–65
 calcium channels and, 64
 Depolarization waves, 121–123, 122*f*. *See also*
 P wave; QRS complex.
 current flow in chest and, 124, 124*f*
 slow conduction of, T wave and, 142
 L-Deprenyl, 693
 Depression, mental, 726–727
 Depth of focus, 602, 602*f*
 Depth perception, 605, 605*f*, 630
 Dermatomes, 582, 582*f*
 Desmopressin, 354–355
 Detoxification, enzymes for, 20
 Detrusor muscle, 306–308, 307*f*, 309
 micturition reflex and, 309
 parasympathetic fibers to, 308
 Deuteranope, 616
 Dexamethasone, 922–923, 924*t*
 Dexamethasone suppression test, 935
 Dextran solution, 281
 α-Dextrinase, 790
 DHEA. *See* Dehydroepiandrosterone
 (DHEA).
 Diabetes insipidus, 295
 central, 354
 nephrogenic, 354–355, 408
 Diabetes mellitus, 939, 950–954
 acidosis in, 393
 arteriosclerosis and, 953
 atherosclerosis and, 829
 brain metabolism in, 749–750
 diagnosis of, 952–953, 953*f*
 end-stage renal disease caused by,
 402, 403
 fatty acids in blood in, 821
 gigantism with, 903
 glomerular filtration rate in, 321
 hyperkalemia in, 361
 ketosis in, 823
 maternal, 1026
 metabolic utilization of nutrients in, 845
 triglycerides in liver in, 822
 type I, 950–951
 C peptide in, 940
 clinical characteristics of, 952*t*
 fetal morbidity in mothers with, 1026
 treatment of, 953
 type II, 950, 951–952
 clinical characteristics of, 952*t*
 large babies of mothers with, 1026
 treatment of, 953
 urinary glucose excretion in, 327
 urine output in, 397
 Diacylglycerol (DAG), 890
 Dialysis, renal, 409–410, 409*f*
 hypertension associated with, 219
 Dialyzing fluid, 409–410, 410*t*
 Diapedesis, 415
 by lymphocytes, 425
 by monocytes, 425
 by neutrophils, 424*f*, 425, 428, 429*f*
 Diarrhea, 802–803
 calcium loss in, 966
 hyponatremia caused by, 294–295
 intestinal absorption capacity and, 797–798

- Diarrhea (*Continued*)
 metabolic acidosis caused by, 392
 psychogenic, 802
 as response to irritation, 787
 severe, 796, 797–798
- Diastole, 105, 105*f*
 duration of, heart rate and, 105
 filling of ventricles during, 105*f*, 106
- Diastolic blood pressure, 158, 168
 age-related increase in, 171, 171*f*
 measurement of, 170–171, 170*f*
- Diastolic pressure curve, 108, 108*f*
- Dicer enzyme, 32–33, 33*f*
- Diet. *See* Food intake.
- Differentiation, cellular, 39–40
- Differentiation inducers, of hematopoietic stem cells, 415
- Diffuse junctions, of smooth muscle, 94–95
- Diffusing capacity, 491–492, 492*f*
 at high altitude, 529
- Diffusion
 of gases. *See also* Carbon dioxide, diffusion of; Oxygen, diffusion of.
 physics of, 485–487, 486*f*
 through respiratory membrane, 485, 486, 487, 489–492, 492*f*
 as molecular and ionic motion, 46
 osmosis and, 290
- Diffusion across capillary walls, 4–5, 4*f*, 179–180, 179*f*
 concentration difference and, 180
 molecular size and, 179–180, 180*t*
- Diffusion coefficient of a gas, 487, 487*t*
 respiratory membrane and, 490–491
- Diffusion potential, 57–58, 57*f*
 resting membrane potential and, 60, 60*f*
- Diffusion through cell membrane, 18, 45, 46–47, 46*f*. *See also* Ion channels; Protein channels.
 vs. active transport, 45–46
 facilitated, 46, 46*f*, 49–50, 49*f*
 in glucose reabsorption, 326, 326*f*
 in sodium reabsorption, 325
 in pores and channels, 46–48, 46*f*, 47*f*, 48*f*, 49*f*
 rate of, 49, 49*f*
 factors affecting, 50–51, 50*f*
 simple, 46, 46*f*
 vs. facilitated diffusion, 49, 49*f*
 of water, 46, 47, 51–52, 51*f*
- Diffusion through interstitium, 180–181
- Diffusion through respiratory membrane, 485, 486, 487, 489–492, 492*f*.
See also Carbon dioxide, diffusion of; Oxygen, diffusion of.
- Digestion, 789–793
 of carbohydrates, 789–790, 790*f*
 pancreatic enzyme for, 781, 790
 of fats, 789, 791–793, 791*f*
 of proteins, 789, 790–791, 791*f*
 enterogastric reflexes and, 767, 768
 pancreatic enzymes in, 781, 791
- Digestive enzymes, 773
 gastric. *See* Pepsin.
 intestinal, 787, 790
 pancreatic, 780–781
 carbohydrates and, 781, 790
 cholecystokinin and, 783
 fats and, 781, 792–793, 792*f*
 loss of, 801
 optimal pH for, 783
 phases of secretion, 782
 proteins and, 781, 791, 791*f*
 regulation of, 782–783, 783*f*
 salivary, 774*f*, 775, 790
- Digestive vesicle, 19, 19*f*, 426
- Digitalis
 in cardiogenic shock, 259
 diuresis caused by, 263
 in heart failure, 258
 with acute pulmonary edema, 261
 decompensated, 263, 263*f*
 ventricular tachycardia caused by, 149
- Digitalis toxicity, T-wave changes in, 142, 142*f*
- Dihydropyridine receptors, 88, 88*f*
- Dihydrotestosterone, 979, 980, 982–983
 chemical structure of, 980*f*
- Diisopropyl fluorophosphate, 86
- Diopeters, 600, 600*f*
- Dipeptidases, 791
- Disaccharides
 dietary sources of, 789–790
 digestion of, 787, 789, 790, 790*f*
- Discharge zone, 565–566, 565*f*
- Disse, spaces of, 837, 837*f*, 838
- Disseminated intravascular coagulation, 459
 in septic shock, 280
- Dissociation constant, 381
- Distal tubule, 306, 306*f*. *See also* Macula densa.
 calcium reabsorption in, 368–369
 diluting segment of, 331
 potassium secretion by, 364, 366, 366*f*
 transport properties of, 331–333, 332*f*, 333*f*
 urine concentration and, 346, 346*f*, 348*t*, 350, 350*f*, 352*f*, 353
- Distensibility, vascular, 167–168, 168*f*. *See also* Vascular compliance.
- Diuretics, 397–399, 398*f*, 398*t*
 for essential hypertension, 226
 in heart failure, 258
 with acute pulmonary edema, 261
 hyponatremia caused by, 294–295
 metabolic alkalosis caused by, 393
- Divergence, in neuronal pathways, 566, 566*f*
- Diving. *See* Deep-sea diving.
- DNA (deoxyribonucleic acid), 27, 27*f*. *See also* Transcription.
 methylation of, 36
 mitochondrial, 16
 nuclear location of, 17, 17*f*
 replication of, 37–38
 structure of, 27–29, 28*f*, 29*f*
 viral, 18
- DNA ligase, 37–38
- DNA polymerase, 37–38
- DNA proofreading, 37–38
- DNA repair, 37–38
- Dominant hemisphere, 701–702
 corpus callosum and, 705
- Donnan effect, 184, 287
- L-Dopa, 693, 727
- Dopamine
 in basal ganglia, 692–693, 692*f*
 Parkinson's disease and, 693
 as central nervous system transmitter, 551
 in norepinephrine synthesis, 732
 prolactin secretion and, 1015
 schizophrenia and, 727
- Dopamine system, in brain, 712, 713, 713*f*
- Doppler flowmeter, 160–161, 161*f*
- Dorsal column–medial lemniscal system, 573–580
 anatomy of, 573–574, 573*f*, 574*f*, 575*f*
 overview of, 573
 position sense and, 580
 rapidly changing sensations in, 579
 signal transmission and analysis in, 577–579, 578*f*
 spatial orientation of fibers in, 574
 types of sensations in, 573
- Dorsal lateral geniculate nucleus, 623–624, 623*f*
- Dorsal respiratory group, 505–506, 506*f*
- Down syndrome, Alzheimer's disease characteristics in, 728
- Dreaming, 712–713, 721
- Drinking, threshold for, 358
- Dropped beads, 145, 145*f*
- Ductus arteriosus, 269–270, 270*f*, 1022, 1022*f*.
See also Patent ductus arteriosus.
 closure of, 270, 1023
- Ductus venosus, 1022, 1022*f*, 1023
- Duodenocolic reflex, 771
- Duodenum. *See also* Small intestine.
 mucus secreted in, 786
 peptic ulcer of, 800, 800*f*, 801
 stomach emptying and, 767–768
- Dural sinuses, negative pressure in, 173
- Dwarfism, 902–903
- Dynamic proprioception, 580
- Dynein, of cilia, 25
- Dynorphin, 587
- Dysarthria, 689
- Dysbarism. *See* Decompression sickness.
- Dysdiadochokinesia, 689
- Dyslexia, 701, 703
- Dysmetria, 689
- Dyspnea, 522
- E**
- Ear. *See* Hearing.
- ECG. *See* Electrocardiogram (ECG).
- Echocardiography, cardiac output estimated by, 240
- Eclampsia, 1011
- Ectopic beat. *See* Premature contractions.
- Ectopic foci, causes of, 146
- Ectoplasm, 16
- Eddy currents, 161
- Edema, 296–300
 capillary filtration and, 185–186
 cerebral. *See* Brain edema.
 extracellular, 297
 in cirrhosis, 298
 excess fluid and, 373, 373*f*
 general causes of, 297
 in heart failure, 298
 in kidney disease, 298
 plasma protein decrease with, 298
 safety factors preventing, 298–300, 299*f*, 373
 specific causes of, 297–298
 generalized, in renal failure, 406
 histamine-induced, 199–200
 hypoproteinemic, in neonate, 1027
 hypoxia associated with, 521
 interstitial fluid pressure and, 189
 interstitial free fluid in, 181, 299
 intracellular, 296
 myxedema, 917–918, 918*f*
 in nephrotic syndrome, 377
 nonpitting, 299
 of optic disc, 748
 pitting, 299
 in potential spaces, 300
- Edinger-Westphal nucleus, 631, 631*f*, 632
- EEG. *See* Electroencephalogram (EEG).
- Effectors, 543
- Efference copy, 683, 687
- Efferent arteriole(s), renal, 304–305, 305*f*, 306, 307*f*, 311*f*
 angiotensin II and, 338, 339
 glomerular filtration rate and, 315, 316, 316*f*
 physiologic control of, 317–318
 reabsorption rate and, 336
 tubuloglomerular feedback and, 320, 320*f*
- Efficiency, of cardiac contraction, 110
- Effusion, 300
- Einthoven's law, 125
- Einthoven's triangle, 125, 125*f*

- Ejaculation, 979
 as sympathetic function, 738, 979
- Ejaculatory duct, 973, 973f, 976
- Ejection, period of, 105f, 106, 108, 108f, 109f
- Ejection fraction, 106
- Elastase, 791
- Elastic recoil, 465
- Elastin, of lungs, 467
- Electric shock
 defibrillation with
 atrial, 152
 ventricular, 151, 151f
 fibrillation caused by, 150, 150f
- Electrical alternans, 145–146, 145f
- Electrical synapses, 546
- Electrocardiogram (ECG)
 in angina pectoris, 141
 atrial contraction and, 122
 in atrial fibrillation, 152, 152f
 in atrial flutter, 152–153, 153f
 in atrioventricular block
 first-degree, 144–145, 144f
 second-degree, 145, 145f
 third-degree (complete), 145, 145f
 in bundle branch block, 136–137, 136f, 137f, 138
 T wave and, 142
 cardiac cycle and, 105, 105f
 current flows and, 123–124, 124f
 in electrical alternans, 145–146, 145f
 high-voltage, 135f, 136f, 137
 premature ventricular contractions with, 146–147
 leads used for, 124–127, 125f, 126f. *See also* Bipolar limb leads.
 axes of, 130, 130f
 in long QT syndrome, 147, 148f
 low-voltage, 137, 137f
 in myocardial ischemia or infarction
 current of injury and, 140–141, 140f, 141f
 in mild ischemia, 142, 142f
 normal, 121–123, 121f
 vectorial analysis of, 131–134, 132f, 133f
 normal voltages in, 123
 in paroxysmal tachycardia
 atrial, 148, 148f
 ventricular, 148–149, 149f
 in partial intraventricular block, 145–146, 145f
 position of heart in chest and, 135
 with premature contractions
 atrial, 146, 146f
 A-V nodal or A-V bundle, 146, 146f
 ventricular, 146–147, 147f
 QRS prolongation in, 137–138, 141
 QRS with bizarre patterns in, 138, 141
 recording methods for, 123
 in sinoatrial nodal block, 144, 144f
 in sinus bradycardia, 143f
 in sinus tachycardia, 143, 143f
 torsades de pointes in, 147, 148f
 vectorial analysis of, 129–142
 atrial T wave in, 133–134, 133f
 axes in, 130, 130f
 axis deviation in, 135–137
 current of injury in, 138–141, 139f, 140f, 141f
 direction of vector in, 129, 130f
 instantaneous mean vector in, 129, 129f
 mean electrical axis in, 134–137, 135f
 of normal ECG, 131–134, 132f, 133f
 P wave in, 133–134, 133f
 of potentials in each lead, 130–131, 130f, 131f
 with premature ventricular contractions, 147, 147f
 principles of, 129–131
- Electrocardiogram (ECG), vectorial analysis of (*Continued*)
 projected vector in, 130, 130f, 131, 131f
 QRS complex in, 131–132, 132f
 T wave in, 133, 133f
 vectorcardiogram in, 134, 134f
 ventricular contraction and, 122–123
 in ventricular fibrillation, 150–151, 151f
 in ventricular hypertrophy, 135–136, 135f, 136f, 137–138
 voltage abnormalities in, 136f, 137, 137f
 voltage and time calibration of, 123
- Electroconvulsive therapy, 727
- Electroencephalogram (EEG), 723, 724
 epilepsy and, 725, 725f, 726
 frequencies of waves in, 723, 724–725, 724f
 normal types of waves in, 723f, 724
 in sleep and wakefulness, 723, 724, 725, 725f
 voltages in, 723, 724–725
- Electrolytes. *See also specific electrolytes.*
 in gastrointestinal secretions, 774–775
 in large intestine, 797–798
 diarrhea and, 797, 802
 renal regulation of, 303, 304f, 311–312
 in stomach contents, 768
- Electromagnetic flowmeter, 160, 160f
 for cardiac output measurement, 240, 240f
- Electromagnetic receptors, 559, 560b
- Electron transport chain, 814–815, 814f
- Electrotonic conduction, 555, 556, 556f
 in retinal neurons, 617–618
- ELISA (enzyme-linked immunosorbent assay), 892, 892f
- Emboli, 459
- Embryo. *See also* Fetus; Implantation.
 ameboid movement by cells of, 24
 cell differentiation in, 40
 early nutrition of, 995, 1005, 1008
- Emission, 979
- Emmetropia, 602, 602f
- Emotional arousal, thyroid-stimulating hormone and, 915
- Emotions. *See* Limbic system.
- Emphysema, pulmonary, 517–518, 518f
 low-voltage ECG associated with, 137
 respiratory surface area in, 491
 ventilation-perfusion abnormalities in, 494, 518
- Enamel, of teeth, 969–970, 969f
 development of, 970, 970f
 mineral exchange in, 971
 resistance to caries, 971
- End plate potential, 84, 85–86, 85f
- End-diastolic pressure, 108
 as preload, 109
- End-diastolic volume, 106, 108, 109f
- Endocochlear potential, 637–638
- Endocrine glands
 anatomical loci of, 881, 882f
 autonomic control of, 734t, 735
 energy from ATP for, 859
 in infancy, problems of, 1026
 overview of, 883t
 regulatory functions of, 5–6
- Endocrine hormones, 881. *See also* Hormones.
- Endocytosis, 18–19, 18f
 adrenocortical hormone synthesis and, 922
 in ameboid movement, 23, 23f
 in capillary endothelium, 178
- Endogenous pyrogen, 875–876
- Endolymph, 637–638, 676, 677
- Endometrial cycle, 995–996, 995f
- Endometriosis, infertility secondary to, 1001
- Endometrium
 estrogen and, 993
 implantation in. *See* Implantation.
 progesterone and, 994
- Endoplasmic reticulum, 12f, 14–15, 15f
 gastrointestinal secretions and, 774, 774f
 Golgi apparatus and, 15, 15f, 20–21
 of muscle fiber. *See* Sarcoplasmic reticulum.
 nuclear membrane and, 17, 17f
 platelets and, 451, 454
 ribosomes and, 14, 20, 20f, 33–34, 34f
 secretory vesicles and, 16
 specific functions of, 20, 20f
- Endoplasmic reticulum vesicles, 15, 15f, 20–21, 20f
- Endorphins, 587
 β -endorphin, 933–934, 933f
- Endostatin, 198
- Endothelial cells
 of arteries and arterioles
 nitric oxide and, 195–196, 196f
 shear stress on, 195–196
 of capillaries, 177–178, 178f
 diffusion through, 179–180
 clotting and, 452, 457, 459
 of hepatic sinusoids, 837
 of lymphatic capillaries, 187, 187f, 188–189
 platelet fusion with, 452
- Endothelial damage
 atherosclerosis and, 827–828, 828f, 829
 endothelin release in, 196
- Endothelial-derived relaxing or constricting factors, 195–196, 196f
- Endothelin, 196
 glomerular filtration rate and, 318
- Endotoxin
 in circulatory shock, 277
 clotting activated by, 459
 fever and, 875–876
- End-stage renal disease (ESRD), 401–402, 402f, 402t. *See also* Renal failure, chronic.
 dialysis for, 409–410, 409f, 410t
 hypertension associated with, 219
 transplantation for, 409
- End-systolic volume, 106, 108, 109f
- Energy abundance, insulin and, 939–940
- Energy equivalent of oxygen, 863
- Energy expenditure, 863–865. *See also* Metabolic rate.
 in cachexia, 852
 components of, 863, 863f
 for daily activities, 863
 for essential metabolic functions, 863–864, 864f
 hypothalamus and, 846, 849
 for nonshivering thermogenesis, 865
 for physical activities, 864, 864t
 for processing food, 864–865
 of pulmonary ventilation, 468
 for skeletal muscle contraction, 73, 74, 75, 76, 78–79
- Energy release
 heat as end product of, 862
 rate of, 861–862. *See also* Metabolic rate.
- Energy sources. *See* Adenosine triphosphate (ATP), as energy currency; Fats, as energy source; Food(s), energy available in; Glucose, energy production from; Protein(s), as energy source; Triglycerides, energy production from.
- Enhancers, 35f, 36
- Enkephalins, 587, 587f
 in basal ganglia, 692–693, 692f
- Enteric lipase, 792
- Enteric nervous system, 755, 756, 756f
 autonomic influences on, 735, 755, 756–757
 defecation reflex and, 771
 gallbladder emptying and, 785
 gastric pepsinogen secretion and, 779
 glandular secretions and, 773

- Enteric nervous system (*Continued*)
 neurotransmitters of, 756–757
 pancreatic secretions and, 782
 peristalsis and, 759
 reflexes in, 757
 sensory fibers and, 755, 757
 small intestine and, 769
 stomach emptying and, 767
- Enteritis, 802
- Enterochromaffin-like cells, 779
- Enterocytes. *See also* Villi, intestinal.
 of crypts, secretions of, 786–787
 digestive enzymes of, 787, 790, 791, 792
 replacement of, 787
- Enterogastric reflexes, 757, 767–768
 reverse, 780
- Enterohepatic circulation, of bile salts, 785
- Enterokinase, 781
- Enzyme-linked immunosorbent assay (ELISA), 892, 892f
- Enzymes, 11, 27
 G-protein activation of, 887, 887f
 hormone receptors linked to, 888, 888f
 membrane proteins as, 13, 14
 reaction rates and, 861–862, 862f
 regulation of, 35, 36–37
 synthetic functions of, 35
- Eosinophilic chemotactic factor, in asthma, 520
- Eosinophils, 423, 423t, 424f, 430
- Epididymis, 973, 973f
 spermatozoal maturation in, 975, 976
- Epidural space, negative pressure in, 183
- Epilepsy, 725–726, 725f. *See also* Seizures.
 neuronal circuits in, 569
- Epinephrine
 adrenal medullary secretion of, 730, 732, 736, 884, 921
 basal level of, 737
 in hypovolemic shock, 275
 adrenergic receptors and, 733
 bronchiolar dilation and, 473
 coronary blood flow and, 247, 248
 fatty acid mobilization caused by, 825
 gastrointestinal smooth muscle and, 755, 756, 757
 glomerular filtration rate and, 318
 glucose availability and, 812
 insulin secretion and, 947
 metabolic rate and, 867
 phosphorylase activation by, 812
 for shock, 281
 sweat glands and, 870
 as sympathomimetic drug, 739
 synthesis of, 732, 884
 thermogenesis and, 873
 as vasoconstrictor, 199, 204
 in skeletal muscle, 244
 vasodilation in skeletal muscles and, 204, 244
- Eplerenone, 332, 333f, 399
- Equilibrium. *See also* Posture; Vestibular apparatus.
 cerebellum and, 686–687
 exteroceptive information and, 678
 footpad pressure and, 678
 neck proprioceptors and, 678
 sensation of, 571
 static, 676–677
 visual information and, 678
- Erectile dysfunction, 985–986
 phosphodiesterase-5 inhibitors for, 196
- Erection
 female, 1000
 penile, 196, 738, 978–979, 979f
- Erythroblastosis fetalis, 415f, 420, 447–448, 1024
- Erythroblasts, 415f, 420. *See also* Proerythroblasts.
- Erythrocytes. *See* Red blood cells (erythrocytes).
- Erythropoietin, 304, 416–417, 416f
 kidney disease and, 304, 406, 416
- Esophageal reflux, 765
- Esophageal secretions, 776–777
- Esophageal sphincter
 lower, 765
 upper, 764
- Esophagus
 achalasia of, 799
 ulcer of, 800
- ESRD. *See* End-stage renal disease (ESRD).
- β-Estradiol, 991–992, 992f
 hepatic degradation of, 993
- Estriol, 991–992, 992f, 993
- Estrogen(s), 987, 988f, 991
 breast development and, 994, 1014
 chemistry of, 991–992, 992f, 993f
 in contraceptive drugs, 1001
 excretion of, 993
 fat deposition and, 994, 1031
 functions of, 993–994
 gonadotropin inhibition by, 997, 998
 hepatic degradation of, 993
 hypersecretion of, 999–1000
 life cycle variations in, 999, 999f
 in luteal phase, 991
 in male, 980
 menstrual cycle and, 995
 osteoporosis and, 969
 in ovarian follicles, 989, 990
 plasma protein binding of, 993
 in pregnancy, 1007f, 1008
 preovulatory surge of luteinizing hormone and, 997–998
 protein deposition in tissues and, 836
 spermatogenesis and, 975
 synthesis of
 in adrenal cortex, 922
 in ovaries, 992, 992f, 993f
 uterine contractility and, 1011–1012
- Estrone, 991–992, 992f, 993
- Ethacrynic acid, 397
- Eunuchism, 985
 female, 999
- Evans blue dye, 290
- Evaporative heat loss, 869, 869f. *See also* Sweating.
 hypothalamic control of, 872, 872f
 by panting, 871
 at very high air temperatures, 869
- Excitation-contraction coupling
 in cardiac muscle, 103–104, 104f
 in skeletal muscle, 87, 88–89, 88f, 89f
- Excitatory postsynaptic potential, 553, 553f, 554, 554f
 dendrites and, 556
 summation of, 553, 554f, 555
- Excitatory presynaptic terminals, 547
- Excitatory receptors, 547, 549–550
- Excitatory stimulus, 565
 reciprocal inhibition and, 566–567, 567f
- Excitatory transmitter, 548
- Excited zone, 565–566, 565f
- Excretion rate, calculation of, 340t
- Exercise. *See also* Sports physiology.
 anaerobic glycolysis in, 860–861
 arterial pressure increase in, 205, 210, 232, 232f
 blood flow control to skeletal muscle and, 191, 195, 196–197, 198, 243–244
 cardiac output during, 210, 230, 230f, 232, 244, 245, 245f
 athletic training and, 1038, 1038f, 1039, 1039f
 circulatory readjustments in, 244–245
 coronary blood flow during, 246
- Exercise (*Continued*)
 energy expenditure in, 864, 864t
 fat utilization in, 825
 gastrointestinal vasoconstriction during, 762
 glucagon secretion and, 948–949
 growth hormone secretion and, 901, 902
 hyperkalemia caused by, 362
 lactic acid produced in, for cardiac energy, 816
 life-prolonging effect of, 1041
 lymphatic pump during, 188
 obesity and, 850, 851
 oxygen debt in, 861
 oxygen diffusing capacity during, 491
 oxygen transport during, 498–499, 499f
 oxygen uptake by blood during, 495–496
 oxygen-hemoglobin dissociation curve and, 500
 pulmonary regulation and, 480, 481f
 respiratory regulation during, 510–511, 510f, 511f
 sweat glands and, 870
 valvular heart lesions and, 269
- Exercise testing, of cardiac reserve, 261–262
- Exocytosis, 19, 21
 in amoeboid movement, 23, 23f
 of catecholamines, 884
 of gastrointestinal secretions, 774
 of peptide hormones, 882
 of protein hormones, 882
- Exophthalmos, in hyperthyroidism, 916, 916f
- Expanded tip tactile receptors, 560f, 572
- Expiratory compliance curve, 467, 467f
- Expiratory reserve volume, 469, 469f
- Expired air, 487t, 489, 489f
- External work, cardiac, 108–109, 108f, 109f
- Exteroreceptive sensations, 571, 678
- Extracellular fluid, 3–4, 286, 286f, 287. *See also* Interstitial fluid; Plasma.
 calcium in. *See* Calcium, in extracellular fluid and plasma.
 in chronic renal failure, 406, 406f
 composition of, 7, 7t, 45, 45f, 287, 288f, 288t
 distribution between interstitium and blood, 373, 373f
 as internal environment, 3, 9
 intracellular fluid and, 3–4
 exchange between compartments, 290
 osmotic equilibrium of, 291–292, 292f
 mixing of, 4–5
 nutrients in, origins of, 5
 osmolality of, 52
 osmolarity of. *See* Extracellular fluid osmolarity.
 pH of, 7, 7t, 380t. *See also* Acid-base regulation.
 potassium concentration in, 364, 364f, 365f, 366f
 regulation of, 7
 carbon dioxide concentration, 6, 7
 oxygen concentration, 6
 sodium in. *See* Sodium, extracellular fluid.
 transport through body, 4–5, 4f
 volume of. *See* Extracellular fluid volume.
- Extracellular fluid osmolarity. *See also* Plasma, osmolarity of.
 in abnormal states, 292–294, 293f, 293t, 294t
 glucose and, 950
 potassium distribution and, 362
 regulation of, 345, 355
 angiotensin II and aldosterone in, 359–360, 359f
 by osmoreceptor-ADH system, 345, 355–357, 355f, 356f, 357f, 358–359, 360, 905
 by thirst, 357–360, 358t, 359f

- Extracellular fluid volume. *See also* Blood volume.
 in abnormal states, 292–294, 293*f*, 293*t*, 294*t*
 aldosterone and, 925, 925*f*
 antidiuretic hormone and, 375–376
 arterial blood pressure and, 217, 217*f*
 angiotensin II and, 221, 374–375
 conditions causing large increases in, 376–378
 depletion of, alkalosis secondary to, 390
 diuretics and, 397, 398*f*
 hypertension and, 218, 219, 220*f*
 measurement of, 289, 289*t*
 regulation of, 370–371
 by renal–body fluid system, 371–373, 372*f*
 salt and, 217–218
 salt appetite and, 360
 testosterone and, 982
 thirst and, 358
- Extracorporeal circulation, in cardiac surgery, 271–272
- Extrapyramidal system, 671
- Extrasystole. *See* Premature contractions.
- Extrinsic pathway of coagulation, 454–455, 455*f*, 456
- Eye movements, 627
 fixation movements, 628–630, 629*f*, 678
 muscular control of, 627–628, 628*f*
 neural pathways for, 628, 628*f*
 vestibular apparatus and, 677
 voluntary, premotor cortex and, 669
- Eyes. *See also* Visual entries.
 accommodation of, 601, 601*f*
 autonomic control of, 631–632, 735
 pupillary reaction to, 632
 autonomic control of, 631–632, 631*f*, 734*t*, 735
 equilibrium maintenance and, 678
 fluid system of, 606–608, 606*f*, 607*f*
 focusing of. *See* Accommodation.
 headache associated with, 592
 lens of. *See* Lens, of eye.
 ophthalmoscopic examination of, 605–606, 605*f*
 optics of, 600–605
 accommodation in, 601, 601*f*
 camera analogy in, 600, 600*f*
 depth of focus in, 602, 602*f*
 depth perception in, 605, 605*f*, 630
 pupillary diameter in, 601–602, 602*f*
 refractive errors in, 602–604, 602*f*, 603*f*, 604*f*
 visual acuity in, 604–605, 604*f*
 protruding, in hyperthyroidism, 916, 916*f*
 pupillary diameter of, 601–602, 602*f*
 autonomic control of, 632
 dark adaptation by, 615
- F**
- Facial recognition areas, 700–701, 700*f*
- Facilitated diffusion, 46, 46*f*, 49–50, 49*f*
 in glucose reabsorption, 326, 326*f*
 in sodium reabsorption, 325
- Facilitated zone, 565–566, 565*f*
- Facilitation of neurons, 545, 555, 565–566
 memory and, 707–708, 707*f*
- F-actin, 75, 75*f*
- FAD (flavin adenine dinucleotide), 854
- Fainting
 acute venous dilation in, 233
 emotional, 204
 in long QT syndromes, 147
 in Stokes-Adams syndrome, 119, 145
- Fallopian tubes
 anatomy of, 987, 987*f*, 988*f*
 entry of ovum into, 1003, 1004*f*
- Fallopian tubes (*Continued*)
 estrogenic effects on, 993–994
 infertility associated with, 1002
 progesterone and, 995
 transport of fertilized ovum in, 1004, 1004*f*
 transport of sperm in, 1000, 1003
- Familial hypercholesterolemia, 828–829
- Fanconi's syndrome, 408
- Farsightedness, 602, 602*f*, 603, 603*f*
- Fasciculus, 72*f*
- Fast muscle fibers, 79
- Fast pain, 583
- Fast sodium channels, 64
 in cardiac muscle, 66, 102, 115
 sinus nodal action potential and, 116
 ventricular action potential and, 115–116
- Fastigial nucleus, 683, 684, 684*f*
 lesions of, 689
- Fasting blood glucose, 952
- Fast-sharp pain pathway, 584–585, 585*f*
- Fast-twitch muscle fibers, 1036, 1036*t*
- Fat cells. *See* Adipocytes (fat cells).
- Fatigue
 of neuromuscular junction, 85–86
 of skeletal muscle, 80–81
 of synapses, 557
 in reverberatory circuit, 567–568
 stabilizing effect of, 569–570, 569*f*
- Fats. *See also* Lipids; Triglycerides.
 absorption of, 797
 bile salts and, 785
 deposits of, 821–822. *See also* Adipose tissue.
 estrogen and, 994, 1031
- dietary
 gallstones and, 786
 types of, 791–792
- digestion of, 789, 791–793, 791*f*
 bile acids and, 783
 bile salts and, 785
 gallbladder emptying and, 785
 pancreatic enzymes for, 781, 783*f*
 in stomach, 792
- emulsification of, 792, 792*f*
- as energy source. *See also* Triglycerides,
 energy production from.
 for athletes, 1035, 1035*f*
 in diabetes mellitus, 951
 growth hormone and, 899
 with high-fat diet, 824
 hormonal regulation of, 825
 insulin and, 943–944, 944*f*, 947
 liver and, 821–822
- in feces, 798
- in foods
 energy available in, 843–844
 metabolic utilization of, 844–845
- glucose storage as, 817
- glucose synthesis from, 817
- malabsorption of, 802
- metabolism of, in liver, 839
- neonatal utilization of, 1025, 1026
- stomach emptying and, 768
- storage of, 850. *See also* Adipose tissue.
 depleted in starvation, 852, 852*f*
 insulin and, 943
- as thermal insulation, 868
- Fatty acids
 absorption of, 797
 bile salts and, 785
 amino acid conversion to, 835
 beta-oxidation of, 822, 822*f*, 839
 chemical structures of, 819
 cholecystikinin release and, 783
 chylomicron release of, 819–820, 820*f*
 as energy source, 822–825, 822*f*
 in absence of carbohydrates, 823, 825
 for cardiac muscle, 248
- Fatty acids, as energy source (*Continued*)
 cortisol and, 929
 regulation of, 825–826
 unavailability of carbohydrates and, 824
 free. *See* Free fatty acids.
 glucagon and, 948
 glucose conversion to, 817
 insulin and, 942
 hepatic degradation of, 821–822
 nonesterified, 820
 placental diffusion of, 1007
- in plasma
 cortisol and, 929
 forms of, 820
 growth hormone and, 899, 900, 901
 protein binding of, 312, 820, 821
 transport of, 820–821, 822
- synthesis of
 from carbohydrate excess, 825
 insulin and, 943
 in liver, 824, 824*f*
 three most common, 819
 transport into mitochondria, 822
 from triglyceride hydrolysis, 789, 792
 triglyceride synthesis from, in intestinal
 epithelium, 797, 819
- Fatty liver disease, nonalcoholic, 838
- Fatty streaks, 827–828
- Feces
 bile in, 840
 clay-colored, 842
 composition of, 798
 fat in, 802
 formation of, 797–798
 intestinal mucus and, 787
 nitrogen in, 845
 water loss in, 285, 286*t*
- Feedback
 enzyme regulation and, 37
 genetic regulation and, 37
 negative, 7–8, 8*f*, 9
 delayed, 9
 in hormone systems, 885
 positive, 8–9, 8*f*
 in hormone systems, 885
- Feedback gain, 7–8
 body temperature and, 874
- Feed-forward control, 9
- Feeding center, hypothalamic, 845
- Female fertility, 1000–1002
- Female hormones, 987–988. *See also* Ovarian
 cycle; Ovarian hormones.
 plasma concentrations of, 988, 988*f*
- Female sexual act, 1000
- Female sexual organs, 987, 987*f*, 988*f*
 in pregnancy, 1009–1010
- Fenestrated capillaries, glomerular, 312
- Fenn effect, 76
- Ferritin, 418*f*, 419–420, 840
- Fertility, female, 1000–1002
- Fertilization, 977, 1003–1004, 1004*f*
 cervical mucus and, 1002
 female orgasm and, 1000
 limitation to one sperm, 977
 prostaglandins and, 976
 time during cycle and, 1000–1001
- Fetal cells, transplantation of, for Parkinson's
 disease, 693
- Fetal zone, of adrenal cortex, 1008
- Fetus. *See also* Embryo.
 circulation in, 1022–1023, 1022*f*
 growth of, 1019, 1019*f*
 hemoglobin of, 1006
 hormones of, uterine contraction and, 1012
 nutrition of, 1005, 1005*f*. *See also* Placenta.
 human chorionic somatomammotropin
 and, 1009

- Fetus (*Continued*)
 organ system development, 1019–1020
 respiratory movements of, 1019–1020
 testosterone in, 980, 981, 981*f*, 984
- FEV₁ (forced expiratory volume in 1 second), 517, 517*f*
- Fever, 875–877, 875*f*
 brain lesions or surgery and, 876
 chills associated with, 876, 876*f*
 cortisol and, 930
 crisis of, 876, 876*f*
 heart rate and, 143
 hypothalamic set-point and, 875–876, 876*f*
 metabolic rate and, 864
 pyrogens and, 875–876
 in septic shock, 280
- Fibrillar proteins, 11, 16–17
- Fibrin, 453–454, 453*f*
 in platelet plug formation, 452, 452*f*
- Fibrinogen, 453–454, 453*f*, 833
 in seminal vesicle fluid, 976
- Fibrinolysin, in menstrual fluid, 996
- Fibrin-stabilizing factor, 451, 454
- Fibroblast growth factor, angiogenesis and, 198
- Fibroblasts, ameboid movement by, 24
- Fibromuscular hyperplasia, 403
- Fick principle, 240–241, 240*f*
- Fields of vision, 627, 627*f*
- Fifth cranial nerve, reticular excitatory signals and, 711–712, 712*f*
- Fight or flight reaction, 739
- Filaments, of cytoskeleton, 16
- Filariasis, lymphatic, 297
- Filling pressure. *See* Mean circulatory filling pressure; Mean systemic filling pressure.
- Filtration coefficient, capillary, 181, 185
 glomerular, 312, 314
 peritubular, 336
- Filtration fraction, glomerular, 312, 315
 calculation of, 342
 reabsorption rate and, 336
- Filtration pressure, mean, at pulmonary capillary, 482, 482*t*
- Filtration pressure, net, 181, 184, 185–186
 abnormal, edema and, 185–186
- First heart sound, 265–266, 267*f*
- First-degree incomplete heart block, 144–145, 144*f*
- Fitness, life-prolonging effect of, 1041. *See also* Exercise.
- Fixation movements of eyes, 628–630, 629*f*, 678
- Flagellum of sperm, 24, 975, 975*f*, 977
- Flatus, 798, 804
- Flavin adenine dinucleotide (FAD), 854
- Flavin mononucleotide (FMN), 854
- Flavoprotein, 814, 823
- Flexor reflex, 661–663, 662*f*, 663*f*
- Flocculonodular lobe, 678, 678*f*, 681, 682*f*
 equilibrium and, 686
 inputs to, 683, 683*f*
 lesions of, 689
 vestibular nuclei and, 682*f*, 683
- Flowmeters, 160–161, 160*f*, 161*f*
 electromagnetic, for cardiac output measurement, 240, 240*f*
- Fluid absorption into capillaries, 181, 186.
See also Net reabsorption pressure.
- Fluid balance
 of intake and output, 285–286, 286*t*
 in neonate, 1024
- Fluid compartments, 286, 286*f*. *See also* Extracellular fluid; Intracellular fluid; Potential spaces.
 measurement of volumes in, 287–290, 289*f*, 289*t*
- Fluid filtration across capillaries, 181–186, 181*f*.
See also Net filtration pressure.
- Fluid retention, renal, in cardiac failure, 256, 257, 262
 decompensated, 257–258, 263
 high-output, 264
 peripheral edema and, 260–261
- Fluid therapy, calculations for, 292–294, 293*f*, 293*t*, 294*t*
- Fluorine, 856–857
 dental caries and, 971
- 9 α -Fluorocortisol, 922, 924*t*
- Fluorosis, 857
- Flush, febrile, 876, 876*f*
- FMN (flavin mononucleotide), 854
- Foam cells, 827–828, 828*f*
- Focal epilepsy, 725, 726
- Focal length, 597*f*, 598–599, 599*f*
- Focal line, 598, 598*f*, 599*f*
- Focal point, 597–598, 597*f*
- Folds of Kerckring, 793, 793*f*
- Folic acid, 854
 in fetus, 1020
 impaired absorption of, 802
 red blood cell production and, 417, 420, 854
- Follicle(s)
 ovarian. *See* Ovarian follicle(s).
 thyroid, 907, 907*f*
 thyroglobulin storage in, 909
- Follicle-stimulating hormone (FSH), 896, 896*t*
 in female, 987, 988–989, 988*f*
 follicular phase and, 989–990, 998
 luteal phase and, 991
 after menopause, 999
 in pregnancy, 1009
 preovulatory surge of, 988*f*, 997, 998
 regulation of cycle and, 996, 997–998, 997*f*
 in male, 983–984, 983*f*
 spermatogenesis and, 975, 983, 983*f*, 984
- Follicular phase, 989–990, 989*f*, 990*f*, 998
- Food(s)
 compositions of, 843, 844*t*
 energy available in, 809–810, 843–844, 844*t*
 regulation of intake and, 843, 845–849, 846*f*, 847*f*, 847*t*
 metabolic utilization of, 844–845
 thermogenic effect of, 864–865, 867
- Food intake, regulation of, 843, 845–849
 factors affecting quantity, 848–849
 neural centers for, 845–848, 846*f*, 847*f*, 847*t*
- Foot processes, of astrocytes, 743*f*, 744
- Foramen ovale, 1022, 1022*f*, 1023
- Forced expiratory vital capacity (FVC), 517, 517*f*
- Forced expiratory volume in 1 second (FEV₁), 517, 517*f*
- Foreign chemicals, renal excretion of, 303, 311–312, 330
- Fornix, 714*f*, 718–719
- Fourth (atrial) heart sound, 266, 267*f*
- Fovea, 609, 610*f*, 616, 617, 617*f*, 619
 accommodation and, 631
 involuntary visual fixation and, 629, 629*f*
 visual cortex representation of, 624
- Fractures
 in hypoparathyroidism, 968
 muscle spasm associated with, 664–665
 repair of, 960
 vertebral, acceleratory forces causing, 532–533
- Frank-Starling mechanism, 110–111, 229
- FRC. *See* Functional residual capacity (FRC).
- Free energy, 809
- Free fatty acids. *See also* Fatty acids.
 in adipose tissue, 825
 in blood, 820–821, 822
 during exercise, 825
 insulin and, 943–944, 944*f*
- Free nerve endings, 560*f*, 571
 fiber types leading from, 572
 as pain receptors, 583
 spatial summation and, 564, 564*f*
 tickle and itch detection by, 572–573
 as warmth receptors, 592
- Free radicals
 high alveolar Po₂ and, 536–537
 oxygen-derived, high alveolar Po₂ and, 536–537
- Free-water clearance, 354
- Frequency principle, 638
- Frequency summation, of skeletal muscle contractions, 80, 80*f*
- Frostbite, 877
- Fructose, 790
 intestinal absorption of, 796
 in liver, 810, 810*f*
 in seminal vesicles, 976
- FSH. *See* Follicle-stimulating hormone (FSH).
- Functional residual capacity (FRC), 469, 469*f*
 in asthma, 520
 determination of, 470–471
 in neonate, 1024
- Furosemide, 331, 331*f*, 397
- Fusiform cells, of cerebral cortex, 697, 698*f*
- FVC (forced expiratory vital capacity), 517, 517*f*
- G**
- G cells, gastric acid secretion and, 779
- G proteins
 calcium-sensing receptor coupled to, 965
 hormone receptors linked to, 887–888, 887*f*
 adenylyl cyclase-cAMP and, 889, 890, 890*f*
 inhibitory, 888
 in olfactory cilium, 649, 649*f*
 in postsynaptic neuron, 548–549, 549*f*
 stimulatory, 888
- GABA (gamma-aminobutyric acid), 551
 in basal ganglia, 692–693, 692*f*
 Huntington's disease and, 692–693, 692*f*, 694
 of granular neurons, 697
 presynaptic inhibition and, 554
- G-actin, 75
- Gain, of control system, 7–8
 for body temperature, 874
- Galactose, 790
 absorption of, 796
 in liver, 810, 810*f*
- Gallbladder, 783–784, 784*f*, 785
 emptying of, 784*f*, 785
- Galloping reflex, 664
- Gallstones, 786, 786*f*
 blocking pancreatic duct, 801
 obstructive jaundice and, 841
- Gamma globulins, 833, 840. *See also* Antibodies.
 in neonate, 1025
- Gamma-aminobutyric acid. *See* GABA (gamma-aminobutyric acid).
- Ganglia, autonomic. *See* Autonomic ganglia.
- Ganglion cells, of retina, 610*f*, 617, 617*f*
 cortical input from, 625, 626
 excitation of, 617, 619–621, 620*f*
 number of, 619
 thalamic input from, 624
 three types of, 619
 visual pathway and, 617, 617*f*
- Gap junctions, 546
 in cardiac muscle, 101–102, 117
 in gastrointestinal smooth muscle, 753
 in unitary smooth muscle, 91
- Gas, gastrointestinal, 798, 804

- Gas exchange. *See* Respiratory membrane; Ventilation-perfusion ratio.
- Gas gangrene, hyperbaric oxygen therapy for, 540
- Gases
- diffusion coefficients of, 487, 487*t*
 - diffusion of
 - physics of, 485–487, 486*f*
 - through respiratory membrane, 485, 486, 487, 489–492, 492*f*
 - solubility coefficients of, 485–486, 486*t*
 - volume-pressure relationship, 535
- Gastric. *See also* Stomach.
- Gastric acid. *See* Hydrochloric acid, gastric.
- Gastric atrophy, 800
- Gastric banding surgery, 851
- Gastric barrier, 778, 799–800
- Gastric bypass surgery, 851
- Gastric glands. *See* Oxyntic (gastric) glands.
- Gastric inhibitory peptide (GIP), 758, 758*t*
- gastric secretion and, 780
 - stomach emptying and, 768
- Gastric phase
- of gastric secretion, 779, 780*f*
 - of pancreatic secretion, 782
- Gastric secretion, 777–780
- gastric glands and. *See* Oxyntic (gastric) glands.
 - inhibition by intestinal factors, 780
 - in interdigestive period, 780
 - phases of, 779, 780*f*
 - pyloric glands and, 777, 778, 779
 - surface mucous cells and, 777, 779
- Gastric ulcer, 800. *See also* Peptic ulcer.
- Gastrin, 758, 758*t*
- gastric acid secretion and, 778, 779
 - molecular structure of, 779, 780
 - secretion of, 777, 778
 - duodenal, 779
 - small intestine peristalsis and, 769
 - stomach emptying and, 767, 768
- Gastrin cells, 779
- Gastritis, 799–800
- Gastrocolic reflex, 757, 771
- Gastroenteric reflex, 769
- Gastroesophageal sphincter, 765
- Gastroileal reflex, 769–770
- Gastrointestinal hormones, 757–759, 758*t*, 761
- glandular secretions and, 774
 - insulin secretion and, 947
 - small intestine peristalsis and, 769
 - stomach emptying and, 768
- Gastrointestinal motility
- autonomic influences on, 735
 - of colon, 770–772, 770*f*, 771*f*. *See also* Defecation.
- enteric nervous system and. *See* Myenteric plexus.
- hormonal control of, 757–759, 758*t*
- movements in. *See* Mixing movements, gastrointestinal; Peristalsis; Propulsive movements.
- muscle properties and. *See* Gastrointestinal smooth muscle.
- parasympathetic tone and, 737
- reflexes affecting, 757
- sensory nerve fibers and, 757
- of small intestine, 768–770, 768*f*, 770*f*
- of stomach
- mixing function of, 765, 766
 - peristalsis in, 766, 767
 - swallowing and, 763–765, 764*f*
 - thyroid hormones and, 913
- Gastrointestinal obstruction, 804, 804*f*
- plasma loss in, 279
- Gastrointestinal secretion(s), 773–788. *See also* Digestive enzymes.
- autonomic control of, 734*t*, 735, 773–774
 - autonomic reflexes and, 738
 - daily volume of, 775*t*
 - esophageal, 776–777
 - functions of, 773
 - gastric, 777–780, 777*f*, 778*f*, 780*f*. *See also* Oxyntic (gastric) glands.
 - glands providing
 - complex, 773, 774*f*
 - secretion mechanism of, 774–775
 - stimulation of, 773–774
 - types of, 773
 - typical cell of, 774*f*
 - of large intestine, 787
 - of liver. *See* Bile.
 - pancreatic. *See* Pancreatic secretions.
 - pH of, 775*t*
 - saliva as, 775–776. *See also* Salivary glands.
 - of small intestine, 786–787, 786*f*
- Gastrointestinal smooth muscle
- electrical activity of, 753–755, 754*f*
 - sympathetic nervous system and, 757
 - as syncytium, 753
 - tonic contraction of, 755
 - wall structure and, 753, 754*f*
- Gastrointestinal tract. *See also* Enteric nervous system.
- anatomy of, 753, 754*f*
 - autonomic control of, 755, 756–757
 - glands and, 734*t*, 735, 738, 773–774
 - autonomic reflexes affecting
 - bowel activity and, 772
 - glands and, 738
 - blood flow in, 759–762
 - arterial blood supply, 760–761, 760*f*
 - during exercise or shock, 762
 - gut activity and, 761
 - through intestinal villi, 761–762, 761*f*
 - nervous control of, 762
 - splanchnic circulation and, 759–760, 760*f*
 - functional aspects of, 753
 - glands in. *See* Gastrointestinal secretion(s).
 - homeostatic functions of, 5
 - reflexes affecting, 757
 - sensory nerve fibers from, 755, 756*f*, 757
 - wall structure of, 753, 754*f*. *See also* Gastrointestinal smooth muscle.
- Gated channels, 47, 48, 48*f*, 49*f*
- G-CSF (granulocyte colony-stimulating factor), in inflammation, 430, 430*f*
- GDP. *See* Guanosine diphosphate (GDP).
- Gene(s), 27–29
- nuclear location of, 17
 - schema of control by, 27, 27*f*
 - silencing of, 33
- Gene expression, 27
- cell differentiation and, 40
 - regulation of, 35–36, 35*f*
 - microRNA in, 32–33, 33*f*
- Gene transcription. *See* Transcription.
- Genetic code, 29, 29*f*
- Geniculocalcarine tract, 623, 623*f*, 625
- Germ cells, primordial, 973, 974*f*
- Germinal epithelium, 987
- GFR. *See* Glomerular filtration rate (GFR).
- GH. *See* Growth hormone (GH; somatotropin).
- Ghrelin, 846, 846*f*, 847*f*, 848
- growth hormone secretion and, 901
- GHRH (growth hormone-releasing hormone), 898, 898*t*, 901–902
- Giant pyramidal cells, 669–670
- Gigantism, 903
- Gigantocellular neurons, 713, 713*f*
- GIP. *See* Gastric inhibitory peptide (GIP).
- Gitelman's syndrome, 408
- Glands. *See* Endocrine glands.
- Glans penis, 978
- Glaucoma, 607–608
- Glial feet, 745. *See also* Foot processes.
- Global aphasia, 703, 704
- Globin, 840
- Globulins, 833. *See also* Immunoglobulin(s).
- Globus pallidus, 690, 690*f*, 691–692, 691*f*
- Huntington's disease and, 694
 - lesions in, 691
 - neurotransmitters in, 692–693, 692*f*
- Glomerular capillaries, 304–306, 311, 311*f*, 312–314, 313*f*
- colloid osmotic pressure in, 314, 314*f*, 315, 315*f*, 316
 - fenestrae of, 178, 312
 - hydrostatic pressure in, 182, 312, 314, 314*f*, 315–316
 - selective permeability of, 178, 179–180, 313–314, 313*f*, 313*t*
- Glomerular filtrate, composition of, 312
- Glomerular filtration, 310–314, 311*f*
- of representative substances, 323, 324*t*
- Glomerular filtration rate (GFR)
- advantages of normal high level, 312
 - aging and, 403, 403*f*
 - autoregulation of, 319–321, 319*f*, 320*f*
 - in cardiac failure, 260
 - in chronic renal failure, 404–405, 405*f*, 405*t*
 - determinants of, 312, 314–316, 314*f*, 315*f*, 316*f*, 316*t*
 - estimation of
 - with creatinine concentration, 341, 341*f*, 342*f*
 - with inulin clearance, 340–341, 340*t*, 341*f*
 - as fraction of plasma flow, 312
 - physiologic control of, 317–319, 318*t*
 - in pregnancy, 1011
- Glomerulonephritis
- acute, 400
 - autoimmune, 442
 - chronic, 403
 - hypertension in, 407
 - nephrotic syndrome in, 404
 - end-stage renal disease caused by, 402
- Glomerulosclerosis, 403
- Glomerulotubular balance, 319, 334–335
- Glomerulus(i), in olfactory bulb, 649*f*, 651
- Glomerulus(i), of kidney, 305–306
- age-related loss of, 403, 403*f*
- Glomus cells, 509
- Glossopharyngeal nerve
- carotid baroreceptors and, 205, 206*f*
 - carotid bodies and, 508*f*, 509
 - in circulatory control, 203
 - swallowing and, 764*f*, 765
 - taste signals and, 647, 648*f*
- Glossopharyngeal neuralgia, 590
- Glucagon, 947–949
- chemistry of, 947
 - fat metabolism and, 948
 - glucose metabolism and, 947–948
 - for hypoglycemic shock, 954
 - insulin and, 947, 949
 - phosphorylase activation by, 812, 948
 - regulation of secretion of, 948–949, 948*f*
 - secretion of, by alpha cells, 939, 947
 - small intestine motility and, 769
 - somatostatin and, 949
- Glucagon-like peptide, appetite and, 848
- Glucocorticoids, 921, 928. *See also* Cortisol.
- deficiency of, 934, 935
 - excess of, 935–936
 - gluconeogenesis and, 817
 - for immunosuppression in transplantation, 449
 - ketogenic effect of, 825

- Glucocorticoids (*Continued*)
 nongenomic effects of, 931
 pregnancy and, 1009
 properties of, 922–923, 924*t*
 protein metabolism and, 835
 for shock, 281
 synthesis of, 922
- Glucokinase, 811, 811*f*, 942, 945, 945*f*
- Gluconeogenesis, 817
 from amino acids, 835
 blood glucose concentration and, 839
 cortisol and, 928
 glucagon and, 947, 948
 insulin and, 942, 944
 in kidneys, 304
 in neonate, 1025
- Glucose
 absorption of, 796
 for athletes, 1035
 for brain cells, 749–750
 from carbohydrate digestion, 790, 790*f*
 central role of, in carbohydrate metabolism, 810, 810*f*
 in cerebrospinal fluid, 747
 circulatory shock and, 277, 281
 cortisol and utilization of, 928
 diffusion through capillary pores, 179, 180*t*
 energy production from, 812
 acetyl-CoA and, 812–813
 citric acid cycle and, 813–814, 813*f*
 efficiency of, 815
 glycolysis and, 812, 812*f*
 oxidative phosphorylation and, 814–815, 814*f*
 by pentose phosphate pathway, 816–817, 816*f*
 as preferred source, 825
 summary of, 815
 in extracellular fluid, normal range of, 7, 7*t*
 facilitated diffusion of, 50, 810–811
 insulin and, 811
 placental, 1007
 in renal reabsorption, 326, 326*f*
 fatty acids derived from, 817
 in fetal metabolism, 1007, 1020
 for gonads, 949
 insulin and, 941–943, 942*f*
 phosphorylation of, 811
 placental diffusion of, 1007
 plasma level of. *See* Blood glucose.
 renal reabsorption of, 311–312, 325–326, 326*f*
 transport maximum for, 326–327, 327*f*
 sodium co-transport of, 54–55, 55*f*, 325–326, 326*f*, 794–795, 795*f*, 796, 811
 solutions of, 294
 isotonic, 291–292
 storage of. *See* Glycogen.
 transport through cell membrane, 810–811.
See also Facilitated diffusion; Sodium co-transport.
 insulin and, 811, 941–942, 942*f*, 943
 urinary, 950, 952
 vasodilation caused by lack of, 194
- Glucose phosphatase, 810, 811
- Glucose tolerance test, 952–953, 953*f*
- Glucose transporters, 50, 325–326, 326*f*. *See also* Sodium co-transport.
 of pancreatic beta cells, 945, 945*f*
- Glucose-dependent insulinotropic peptide, 758
 gastric secretion and, 780
 stomach emptying and, 768
- Glucose-6-phosphate, 810, 811
 glycogen synthesis from, 811, 811*f*
- Glucostatic theory of hunger and feeding, 849
- Glucuronic acid, steroids conjugated to, 924
- Glutamate
 at A δ pain fiber endings, 585
 in basal ganglia, 692–693
 at C pain fiber endings, 586
 as central nervous system transmitter, 551
 cochlear hair cells and, 637
 of granular neurons, 697
 as photoreceptor transmitter, 617
 schizophrenia and, 727
 umami taste and, 646
- Glutamic acid, 834
- Glutamine
 as amino radical donor, 834
 ammonium ion produced from, 388–389, 389*f*
- Gluten enteropathy, 801
- Glycerol, 789, 819
 as energy source, 822
 glucose synthesis from, 817
 triglyceride hydrolysis and, 820
- Glycerol-3-phosphate, 822
- α -Glycerophosphate, 820, 824, 824*f*, 825
- Glycine, as central nervous system transmitter, 551
- Glycinuria, simple, 408
- Glycocalyx, 14
 endothelial, clotting activation and, 456–457
- Glycogen, 12, 14, 20, 811–812
 glucose storage as, 811, 817
 as anaerobic energy source, 860–861
 compared to fat storage, 824–825
 depleted in starvation, 852
 insulin and, 941, 942
 in muscle, 941
 in skeletal muscle, 78, 80–81, 811, 941
 during exercise, 1032, 1032*t*, 1035
 recovery of, 1034, 1035*f*
- Glycogenesis, 811, 811*f*
- Glycogen-lactic acid system, 1033–1034, 1033*f*, 1034*b*, 1036
- Glycogenolysis, 811–812, 811*f*
 glucagon and, 947–948
- Glycolipids, of cell membrane, 14
- Glycolysis, 22, 812, 812*f*, 815
 anaerobic, 815–816, 860–861, 1033
 in cardiac muscle, 248
 feedback control of, 815
 glycerol used in, 822
 in shocked tissue, 278
 in skeletal muscle, 78, 79, 1033
 hypertrophy and, 81
- Glycoproteins, of cell membrane, 14
- Glycosuria, renal, 408–409
- GM-CSF (granulocyte-monocyte colony-stimulating factor), in inflammation, 430, 430*f*
- GMP (guanosine monophosphate). *See* Cyclic guanosine monophosphate (cGMP).
- GnRH. *See* Gonadotropin-releasing hormone (GnRH).
- Goblet cells, of gastrointestinal tract, 773
 in crypts of Lieberkühn, 786, 786*f*
- Goiter
 antithyroid substances and, 915, 917
 endemic, 917
 hypothyroidism with, 917
 idiopathic nontoxic, 917
 toxic. *See* Hyperthyroidism.
- Goitrogenic substances, 917
- Goldblatt hypertension, 223–224, 223*f*, 403
- Goldman equation, 58
- Goldman-Hodgkin-Katz equation, 58
- Golgi apparatus, 12*f*, 15, 15*f*, 16
 gastrointestinal secretions and, 774, 774*f*
 platelets and, 451, 454
 specific functions of, 20–21, 20*f*
- Golgi tendon organs, 560*f*, 657, 661, 661*f*
 cerebellar input from, 661
 feedback to motor cortex, 672
 nerve fibers from, 564, 656*f*
- Gonadotropes, 896, 896*t*
- Gonadotropic hormones. *See also* Follicle-stimulating hormone (FSH); Luteinizing hormone (LH).
 female infertility and, 1001
 female sexual cycle and, 988–991, 990*f*
 life cycle variation in, 998*f*
 in male, 983–984, 983*f*
 pineal gland and, 986
- Gonadotropin-releasing hormone (GnRH), 898, 898*t*
 in childhood, 999
 in female, 987, 988, 996–997, 997*f*
 in male, 983, 983*f*
 genetic deficiency of, 985, 985*f*
 puberty and, 984
- Gradient-time transport, 327–328
- Grand mal epilepsy, 725–726, 725*f*
- Granular cells, of cerebral cortex, 697, 698*f*
- Granular endoplasmic reticulum, 14, 15*f*, 20, 20*f*
- Granule cell layer, of cerebellum, 684–685, 684*f*
- Granule cells, in olfactory bulb, 650, 652
- Granulocyte colony-stimulating factor (G-CSF), in inflammation, 430, 430*f*
- Granulocyte-monocyte colony-stimulating factor (GM-CSF), in inflammation, 430, 430*f*
- Granulocytes, 423, 423*t*, 424, 424*f*. *See also* Basophils; Eosinophils; Neutrophils.
 produced in inflammation, 429, 430, 430*f*
- Granulosa cell tumor, 1000
- Granulosa cells, 987, 989, 989*f*, 990. *See also* Corona radiata.
 of corpus luteum, 991
 estrogen synthesis in, 992, 993*f*
 inhibin secreted by, 991, 997
- Graves disease, 916
- Gravitational pressure
 arterial pressure and, 174
 reference level and, 174–175, 174*f*
 venous pressure and, 172–173, 173*f*, 174
- Gravity. *See also* Vestibular apparatus.
 acceleratory forces and, 531–533, 531*f*, 532*f*
 brain stem nuclei and, 673–674
 weightlessness and, 533–534
- Gray ramus(i), 729–730, 730*f*
- Greater circulation, 157
- Ground substance, 20
 of bone, 957, 958
- Growth, thyroid hormones and, 912
- Growth factors, 39
- Growth hormone (GH; somatotropin), 895, 896*t*, 898–904
 abnormalities of secretion of, 902–904, 903*f*
 aging and, 901, 904
 carbohydrate utilization and, 899–900
 cartilage and bone growth and, 900
 cells secreting, 896, 896*t*, 897
 daily variations in secretion, 901, 901*f*
 diabetogenic effect of, 900
 fat utilization and, 899
 general growth-promoting effect of, 898–899, 899*f*
 in hypoglycemia, 901, 949
 insulin and, 900, 945, 945*f*, 947
 ketogenic effect of, 825
 metabolic effects of, 899
 metabolic rate and, 864
 plasma concentration of, 901
 protein deposition in tissues and, 899, 904
 protein synthesis and, 835, 899

- Growth hormone (GH; somatotropin) (*Continued*)
 regulation of secretion of, 901–902, 901*t*, 902*f*
 short duration of action, 901
 somatomedins and, 900–901
 spermatogenesis and, 975
 therapy with
 for dwarfism, 902–903
 in older people, 904
- Growth hormone–inhibitory hormone, 898, 898*t*, 901–902, 949
- Growth hormone–releasing hormone (GHRH), 898, 898*t*, 901–902
- Growth inducers, of hematopoietic stem cells, 415
- GTP. *See* Guanosine triphosphate (GTP).
- GTP-binding proteins. *See* G proteins.
- Guanine, 27, 28, 28*f*, 30, 31*t*
- Guanosine diphosphate (GDP), hormone receptors and, 887, 887*f*
- Guanosine monophosphate (GMP). *See* Cyclic guanosine monophosphate (cGMP).
- Guanosine triphosphate (GTP), 810, 859
 hormone receptors and, 887, 887*f*
- Guanlyl cyclase
 penile erection and, 978–979
 in smooth muscle, 97
- Gynecomastia, tumor-induced, 985
- H**
- H band, 72*f*
- Habituation, 706, 707, 718
- Hagfish, 213
- Hair(s)
 estrogens and, 994
 olfactory, 649
 testosterone and, 981
- Hair cells
 of cochlea, 634–635, 636–638, 636*f*, 637*f*
 loudness and, 638
 retrograde pathways to, 641–642
 of vestibular apparatus, 675–676, 675*f*, 676*f*, 677, 677*f*
- Hair end-organ, 560*f*, 572
 adaptation of, 562, 562*f*
- Haldane effect, 503–504, 504*f*
- Hallucinations, hippocampal seizures with, 719
- Hand skills, cortical control of, 669
- Hashimoto disease, 917
- Haustrations, 770
- Haversian canal, 959–960, 960*f*
- Hay fever, 443
- HDLs. *See* High-density lipoproteins (HDLs).
- Head orientation, maculae and, 674–676
- Head rotation
 cortical control of, 669
 vestibular system and, 676, 677, 677*f*, 678
- Headache, 590–592, 591*f*
- Head-down position, for shock, 281
- Hearing, 633–643
 abnormalities of, 642, 642*f*
 attenuation reflex in, 634
 bone conduction and, 634, 642, 642*f*
 central mechanisms in, 639–642, 639*f*, 640*f*
 retrograde pathways in, 641–642
 cochlea in, 634–639
 functional anatomy and, 634–635, 634*f*, 635*f*
 organ of Corti and, 634–635, 634*f*, 636–638, 636*f*, 637*f*, 641–642
 ossicular system and, 633–634, 633*f*
 traveling wave and, 635, 635*f*, 636*f*
 direction of sound and, 641
 frequency of sound and, 638–639, 638*f*
 auditory cortex and, 640
 auditory pathways and, 639–640
 loudness and, 638–639, 638*f*
- Hearing, loudness and (*Continued*)
 attenuation reflex and, 634
 auditory pathways and, 639
 ossicular system in, 633–634, 633*f*
 of sound patterns, 640–641
 speech and, 703, 704–705, 704*f*
 tympanic membrane in, 633–634, 633*f*
- Heart. *See also* Cardiac *entries*.
 athletic training and, 1038, 1038*f*, 1038*t*, 1039, 1039*f*, 1039*t*
 autonomic regulation of, 110, 111, 111*f*, 119–120, 734*t*, 735
 blood flow through, 101, 101*f*
 as blood reservoir, 175
 electrical currents in region of, 124, 124*f*
 enlargement of. *See* Cardiac hypertrophy.
 excitatory and conductive system of, 115–118, 116*f*. *See also* Bundle branches; Purkinje fibers.
 cardiac cycle and, 104–105
 control of, 118–120
 muscle fibers of, 101
 spread and timing of impulse, 118, 118*f*
 velocity of conduction in, 103, 117
 fetal, 1019
 Frank-Starling mechanism and, 110–111, 229
 lactic acid as energy for, 816
 oxygen consumption by, 109
 regulation of pumping by, 110–112, 231
 rupture of, 251
 structure of, 101*f*
 work output of, 107–109, 108*f*, 109*f*, 110
 during exercise, 1038, 1038*f*
- Heart failure. *See* Cardiac failure.
- Heart rate
 arterial pressure regulation and, 205
 atrial reflex control of, 208–209
 body temperature and, 112, 143
 duration of cardiac cycle and, 105
 duration of contraction and, 104
 from electrocardiogram, 123
 exercise and, 244, 245
 athletic training and, 1039, 1039*f*
 hypothalamus and, 715
 in hypovolemic shock, 274
 irregular, 144, 144*f*
 in atrial fibrillation, 152
 parasympathetic regulation of, 201
 right atrial wall stretch and, 110, 229–230
 slow, 143–144, 143*f*
 sympathetic stimulation of, 111, 120, 143
 cardiac output and, 231
 vasomotor center and, 203
 thyroid hormones and, 913
 vagal stimulation and, 111, 119–120
- Heart sounds, 107, 265–268
 auscultation of, 266, 266*f*
 frequencies of, 265, 266*f*
 normal, 265–266
 with patent ductus arteriosus, 267*f*, 270
 with valvular lesions, 267–268, 267*f*
- Heart-lung machines, 271–272
- Heat. *See also* Warmth receptors.
 as metabolic end product, 862
 metabolic rate measurement and, 862–863
 from nonshivering thermogenesis, 865
- Heat loss, 868–871
 blood flow to skin and, 868, 868*f*
 evaporative. *See* Evaporative heat loss; Sweating.
 insulator system of body and, 868
 mechanisms of, 868–870, 869*f*
 panting in, 871
 at very high air temperatures, 869
 to water vs. air, 869, 876
- Heat production. *See* Thermogenesis (heat production).
- Heat-sensitive neurons, 871
- Heatstroke, 876–877, 1040
- Helicobacter pylori*, 801
- Helicotrema, 635, 635*f*
 traveling wave toward, 635, 636
- Helium, in deep diving, 539
- Helium dilution method, 470–471
- Helper T cells, 436, 437, 440–441, 441*f*
 cyclosporine and, 449
- Hematocrit, 165, 165*f*, 287
 in blood volume calculation, 290
 at high altitude, 529, 530
 splenic reservoir of red cells and, 175
 viscosity of blood and, 165, 165*f*
- Hematopoietic stem cells, pluripotential, 414–415, 414*f*, 423–424
- Heme, 840
- Hemiballismus, 691
- Hemoglobin. *See also* Oxygen-hemoglobin dissociation curve.
 acid-base buffering by, 383, 413
 combination with carbon monoxide, 501–502, 501*f*
 combination with oxygen, 418, 498–499, 498*f*, 499*f*
 degradation of, 419–420, 840
 deoxygenated, in cyanosis, 521–522
 fetal, 1006
 oxygen transport by, vs. dissolved state, 498, 501
 oxygen transport capacity of, 413
 oxygen-buffering function of, 6, 499
 high alveolar P_{O_2} and, 536, 537
 quantity in red blood cells, 413
 quantity in whole blood, 413
 at high altitude, 529
 red blood cells and, 413
 structure of, 418, 418*f*
 synthesis of, 417, 417*f*
- Hemoglobin S, 420
- Hemolysins, 446
- Hemolysis, in transfusion reactions, 446
- Hemolytic anemia, 420
- Hemolytic jaundice, 841–842
- Hemophilia, 458
- Hemorrhage. *See also* Bleeding tendencies.
 adjustment to
 blood volume and, 373–374
 delayed compliance in, 168
 renin-angiotensin system in, 221, 221*f*
 sympathetic control in, 168
 vasopressin in, 199
 venous constriction in, 175
 anemia secondary to, 420
- Hemorrhagic shock. *See* Hypovolemic shock.
- Hemosiderin, 418*f*, 419
- Hemostasis. *See also* Blood coagulation.
 definition of, 451
 events in, 451
 clot dissolution or fibrosis, 453
 clot formation, 452, 452*f*
 platelet plug formation, 451–452
 vascular constriction, 451
- Henderson-Hasselbalch equation, 382
 blood CO_2 measurement and, 515
- Henry's law, 485–486
- Heparin, 457
 clinical use of, 459, 460
 from mast cells and basophils, 431, 439, 457
- Hepatic arterioles, 837
- Hepatic artery, 837*f*, 838
- Hepatic coma, 835
- Hepatic vein, 837*f*, 838
 elevated pressure in, 838
- Hepatitis, jaundice in, 841

- Hepatocyte growth factor, 838
Hepatocytes, bile secretion by, 783
Hereditary spherocytosis, 420
Hering-Breuer inflation reflex, 506
Hering's nerves
 baroreceptors and, 205–206, 206*f*
 chemoreceptors and, 208
Hermaphroditism, 1026
Herpes zoster, 590
Hexagonal reference system, 130
Hexokinase, 811
High altitude
 acclimatization to, 510
 alveolar P_{O_2} and, 527, 528–530
 work capacity and, 530, 530*t*
 acute hypoxia at, 528
 alveolar P_{CO_2} at, 527, 528*t*, 529
 alveolar P_{O_2} at, 499, 527, 528*t*
 acclimatization of natives, 529–530, 530*f*
 acclimatization over time, 528–529
 breathing pure oxygen, 528, 528*t*
 alveolar ventilation at, 510
 arterial oxygen saturation at, 527, 528*f*, 528*t*
 barometric pressures at, 527, 528*t*
 mountain sickness at
 acute, 530
 chronic, 530–531
 polycythemia at, 421
 red blood cell production at, 416
 tissue vascularity increase at, 197–198
 work capacity at, 530, 530*t*
High-density lipoproteins (HDLs), 821
 atherosclerosis and, 829
High-energy phosphate compounds. *See*
 Adenosine triphosphate (ATP);
 Phosphocreatine.
High-fat diet, adaptation to, 824
Hindbrain, motor control and, 694
Hippocampus, 714, 714*f*, 718–719
 learning and, 719
 memory storage and, 709, 719
 olfaction and, 651
 schizophrenia and, 727
Hirschsprung disease, 802
His bundle. *See* Atrioventricular (A-V) bundle.
Histamine
 anaphylaxis and, 443
 in asthma, 520
 bronchiolar constriction caused by, 473
 gastric acid secretion and, 778, 779, 801
 hay fever and, 443
 from mast cells and basophils, 431, 439
 shock induced by, 280
 urticaria and, 443
 as vasodilator, 199–200
Histiocytes, 426, 428
Histones, 36, 38, 40
Hives, 443
HLA (human leukocyte antigen complex), 449
HMG-CoA reductase, 827
 statins and, 829
Homeostasis, 4. *See also* Control systems of body.
 automaticity of body and, 9
 circulatory system and, 4–5, 4*f*
 nutrients and, 5
 in premature infant, 1027
 protection of body and, 6
 regulatory systems and, 5–6
 removal of metabolic products and, 5
 reproduction and, 6
Homonymous hemianopsia, 627
Horizontal cells, 609, 610*f*, 617, 617*f*
 function of, 618
 inhibitory, 620, 620*f*
 neurotransmitters released by, 617
Hormone response element, 888, 889*f*
 for cortisol, 931
 for thyroid hormones, 910, 911*f*, 913*f*
Hormone-gated receptors, of smooth muscle, 97
Hormones, 881–893. *See also* Endocrine glands.
 anatomical loci of sources of, 881, 882*f*
 chemical messenger systems and, 881
 clearance from blood, 886
 concentrations of, in blood, 884–885
 measurement of, 891–892, 892*f*
 general classes of, 881–884
 insulin secretion stimulated by, 947
 mechanisms of action, 886–891
 genetic machinery and, 888–889, 891
 intracellular signaling in, 887–889, 887*f*, 888*f*, 889*f*
 receptors in, 886–889
 second messengers in, 888, 889–891, 889*b*, 890*b*, 890*f*
 overview of, 883*t*
 regulatory functions of, 5–6
 secretion of, 884–885, 885*f*
 cyclical variations in, 885
 feedback control of, 885
 structures of, 881–884
 synthesis of, 881–884
 transport of, in blood, 885–886
Hormone-sensitive lipase, 820, 825
 insulin and, 943
Horner's syndrome, 632
Human chorionic gonadotropin
 for female infertility, 1001
 fetal testes and, 984, 1008
 in pregnancy, 1007–1008, 1007*f*
Human chorionic somatomammotropin, 1009, 1014
Human chorionic thyrotropin, 1009
Human growth hormone, 902–903. *See also* Growth hormone (GH; somatotropin).
Human leukocyte antigen (HLA) complex, 449
Human placental lactogen, 1009
Humidification of air, 487, 487*t*
Humoral immunity, 433, 434, 435*f*, 437–439, 437*f*. *See also* Antibodies; B lymphocytes.
Hunger, 845. *See also* Appetite.
 hypothalamus and, 716
Hunger contractions, 766
Hunger pangs, 766
Huntington's disease, 694
Hyaline membrane disease, 1022. *See also* Neonatal respiratory distress syndrome.
Hyaluronic acid, 20
 in proteoglycan filaments, 180
Hyaluronidase, in acrosome, 975, 977
Hydrocephalus, 748
Hydrochloric acid, gastric
 deficiency of, 778, 800
 emotional stimuli and, 780
 organisms destroyed by, 433
 pepsinogen secretion and, 778, 779
 peptic ulcer and, 800, 801
 treatment and, 801
 pH of, 380, 380*t*, 777
 pepsin activity and, 791
 protein digestion and, 791
 secretin release caused by, 782
 secretion of, 777–778, 777*f*, 778*f*
 stimulation of, 778, 779
Hydrocortisone. *See* Cortisol.
Hydrogen atoms
 from fatty acid oxidation, 823
 oxidation of, 814–815
 from pentose phosphate pathway, 816–817, 816*f*
Hydrogen ATPase, 324–325, 387–388, 387*f*
Hydrogen bonding
 in DNA, 28, 29
 in DNA replication, 37
 in protein synthesis, 32
 in proteins, 831
 in transcription, 30
Hydrogen gas, in large intestine, 804
Hydrogen ions. *See also* Acid-base disorders; Acid-base regulation; pH.
 acids and, 379–380
 arterial blood, chemoreceptors and, 208
 arteriolar dilation or constriction and, 200
 cerebral blood flow and, 744
 concentration in body fluids, 380, 380*t*
 precise regulation of, 379
 in oxidative phosphorylation, 814–815, 814*f*
 primary active transport of, 54
 renal excretion of, with reduced GFR, 404, 405*f*
 renal secretion of, 311–312, 326, 326*f*, 332–333, 334
 aldosterone excess and, 926
 bicarbonate reabsorption and, 385, 386–388, 386*f*, 387*f*, 390–391, 390*t*
 factors affecting, 390–391, 390*t*
 respiratory control by, 507, 507*f*, 508, 508*f*
 chemoreceptors and, 509
 high altitude and, 529
 sodium counter-transport of, 55, 55*f*, 326, 326*f*
 intestinal, 794–795
 sour taste and, 645
 vasodilation associated with, 97
Hydrogen peroxide, oxidation by, 15–16
 high alveolar P_{O_2} and, 536–537
 of iodide, 908
 in leukocytes, 426
Hydrogen-potassium ATPase pump, 324–325
 gastric acid secretion and, 777–778, 778*f*
 potassium reabsorption and, 364.
Hydrolase enzymes, in lysosomes, 15, 19–20
Hydrolysis, 789
Hydronephrosis, 315
Hydrostatic pressure
 in capillaries. *See* Capillary pressure.
 in interstitium. *See* Interstitial fluid hydrostatic pressure.
 reabsorption in kidney and, 335–337, 335*f*, 336*t*, 337*f*
 venous pressure and, 172–173
Hydroxyapatite
 of bone, 957, 958
 of teeth, 969, 970, 971
 β -Hydroxybutyric acid, 823
 ketosis and, 823, 852
Hydroxyl ions, of neutrophils and macrophages, 426
Hydroxymethylglutaryl CoA (HMG-CoA) reductase, 827
 statins and, 829
17 α -Hydroxyprogesterone, 992
Hyperalgesia, 583–584, 590
Hyperbaric oxygen therapy, 540
Hyperbarism, 535
Hyperbilirubinemia, physiologic, 1024, 1024*f*
Hypercalcemia, 367, 956. *See also* Calcium, in extracellular fluid and plasma.
 in hyperparathyroidism, 968
Hypercapnia, 522
 dyspnea secondary to, 522
Hyperchloremic metabolic acidosis, 395, 395*t*
Hypercholesterolemia, familial, 828–829
Hypereffective heart, 231, 231*f*
Hyperemia
 active, 194
 reactive, 194
Hyperglycemia, gigantism with, 903

- Hyperinsulinemia, 951, 952
 Hyperinsulinism, 953
 Hyperkalemia, 361
 acidosis secondary to, 391
 aldosterone deficiency and, 926
 in mineralocorticoid deficiency, 924
 Hyperlipidemia, coronary artery disease and, 829
 Hypernatremia, 294, 295–296, 295t
 Hyperopia, 602, 602f, 603, 603f
 Hyperosmotic dehydration, 295, 295t
 Hyperosmotic overhydration, 295t, 296
 Hyperosmotic solution, 292
 Hyperparathyroidism
 primary, 967–968
 secondary, 968
 in chronic renal failure, 407
 Hyperpolarization
 of cardiac fibers, 66f, 67, 120
 atrioventricular nodal, 120
 sinus nodal, 116, 120
 of photoreceptor membrane, 612–613, 617–618
 of postsynaptic membrane, 554
 of smooth muscle, 97
 gastrointestinal, 755
 Hypersensitivity, 443–444
 Hypertension
 acute neurogenic, 224–225
 in aldosteronism, primary, 219–220
 Alzheimer's disease and, 728
 in aortic coarctation, 224
 atherosclerosis and, 829
 cerebral blood flow and, 744–745, 745f
 chronic
 definition of, 218
 impaired renal fluid excretion and, 218–220, 218f, 220f
 lethal effects of, 218
 coronary artery disease and, 829
 endothelial damage in, 196
 essential (primary), 225–226, 226f
 treatment of, 226
 genetic causes of, 225
 Goldblatt types of, 223–224, 223f
 kidney disease and, 406, 407
 dialysis and, 219
 as end-stage renal disease, 402
 as nephrosclerosis, 403
 left ventricular hypertrophy in, 135–136, 135f, 137
 in preeclampsia, 224, 1011
 pregnancy-induced, 1009
 renal artery stenosis and, 223–224, 223f
 renal ischemia and, 224
 renin-angiotensin system and, 223–224, 223f
 stroke secondary to, 745
 volume-loading, 218–219, 218f, 220f
 combined with vasoconstriction, 224–225
 Hyperthyroidism, 916, 916f
 cardiac output in, 233
 in neonate, 1026
 Hypertonic solutions, 292, 292f
 fluid shifts and osmolarities caused by, 293, 293f
 Hyperventilation, alkalosis secondary to, 392
 Hypocalcemia, 367, 956, 956f. *See also* Calcium, in extracellular fluid and plasma.
 hyperparathyroidism secondary to, 968
 Hypochlorhydria, 800
 Hypochromic anemia, 419
 microcytic, 415f, 420
 Hypoeffective heart, 231, 231f
 Hypogastric plexus, 729, 730f
 bladder and, 308
 Hypoglycemia
 cortisol secretion in, 949
 epinephrine and, 949
 growth hormone secretion in, 901, 949
 Hypoglycemic shock, 943
 Hypogonadism
 female, 999
 male, 985, 985f
 Hypokalemia, 361
 aldosterone excess and, 925–926
 alkalosis secondary to, 391
 Hyponatremia, 294–295, 295t, 296f
 Hypo-osmotic dehydration, 294–295, 295t
 Hypo-osmotic overhydration, 295, 295t
 Hypo-osmotic solution, 292
 Hypoparathyroidism, 967
 Hypophosphatemia
 congenital, 969
 renal, 408
 Hypotension, antidiuretic hormone and, 905
 Hypothalamic inhibitory hormones, 897–898, 898t
 Hypothalamic releasing hormones, 897–898, 898t
 Hypothalamic-hypophysial portal vessels, 897–898, 897f
 Hypothalamus, 714, 714f, 715–718, 716f
 amygdala and, 719
 autonomic control by, 739, 739f
 behavioral functions of, 717
 blood-brain barrier and, 748–749
 hunger and satiety centers of, 845–846, 846f
 anorexia and, 852
 leptin and, 849
 neurons and neurotransmitters in, 846–847, 847f, 847t, 849
 obesity and, 850–851
 lesions in, 717
 osmoreceptors in, 355, 356f, 905
 pain signals and, 587
 pineal gland and, 986
 pituitary and
 anterior, 716–717, 897–898, 897f, 898t, 901–902
 posterior, 895, 897, 904, 904f, 905, 906
 reward and punishment functions of, 717–718
 sleep and, 722
 temperature regulation and. *See* Temperature, body, hypothalamic regulation of.
 vasodilator system and, 204
 vasomotor center controlled by, 204
 vegetative and endocrine control functions of, 715–717
 visual fibers to, 623
 Hypothermia, 877
 artificial, 877
 deep body temperature receptors and, 872
 Hypothyroidism, 917–918, 918f
 cardiac output in, 234
 in fetal life, infancy, or childhood, 918
 menstrual irregularities in, 999
 in neonate, 1026
 Hypotonia
 deep cerebellar nuclei and, 689
 motor cortex lesions with, 673
 Hypotonic solutions, 292, 292f
 fluid shifts and osmolarities caused by, 293, 293f
 Hypoventilation, hypoxia secondary to, 520
 hypercapnia and, 522
 oxygen therapy in, 521
 Hypovolemic shock, 274–279
 arterial pressure and, 274–275, 274f
 bleeding volume and, 274–275, 274f
 Hypovolemic shock (*Continued*)
 cardiac output and, 274–275, 274f
 in dehydration, 279
 fluid therapy for, 280
 gastrointestinal vasoconstriction in, 762
 irreversible, 278–279, 278f
 nonprogressive (compensated), 275–276
 in plasma loss, 279
 progressive, 275, 275f, 276–278, 276f
 in trauma, 279
 treatment of, 280–281
 Hypoxia
 acute, at high altitude, 528
 anaerobic energy during, 860
 in anemia, 420–421, 521
 causes of, 520, 521
 dyspnea secondary to, 522
 effects on the body, 521
 erythropoietin secretion in, 304, 416
 in neonate, 1021
 neuronal depression in, 557
 polycythemia secondary to, 421
I
 I bands, of skeletal muscle, 71, 72f
 I cells, intestinal, 783
 IDLs (intermediate-density lipoproteins), 821
 Ig. *See* Immunoglobulin *entries*.
 Iggo dome receptor, 572, 572f
 IL. *See* Interleukin *entries*.
 Ileocecal sphincter, 756, 769–770, 770f
 Ileocecal valve
 feedback control of, 770
 function of, 769–770, 770f
 ileal peristalsis and, 769, 770f
 Image formation. *See also* Visual image(s).
 by lenses, 599–600, 599f
 on retina, 601
 Imipramine, 727
 Immune system, homeostatic functions of, 6
 Immunity. *See* Acquired (adaptive) immunity; Innate immunity.
 Immunization, 433, 437, 442.
 Immunoglobulin(s), 437–438, 437f. *See also* Antibodies.
 Immunoglobulin E (IgE), 431, 438
 allergy and, 443–444
 Immunoglobulin G (IgG), 438
 Immunoglobulin M (IgM), 438
 transfusion reaction caused by, 446
 Immunosuppression
 by cortisol, 930, 931
 for transplantation, 449–450
 Impedance matching, by ossicular system, 633–634
 Impermeant solutes, 291, 292
 Implantation, 1004, 1004f, 1005f
 endometrial nutrients and, 995, 1004, 1008
 Inanition, 851
 hypothalamic feeding center and, 845
 Incisura, in aortic pressure curve, 107, 169f, 170f
 aortic regurgitation and, 169
 Incomplete intraventricular block, 145–146, 145f
 Incontinence, overflow, 310
 Incus, 633, 633f
 Indicator-dilution method, 241, 241f, 287–290, 289f, 289t
 Indifferent electrode, 126
 Infant. *See also* Child; Neonate.
 allergy in, 1026
 endocrine problems in, 1026
 premature, 1026–1027
 retrolental fibroplasia in, 197–198, 1027
 Inferior colliculus, 639–640, 639f
 Inferior olivary nuclei, 670, 683

- Inferior olive
 basal ganglia and, 690f
 cerebellum and, 683, 684, 684f, 686, 687
 Inferior salivatory nucleus, 648
 Infertility
 female, 1001–1002
 male, 977, 978
 Inflammation, 428
 atherosclerosis and, 828, 829
 chemotaxis of leukocytes in, 424f, 425
 complement system in, 439
 cortisol and, 930–931
 in allergic reactions, 931
 intracellular edema secondary to, 296
 macrophages and neutrophils in, 428–430, 429f, 430f
 mast cells in, 431
 stages of, 930
 walling-off effect of, 428
 Inflammatory cytokines, anorexia-cachexia and, 852
 Infrared radiation, 868–869
 Ingestion of food, 763
 mastication in, 763
 swallowing in, 763–765, 764f
 Inhibin
 in female, 991, 997, 998
 in male, 984
 Inhibition circuit, reciprocal, 566–567, 567f
 Inhibitory neuronal circuits, 569
 Inhibitory postsynaptic potential, 553f, 554–555
 dendrites and, 556
 summation and, 555
 Inhibitory presynaptic terminals, 547
 Inhibitory receptors, 547, 549, 550
 Inhibitory transmitter, 548
 Inhibitory zone, 566
 Injury potential. *See* Current of injury.
 Innate immunity, 433. *See also* Complement system; Natural killer lymphocytes; Phagocytosis.
 Inositol, in cephalin synthesis, 826
 Inositol triphosphate (IP₃), 890
 INR (international normalized ratio), 461
 Insensible water loss, 285, 286t
 heat loss caused by, 869
 Inspiratory capacity, 469, 469f
 Inspiratory compliance curve, 467, 467f
 Inspiratory reserve volume, 469, 469f
 Insulin, 939–947
 appetite and, 846, 846f, 847f, 848
 blood cholesterol and, 827
 carbohydrate absence and, 825
 carbohydrate metabolism and, 941–943, 942f, 947
 chemistry of, 940, 940f
 circulatory shock and, 277
 control of secretion of, 945–947, 946f
 cortisol and, 928
 energy abundance and, 939–940
 energy storage and, 849
 factors affecting secretion of, 946t
 fat storage and, 943
 fat synthesis and, 825
 fat utilization and, 943–944, 944f, 947
 glucagon and, 949
 glucose transport into cells and, 811, 941
 growth hormone and, 900, 945, 945f, 947
 mechanisms of secretion of, 945, 945f
 overtreatment with, brain metabolism and, 749–750
 plasma half-life of, 940
 plasma level of, 952
 potassium homeostasis and, 361
 protein storage and, 835, 945
 protein synthesis and, 835, 944
 Insulin (*Continued*)
 receptor activation by, 940–941, 941f
 small intestine peristalsis and, 769
 somatostatin and, 949
 in switching between carbohydrates and lipids, 947
 synthesis of, 940, 940f
 treatment of diabetes with, 953
 Insulin receptors, 940–941, 941f
 Insulin resistance, 950, 951–952, 952b, 953
 growth hormone–induced, 900
 Insulin shock, 953–954
 Insulinase, 940
 Insulin-like growth factor 1 (somatomedin C), 900–901
 Insulin-like growth factors (somatomedins), 900–901
 Insulinoma, 953
 Insulin-receptor substrates, 940–941, 941f
 Integral membrane proteins, 13f, 14
 Integrins, on neutrophils, 428
 Intelligence, 701
 Intention tremor, 687–688, 689
 Intercalated cells, renal, 332–333, 332f
 hydrogen ion secretion by, 54, 333, 387–388, 387f
 potassium reabsorption by, 364
 Intercalated disks, 101–102, 102f
 of Purkinje fibers, 117
 Interleukin(s), 881
 Interleukin-1 (IL-1)
 fever and, 875–876, 930
 in inflammation, 430, 430f
 in lymphocyte activation, 436, 441f
 Interleukin-2 (IL-2), from helper T cells, 440, 441
 Interleukin-3 (IL-3), hematopoietic stem cells and, 415
 Intermediate-density lipoproteins (IDLs), 821
 Intermediolateral horn, 729, 730f
 Internal capsule, of brain, 690, 690f
 International normalized ratio (INR), 461
 Interneurons, in motor control, spinal, 655f, 656
 Internodal pathways, cardiac, 115, 116f, 117, 117f
 Interphase, 37, 38
 Interphase nucleus, 17, 17f
 Interplexiform cells, 617
 Interposed nucleus, 683, 684, 687
 lesions of, 689
 Interstitial cells of Cajal, 754
 Interstitial fluid, 180–181, 180f, 286, 286f, 287. *See also* Lymphatic system.
 carbon dioxide partial pressure (P_{CO₂}) in, 497–498, 498f
 composition of, 287, 288t
 fibrinogen leaking into, 453–454
 osmolarity of, 288t, 291
 oxygen partial pressure (P_{O₂}) in, 496–497, 496f
 pH of, 380, 380t
 plasma proteins in, 184, 185, 189
 protein concentration in, 185, 187, 189
 renal, physical forces and, 335–337, 335f, 336t, 337f
 renal medullary, hyperosmotic, 347–349, 349f, 350–352, 350f, 351f, 352f, 353
 impaired formation of, 354
 transport between plasma and, 4–5, 4f
 volume of, 189
 calculation of, 290
 Interstitial fluid colloid osmotic pressure, 181, 181f, 184, 184t, 185t
 in lungs, 481, 482t
 lymph flow and, 188, 189
 Interstitial fluid hydrostatic pressure, 181, 181f, 182–184, 184t, 185t
 lymph flow and, 187–188, 187f, 189
 negative, 182, 183–184, 189
 edema and, 298–299, 299f, 300
 in lungs, 481, 482, 482t
 in potential spaces, 300
 Interstitial nephritis, 403
 Interstitium, 180–181, 180f
 excess extracellular fluid in, 373, 373f
 free fluid in, 180f, 181, 183, 299
 ground substance in, 20
 Intestinal obstruction, plasma loss in, 279. *See also* Gastrointestinal obstruction.
 Intestinal phase
 of gastric secretion, 779, 780, 780f
 of pancreatic secretion, 782
 Intestine. *See* Large intestine (colon); Small intestine.
 Intra-abdominal pressure, venous pressure in legs and, 172
 Intracellular edema, 296
 Intracellular fluid, 3, 286, 286f
 buffers in
 phosphate as, 383
 proteins as, 383–384
 composition of, 45, 45f, 287, 288f, 288t
 extracellular fluid and, 3–4
 exchange between compartments, 290
 osmotic equilibrium of, 291–292, 292f
 of neuronal somal, 553
 osmolality of, 52
 osmolarity of, 288t, 291
 in abnormal states, 292–294, 293f, 293t, 294t
 pH of, 380, 380t
 volume calculation of, 290
 in abnormal states, 292–294, 293f, 293t, 294t
 Intracranial pressure. *See* Cerebrospinal fluid pressure.
 Intrafusal muscle fibers, 656, 656f, 657–658, 657f, 659, 660
 Intramural plexus. *See* Enteric nervous system.
 Intraocular pressure, 607–608, 607f
 Intrapleural pressure, cardiac output curve and, 234, 234f, 235, 235f
 Intrapleural space, negative pressure in, 183
 Intravenous solutions, nutritive, 294. *See also* Saline solutions.
 Intraventricular block, partial, 145–146, 145f
 Intrinsic factor, 417, 420, 800
 secretion of, 777, 778
 Intrinsic pathway of coagulation, 454–456, 456f
 Inulin, water reabsorption and, 334
 Inulin clearance, 340–341, 340t, 341f, 343
 Inulin space, 289
 Iodide
 antithyroid activity of, 915, 917
 dietary
 absorption of, 907
 deficiency of, 917, 918
 requirement for, 856, 907
 oxidation of, 908, 908f
 radioactive, for hyperthyroidism, 917
 in thyroid hormone synthesis, 908–909, 908f, 909f, 914
 Iodide trapping, 908, 914
 deficient mechanism of, 917
 high iodide concentration and, 915
 thiocyanate and, 915
 Iodinase, 908–909
 Iodine, 856. *See also* Iodide.

- Ion channels, 14. *See also* Acetylcholine-gated ion channels; Calcium ion channels; Chloride ion channels; Potassium ion channels; Protein channels; Sodium ion channels; Voltage-gated channels.
- of adrenergic or cholinergic receptors, 732–733
- G-protein-activated
- hormones and, 887
 - in postsynaptic membrane, 549, 549f
- of interstitial cells of Cajal, 754
- in postsynaptic membrane, 548, 550
- G-protein-activated, 549, 549f
 - receptors linked to, 887
- Ionizing radiation, cancer caused by, 41
- Ionophore component, of postsynaptic receptor, 548
- Ions, in cell, 11
- IP₃ (inositol triphosphate), 890
- Iris, innervation of, 631, 631f, 632
- Iron, 418–419, 856
- absorption of, 419, 796
 - atherosclerosis and, 829
 - daily loss of, 419
 - fetal accumulation of, 1020, 1020f
 - functions of, 418
 - from hemoglobin degradation, 840
 - neonatal need for, 1025
 - in pregnancy, 1010
 - transport, storage and metabolism of, 418–419, 418f, 840
- Iron lung, 522f, 523
- Iron sulfide proteins, 814
- Irritant receptors, in airways, 512
- Ischemia. *See also* Cerebral ischemia; Myocardial ischemia; Renal ischemia.
- intracellular edema secondary to, 296
 - as pain stimulus, 584
 - visceral, 588
- Ischemic heart disease, 246, 248–250. *See also* Myocardial ischemia.
- Islets of Langerhans, 939, 939f
- adenoma of, 953
- Isograft, 449
- Isogravimetric method, for capillary pressure measurement, 182, 182f
- Isohydic principle, 383–384
- Isomaltase, 787
- Isometric contraction
- of skeletal muscle, 79, 79f
 - of ventricle, 106
- Isometric relaxation, of ventricle, 106
- Isopropyl norepinephrine, 733
- Isosmotic solutions, 292
- Isotheneria, 405, 406f
- Isotonic contraction, of skeletal muscle, 79, 79f
- Isotonic solutions, 291–292, 292f
- Isovolumic contraction, 105f, 106, 108, 108f, 109f
- Isovolumic relaxation, 105f, 106, 108, 108f, 109f
- Itch detection, 572–573
- anterolateral system and, 573
 - scratch reflex and, 664
- J**
- J point, 138–140, 139f
- J receptors, in lung, 512
- Jacksonian epilepsy, 726
- Janus kinases (JAKs), leptin receptor and, 888, 888f
- Jaundice, 841–842
- neonatal, 1024, 1024f
 - in transfusion reactions, 448
- Joint angulation, position receptors and, 580
- Joint receptors
- adaptation of, 562, 562f
 - of neck, 678
 - predictive function of, 563
 - Ruffini's endings as, 572
- Joint spaces, effusion in, 300
- Junctional potential, 96
- Juxtaglomerular apparatus, 195, 320, 320f, 331
- Juxtamedullary nephrons, 306, 307f
- countercurrent mechanism and, 306, 307f, 348
- K**
- Kallidin, 199, 761
- Kallikrein, 199
- in salivary glands, 776
- Keratoconus, 604
- Kernicterus, 448
- Keto acids
- amino acid synthesis from, 834, 834f, 840
 - conversion of amino acids to, 834, 835
 - in diabetes mellitus, 953
 - oxidation of, 835
- Ketogenesis, 835
- α -Ketoglutaric acid, 834
- Ketone bodies, 823, 824
- insulin lack and, 944
 - in starvation, 852
- Ketosis, 823–824
- hormonally induced, 825
 - by growth hormone, 899
 - insulin lack and, 944
 - in starvation, 852
- Kidney(s). *See also* Renal entries.
- acid-base balance and. *See* Acid-base regulation, kidneys in.
 - anatomy of, physiologic, 304–306, 305f, 306f, 307f
 - arterioles of. *See* Afferent arteriole(s), renal; Efferent arteriole(s), renal.
 - blood flow control in, 195
 - blood pressure and. *See* Arterial blood pressure control, by renal–body fluid system; Renin-angiotensin system.
 - blood supply of, 304–305, 305f
 - drugs and, 330
 - fetal, 1020
 - functions of, 303–304
 - gluconeogenesis in, 817
 - homeostatic functions of, 5
 - interstitial fluid pressure in, 183
 - irritation of, intestinal activity and, 772
 - in neonate, 1024
 - oxygen consumption by, 316, 317f
 - reabsorption by, 311f, 312, 323, 324f
 - arterial pressure and, 337
 - calculation from renal clearance, 340t, 342–343, 343t
 - in different parts of nephron, 329–334
 - glomerulotubular balance and, 334–335
 - hormonal control of, 337–339, 338f, 338t, 339f
 - hydrostatic and osmotic forces in, 335–337, 335f, 336t, 337f
 - mechanisms of, 323–329
 - regulation of, 334–339
 - of representative substances, 323, 324t. *See also specific substances.*
 - summary of, 334, 334f
 - transport maximum for, 326–327, 327f, 327t
 - secretion by, 311f, 312, 323, 334
 - calculation from renal clearance, 340t, 342–343
 - counter-transport in, 326, 326f
 - of hydrogen ions, 311–312, 326, 326f, 332–333, 334
 - of organic acids and bases, 329f, 330
 - of potassium, 311–312, 332, 333, 333f, 337–338
 - transport maximum for, 326, 327, 327t
 - shock-related lesions in, 277–278
- Kidney disease, 399. *See also* Renal failure.
- anemia in, 304
 - edema in, 298
 - hypertension and, 406, 407
 - in end-stage renal disease, 402
 - in nephrosclerosis, 403
 - nephrotic syndrome in, 404
 - osteomalacia and rickets in, 969
 - tubular disorders, 408–409
- Kidney function testing, clearance methods for, 341f, 342f
- Kidney stones, in hypoparathyroidism, 968
- Kidney transplantation, 409
- Kilocalorie, 862
- Kinesiology, 81
- Kinesthesia, 580
- Kinetic energy, of blood flow, cardiac work and, 108
- Kininogen, high-molecular-weight, 455
- Kinins, 199
- Kinocilium, 675–676, 675f
- Klüver-Bucy syndrome, 720
- Knee jerk, 660, 660f
- Korotkoff sounds, 170–171
- Krause's corpuscle, 560f
- Krebs cycle. *See* Citric acid cycle.
- Kupffer cells, 427, 427f, 837, 839
- Kwashiorkor, 843, 854
- growth hormone in, 901, 902f
- Kyphosis, in acromegaly, 903–904
- L**
- Labeled line principle, 559
- Labor, 1012–1013, 1012f
- Labor pains, 1013
- Lacrimal glands, autonomic control of, 734t, 735
- Lactase, 787, 790
- Lactation, 1014–1016
- metabolic drain on mother from, 1016
 - oxytocin and, 716, 905–906
 - parathyroid enlargement in, 965
- Lactic acid
- from anaerobic glycolysis, 816, 860–861
 - as energy source for heart, 816
 - ischemic pain and, 584
 - from muscle glycogen, 1033–1034, 1033f
 - reconversion to pyruvic acid, 816
 - removal of, 1033–1034
 - shock and, 278
 - in skeletal muscle, 78
 - as vasodilator, 243–244
 - in sweat, 870
- Lactic acid oxygen debt, 1034, 1034f
- Lactic dehydrogenase, zinc in, 856
- Lactose, 789–790
- Lactotropes, 896, 896t
- Laminar flow, of blood, 161, 161f, 162
- Language, 699–700, 699f, 702, 703–705, 704f. *See also* Speech.
- Large intestine (colon)
- absorption in, 797–798
 - active transport in, 55–56, 55f
 - of chloride, 795, 797, 926
 - of sodium, 795, 797, 926
 - bacterial action in, 798, 804
 - disorders of, 802–803. *See also* Diarrhea.
 - functions of, 770
 - gas in, 798, 804
 - movements of, 770–772, 770f, 771f. *See also* Defecation.
 - obstruction of, 804, 804f
 - secretions of, 787
 - bicarbonate in, 795
 - storage function of, 797
- Larynx, 474–475, 474f
- Lateral geniculate body, 623–624, 623f

- Lateral inhibition, 578–579, 578f
 in auditory system, 640
 in cerebellum, 685
 in motor system, 656
 in retina, 618, 618f, 620, 620f
- Lateral lemniscus, 639, 639f
- Lateral motor system of the cord, 671
- Law of the gut, 759
- LDLs. *See* Low-density lipoproteins (LDLs).
- Learned patterns of movement, 690, 695
- Learning
 hippocampus in, 719
 neuronal connectivity and, 708
 reflexive, 709
 reward or punishment and, 718
- Lecithin
 in bile, 784, 784t, 786, 792
 chemical structure of, 826, 826f
- Left atrial pressure, 478, 478f
- Left-sided heart failure, 481
- Pulmonary edema and, 482–483, 482f
- Left bundle branch block
 left axis deviation in, 136, 136f
 T wave and, 142
- Left ventricle
 volume-pressure curves of, 108–109, 108f, 109f
 work done by, 107–109, 108f, 109f
- Left ventricular dilatation, QRS prolongation in, 137–138
- Left ventricular hypertrophy. *See also* Cardiac hypertrophy; Ventricular hypertrophy.
 aortic valve lesions and, 268
 electrocardiogram with, 135–136, 135f, 137
 QRS prolongation in, 137–138
- Left-to-right shunt, 269. *See also* Patent ductus arteriosus.
- Lengthening reaction, 661
- Lens, of eye
 accommodation of, 601, 601f
 autonomic control of, 631–632, 735
 pupillary reaction to, 632
 in analogy to camera, 600, 600f
 cataracts in, 604
- Lenses, physical principles of
 concave, 598, 598f
 convex, 597–598, 597f
 cylindrical, 598, 598f, 599f
 focal length of, 597f, 598–599, 599f
 focal point of, 597–598, 597f
 image formation by, 599–600, 599f
 refractive power of, 599f, 600, 600f
- Leptin, 846, 846f, 847f
 as cytokine hormone, 881
 fat storage and, 849
 obesity and, 851, 865
- Leptin receptor, 888, 888f
- Leukemias, 431–432
- Leukocyte pyrogen, 875–876
- Leukocytes (white blood cells), 423–425.
See also specific cell types.
 ameboid movement by, 24
 concentration of, in blood, 423
 genesis of, 423–424, 424f
 life span of, 424–425
 types of, 423
 as percentages, 423, 423t
- Leukopenia, 431
- Leukorrhea, during menstruation, 996
- Leukotrienes, bronchoconstriction caused by, 443
- Lever systems, in skeletal muscle function, 81, 81f
- Leydig cell tumors, 985
- Leydig cells, 974f, 975, 979–980, 980f
- LH. *See* Luteinizing hormone (LH).
- Licorice, 924–925
- Liddle's syndrome, 408–409
- Lidocaine, for paroxysmal tachycardia, 148
- Ligand-gated channels, 47, 48
- Ligands, 14, 19
- Light and dark adaptation, 614–615, 614f
- Limb leads. *See* Bipolar limb leads.
- Limbic association area, 699f, 700
- Limbic cortex, 714–715, 714f, 720
- Limbic system, 714–715, 714f. *See also*
 Amygdala; Hippocampus;
 Hypothalamus.
 Alzheimer's disease and, 727
 gonadotropin-releasing hormone and, 997
 manic-depressive illness and, 727
 motivation and, 695
 olfaction and, 651
 Parkinson's disease and, 693
 psychomotor seizure and, 726
 reward and punishment functions of, 717–718
 schizophrenia and, 727
- Liminal zone, 565–566, 565f
- Linear acceleration, of head, 676–677
- Linear acceleratory forces, 532–533, 532f
- Lingual glands, 792
- Lingual lipase, 792
- Lipase(s)
 in adipose tissue, 821, 826, 943
 glucagon and, 948
 enteric, 792
 hormone-sensitive, 820, 821, 825
 insulin and, 943
 intestinal, 787
 lingual, 792
 in macrophages, 426
 pancreatic, 781, 792–793, 792f
- Lipase inhibitor, for weight loss, 851
- Lipid bilayer, 13–14, 13f, 45, 46, 46f. *See also*
 Cell membrane.
- Lipids. *See also* Cholesterol; Fats; Phospholipids.
 absorption of, bile salts and, 785
 of cell membranes, 12, 13
 glycolipids, 14
 in cells, 12
 classification of, 819
 synthesis of, in endoplasmic reticulum, 20, 20f
 transport of, in body fluids, 819–821
- Lipodystrophy, 822
- Lipopolysaccharide. *See* Endotoxin.
- Lipoprotein(a), 829
- Lipoprotein lipase, 819–820, 820f
 insulin and, 943
- Lipoproteins, 821. *See also* High-density lipoproteins (HDLs); Low-density lipoproteins (LDLs).
 insulin and, 944
 phospholipids in, 826
- Lipostatic theory of hunger and feeding, 849
- β -Lipotropin, 933–934, 933f
- Lissauer, tract of
 pain signals in, 585f
 thermal signals in, 593
- Liver, 837–842. *See also* Hepatic *entries*.
 acetoacetic acid formed in, 823–824
 adrenocortical hormones metabolized in, 924
 amino acid storage by, 833
 anatomic organization of, 837, 837f
 B lymphocyte processing in, 435
 bile salt synthesis by, 785
 bile secretion by, 783–784, 784f, 785
 as blood reservoir, 175, 838
 capillaries of, permeability of, 178, 179–180
 coagulation factors formed in, 840
 detoxifying function of, 840
- Liver (*Continued*)
 excretory functions of, 840
 fatty acid degradation in, 823
 glucose buffer function of, 839, 949
 glycogen in, 811, 811f
 homeostatic functions of, 5
 insulin action on, 942
 iron storage in, 840
 lipids in, 821–822
 lymphatic system in, 837, 837f, 838
 macrophages in, 427
 metabolic functions of, 839–840
 monosaccharides in, 810, 810f
 neonatal function of, 1025
 protein synthesis in
 cortisol and, 929
 of plasma proteins, 833
 regeneration of, 838
 shock-related injury to, 277, 278f
 sinusoids of, 837, 837f
 blood flow in, 838
 phagocytosis of bacteria in, 839
 reticuloendothelial cells of, 759–760, 837
 vascular system of, 837f, 838
 vitamin storage in, 840
- Liver disease, 838. *See also* Cirrhosis.
 bilirubin and, 840, 841–842
 clotting factor deficiencies in, 457–458
- Local sign principle, 662–663
- Lochia, 1013–1014
- Locomotive reflexes, 663–664
- Locus ceruleus, and norepinephrine system, 551, 712–713, 713f
- Long QT syndromes, 147, 148f
- Loop diuretics, 331, 331f, 397–398, 398t
- Loop of Henle, 306, 306f
 calcium reabsorption in, 368–369
 glomerulotubular balance of, 335
 magnesium reabsorption in, 370
 transport properties of, 330–331, 330f, 331f
 urine concentration and, 346, 346f, 352–353, 352f
 hyperosmotic medulla and, 348–349, 348t, 349f
- Loudness, 638–639, 638f
 attenuation reflex and, 634
 auditory pathways and, 639
- Low-density lipoproteins (LDLs), 821
 adrenocortical hormone synthesis and, 922
 atherosclerosis and, 828–829
 receptors for
 mutations affecting, 827, 828–829
 statins and, 829
- Low-pressure receptors, 208
- Lumirhodopsin, 611–612, 611f
- Lung(s). *See also* Pulmonary *entries*.
 as blood reservoir, 175, 478
 blood volume in, 157, 478–479
 circulation of. *See* Pulmonary circulation.
 compliance of, 467, 467f
 hypoxia and, 520
 thoracic cage and, 468
 consolidation of, 518
 elastic forces of, 465, 467
 surface tension and, 467–468
 work and, 468
 macrophages in, 427
 massive collapse of, 519, 519f
 neonatal expansion of, 1021, 1021f
 recoil pressure of, 467
 shock-related injury to, 277–278
- Lupus erythematosus, 442
 chronic glomerulonephritis in, 403
- Luteal phase, 989f, 990–991
- Lutein cells, 990–991
- Luteinization, 990–991
- Luteinization-inhibiting factor, 991

- Luteinizing hormone (LH), 896, 896*t*
 in female, 987, 988–989, 988*f*
 follicular phase and, 989–990
 luteal phase and, 991
 after menopause, 999
 ovulation and, 990, 990*f*
 in pregnancy, 1009
 preovulatory surge of, 885, 988*f*,
 997–998, 1001
 regulation of cycle and, 996, 996*f*,
 997–998, 997*f*
 in male, 983–984, 983*f*
 spermatogenesis and, 975
- Lymph
 formation of, 187
 in liver, 838
 intestinal absorption into, 187
 rate of flow, 187–189, 187*f*
- Lymph nodes
 macrophages in, 426–427
 structure of, 426–427, 427*f*
- Lymphatic capillaries, 186*f*, 187, 187*f*,
 188, 188*f*
 pumping by, 188–189
- Lymphatic pump, 188, 189
- Lymphatic system, 181, 186–189, 186*f*
 cerebral substitute for, 747
 chylomicrons in, 797, 819
 edema and, 297, 300
 interstitial fluid pressure and, 183–184, 189
 interstitial fluid protein concentration
 and, 187, 189
 interstitial fluid volume and, 189
 intestinal villi and, 769, 793*f*, 794
 in liver, 837, 837*f*, 838
 net filtration and, 185
 potential spaces drained by, 300
 pulmonary, 477, 481, 482, 482*f*
 valves in, 187, 187*f*, 188, 188*f*
- Lymphedema, 297
- Lymphoblast, 423–424, 424*f*
- Lymphocytes, 423, 423*t*, 424, 434, 435*f*.
See also B lymphocytes;
 T lymphocytes.
 activation of clones of, 436
 life span of, 425
 preprocessing of, 434–435
 tolerance and, 442
 specificity of, 435–436, 436*f*
- Lymphocytic leukemias, 431
- Lymphocytic lineage, 423–424, 424*f*
- Lymphocytopenia, cortisol-induced, 931
- Lymphoid tissues, 434
 cortisol-induced atrophy of, 931
- Lymphokines, 436, 440–441, 441*f*, 881
- Lysine monohydrochloride, for alkalosis, 393
- Lysis
 by antibodies, 438
 by complement system, 439, 439*f*
 in transfusion reaction, 446
- Lysoferrin, 20
- Lysosomes, 12*f*, 15, 19–20, 19*f*
 amino acids released by, 833
 circulatory shock and, 277
 glucocorticoids and, 281
 inflammation and, 930
 of leukocytes, 426
 in thyroid hormone release, 909
- Lysozyme, 20, 433
 in saliva, 776
- Lytic complex, 439, 446
- M**
- M line, 73*f*
- Machinery murmur, 270
- Macrocytes, 417
- Macromotor units, 82
- Macrophages, 425–426
 alveolar, 427, 428, 474
 amoeboid movement by, 24, 425
 as antigen-presenting cells, 440
 atherosclerosis and, 827–828, 828*f*
 chemotaxis by, 439
 helper T cells and, 441
 hemoglobin uptake by, 419–420
 hepatic (Kupffer cells), 427, 427*f*, 837, 839
 in inflammation, 428–430, 430*f*
 in lymphocyte activation, 436, 437
 in milk, 1016
 in monocyte-macrophage system, 426–428,
 427*f*
 opsonization and, 439
 pinocytosis in, 18
 pyrogens released by, 875–876
 tissue, 426–428
 development from monocytes, 429
 hemoglobin incorporated by, 840
 platelet removal by, 451–452
 response to infection, 428
- Macula densa, 195, 306, 306*f*, 320, 320*f*, 331
 glomerular filtration rate and, 319–320,
 320*f*
- Maculae, 674–675, 675*f*, 676–677
 hair cells of, 675–676, 675*f*
 linear acceleration and, 676–677
- Magnesium, 856
 in bone, 957–958
 extracellular fluid concentration of, 369,
 370, 856
 intestinal absorption of, 796
 renal excretion of, 369–370
- Magnet reaction, 663
- Magnocellular neurons, 356, 897
- Major basic protein, 430
- Major histocompatibility complex (MHC)
 proteins, 440, 440*f*, 441*f*
- Malabsorption, 801–802
- Male climacteric, 984
- Male hormones
 androgenic. *See* Androgens; Testosterone.
 hypothalamic-pituitary axis and,
 983–984, 983*f*
- Male hypogonadism, 985, 985*f*
- Male sexual act, 978–979
- Male sexual organs, 973, 973*f*
- Malleus, 633, 633*f*
- Malnutrition, and metabolic rate, 864. *See also*
 Starvation.
- Malocclusion, 971–972
- Malonyl-CoA, 824, 824*f*, 825
- Maltase, 787, 790
- Maltose, 790
- Manic-depressive psychosis, 727
- Mannitol, for brain edema, 749
- Marginal ulcer, 800
- Margination, 424*f*, 428, 429*f*
- Mark time reflex, 664
- Mass discharge, 738
- Mass movements, in colon, 770–771
- Mass reflex, 665
- Mast cells, 431
 allergies and, 443
 asthma and, 520
 complement fragments and, 439, 439*f*
 eosinophil chemotactic factor of, 430
 heparin produced by, 431, 439, 457
- Mastication, 763
- Maximum expiratory flow, 516–517, 516*f*
- Mayer waves, 210–211
- M-CSF (monocyte colony-stimulating factor),
 in inflammation, 430, 430*f*
- Mean circulatory filling pressure, 236, 236*f*
- Mean electrical axis of ventricles, 134–137, 135*f*
 conditions causing deviation of, 135–137
- Mean filtration pressure, at pulmonary
 capillary, 482, 482*t*
- Mean pulmonary filling pressure, in left-sided
 heart failure, 259
- Mean QRS vector, 129, 135, 135*f*
- Mean systemic filling pressure, 235, 235*f*,
 236–237, 236*f*, 238–239, 238*f*
 in decompensated cardiac failure, 262–263
 exercise and, 244–245
 after myocardial infarction, 255–256
 fluid retention and, 256, 258
 in neurogenic shock, 279
- Meat, digestion of
 collagen in, 791
 elastin in, 791
- Mechanical pain stimuli, 583
- Mechanical ventilation, 522–523, 522*f*
- Mechanical work, energy of ATP for, 22, 23
- Mechanoreceptive senses, 571
- Mechanoreceptors, 559, 560*b*. *See also specific*
receptor types.
 adaptation of, 562–563, 562*f*
 of skin and deep tissues, 559, 560*b*, 560*f*
- Meconium, 1020
- Medial forebrain bundle, 715, 717
- Medial geniculate nucleus, 639, 639*f*, 640
- Medial lemniscus(i), 573, 574, 574*f*, 575*f*
- Medial longitudinal fasciculus, 628, 628*f*, 630
 vestibular signals in, 678
- Medial motor system of the cord, 671
- Median eminence, 897, 897*f*, 898
- Medulla. *See also* Brain stem.
 chemoreceptor trigger zone in, 804
 circulatory control by, 202, 202*f*, 203, 204*f*
 baroreceptor signals and, 206
 pyramids of, 669, 670*f*
 respiratory control by, 505–508, 506*f*, 507*f*,
 508*f*, 509. *See also* Respiratory center.
 reticular inhibitory area in, 712, 712*f*
 swallowing and, 764, 765
- Medullary collecting duct, 333–334, 333*f*
- Medullary reticular nuclei, 673, 673*f*, 674
 decerebrate rigidity and, 674
- Medullary reticulospinal tract, 674, 674*f*
- Megacolon, 802
- Megaesophagus, 799
- Megakaryocytes, 423, 424, 451
- Megaloblastic anemia, 415*f*, 420
- Meiosis
 in ovary, 1003
 in testis, 974, 974*f*
- Meissner's corpuscles, 560*f*, 571, 572
 vibrations detected by, 572, 579
- Meissner's plexus. *See* Submucosal plexus.
- Melanin
 Addison disease and, 934
 of retina, 609–611
 of skin, 934
- Melanocortin receptors, 846–847, 847*f*,
 849, 851
 anorexia and, 852
- Melanocyte-stimulating hormone, 933–934,
 933*f*
 α form of, 846, 847, 847*f*, 849, 933–934, 933*f*
 obesity and, 851
 β form of, 933–934, 933*f*
 γ form of, 933–934, 933*f*
- Melatonin, pineal gland secretion of, 986
- Membrane. *See* Cell membrane.
- Membrane potential(s). *See also* Action
 potential(s); Receptor potentials;
 Resting membrane potential.
 diffusion potential, 57–58, 57*f*
 resting membrane potential and, 60, 60*f*
 measurement of, 58–59, 58*f*, 59*f*
 oscilloscope in, 69, 69*f*
 of olfactory cells, 650

- Membrane transport, 45–56. *See also* Active transport; Diffusion.
 basic mechanisms of, 45–46, 46f
 energy of ATP for, 22–23, 22f
- Membranous labyrinth, 674, 675f
- Memory, 545, 706–707
 Alzheimer's disease and, 727–728
 classification of, 706–707
 hippocampus and, 709, 719
 intermediate long-term, 706, 707–708
 long-term, 706, 708
 thalamus and, 712
 reward or punishment and, 718
 short-term, 706, 707
 consolidation of, 708–709
 Wernicke area and, 701
 working, 703, 706
- Memory B cells, 437
- Memory T cells, 440
- Memory traces, 706
- Menarche, 988, 998–999
- Meningitis, headache of, 591
- Menopause, 987, 998f, 999, 999f
 osteoporosis secondary to, 969, 994
- Menstrual cycle, 988, 995–996, 995f. *See also* Ovarian cycle.
 absent, 999
 anovulatory, 998, 1001
 irregular, 999
 thyroid hormones and, 914, 999
- Menstruation, 995–996
 leukorrhea during, 996
 prevented by human chorionic gonadotropin, 1007, 1008
- Merkel's discs, 572, 572f
- Meromyosin, 72f
- Mesencephalon
 motor function and, 670f, 673
 reticular substance of, 711
- Mesenteric ganglia, 757
- Mesolimbic dopaminergic system, 727
- Messenger RNA (mRNA), 29f, 31–32, 32f. *See also* Transcription; Translation.
 microRNA and, 32–33, 33f
- Metabolic clearance rate, of hormone, 886
- Metabolic end products, removal of, 5
- Metabolic rate, 862–863. *See also* Energy expenditure.
 ADP in control of, 862
 basal. *See* Basal metabolic rate (BMR).
 blood flow to tissue and, 192, 192f
 cardiac output and, 234
 epinephrine and, 736
 estrogens and, 994
 factors determining, 867
 interstitial fluid PCO_2 and, 498, 498f
 after a meal, 864–865
 measurement of, 862–863
 in neonate, 1025
 thermogenesis and, 873
- Metabolic syndrome, 951
- Metabolism
 blood flow and, cerebral, 743
 of cardiac muscle, 248
 definition of, 862
- Metaphase, 38f, 39
- Metarhodopsin, 611–612, 611f, 613, 614
- Metarterioles, 177, 178f
 in local blood flow control, 193, 193f
 sympathetic innervation of, 201
 vasomotion of, 178–179, 193
- Metastatic calcification, in
 hyperparathyroidism, 968
- Methacholine, 86
- Methane, in large intestine, 804
- Methoxamine, as sympathomimetic drug, 739
- Methyl alcohol, acidosis caused by, 393
- Methylmercaptan, 650
- Methylprednisone, 922, 924t
- MHC (major histocompatibility complex)
 proteins, 440, 440f, 441f
- Micelles, 785, 786, 792, 793, 797
- Michaelis-Menten equation, 861
- Microcirculation, 177–178, 178f. *See also* Capillaries.
- Microcytic, hypochromic anemia, 415f, 420
- Microglia, 428
- Microgravity, 533–534
- Microprocessor complex, 32–33
- MicroRNA (miRNA), 31, 32–33, 33f
- Microtubules, 11, 16, 17, 17f
 of cilia, 24, 25
 of flagellum, 975, 975f
 of mitotic apparatus, 17, 38–39
- Microvilli
 of intestinal epithelium, 790, 791, 794, 794f
 gluten and, 801
 of taste bud, 646, 647f
- Micturition, 306
 abnormalities of, 310
- Micturition reflex, 306, 309–310, 738
 neurologic injury and, 310
- Micturition waves, 309, 309f
- Middle cerebral artery, blockage of, 745
- Migraine headache, 591
- Milk
 composition of, 1016, 1016t
 ejection of, 906, 1015–1016
- Mineral(s), 855–857. *See also specific minerals.*
 body content of, 856t
 daily requirements of, 856t
- Mineralocorticoid receptor, 891, 926, 926f
- Mineralocorticoid receptor antagonists, 399
- Mineralocorticoids, 921. *See also* Aldosterone.
 deficiency of, 924, 934
 properties of, 922–923, 924t
 synthesis of, 921–922
- Minimal change nephropathy, 313–314, 404
- Minute respiratory volume, 471
- Minute work output, cardiac, 107–108
- Miosis, 632
- miRNA. *See* MicroRNA (miRNA).
- Mirror neurons, 668
- Mitochondria, 12f, 16, 16f, 21–23, 22f
 citric acid cycle in, 813
 exchangeable calcium in, 967
 fatty acid metabolism in, 822–823
 fatty acid transport into, 822
 high altitude and, 529
 oxidative phosphorylation in, 814–815, 814f
 of photoreceptors, 609, 610f
 of platelets, 451, 454
 of presynaptic terminals, 547, 547f
 of skeletal muscle, 73, 73f
 in fast vs. slow fibers, 79
 of sperm, 975, 975f
 thyroid hormones and, 911–912
- Mitochondrial uncoupling protein, 873
- Mitosis, 17, 37, 38–39, 38f
 prevention of, with colchicine, 39
- Mitral cells, 651, 651f, 652
- Mitral regurgitation
 circulatory dynamics in, 268–269
 murmur of, 267–268, 267f
- Mitral stenosis
 circulatory dynamics in, 268–269
 murmur of, 267f, 268
 pulmonary capillary pressure in, 483
- Mitral valve, 106–107, 107f
 first heart sound and, 265, 266, 266f
- Mixed acid-base disorders, 394–395, 394f
- Mixing movements, gastrointestinal, 759
 of colon, 770
 of small intestine, 768–769, 768f
- Mixing waves, gastric, 766
- Modality of sensation, 559
- Modiolus, 635, 636–637, 637f
- Molecular layer, of cerebellum, 684–685, 684f
- Monoamine oxidase, of adrenergic nerve endings, 732
- Monoamine oxidase inhibitors, 727
- Monocyte colony-stimulating factor (M-CSF), in inflammation, 430, 430f
- Monocyte-macrophage system, 426–428, 427f
- Monocytes, 423, 423t, 424, 425
 atherosclerosis and, 827–828, 828f
 diapedesis by, 425
 in inflammation, 429
 increased production of, 429, 430, 430f
- Monoglycerides, 791f, 792, 792f
 absorption of, 797
 bile salts and, 785, 792
 resynthesis of triglycerides from, 797, 819
- Monosaccharides, 789, 790
 absorption of, 796
 in liver cells, 810, 810f
- Morphine, respiratory depression caused by, 512
- Morula, 1008–1009
- Mossy fibers, 684–685, 684f
- Motilin, 758–759, 758t
 small intestine peristalsis and, 769
- Motion sickness
 nausea in, 804
 in spacecraft, 533
 vomiting in, 804
- Motivation, 695. *See also* Limbic system; Punishment centers; Reward centers.
- Motor aphasia, 704
- Motor apraxia, 669
- Motor cortex, 667–673. *See also* Premotor area; Supplementary motor area.
 basal ganglia and, 689, 690f, 691
 cerebellar input from, 682, 683, 686, 687, 687f
 cerebrotocerebellum and, 688
 columnar arrangement of neurons in, 671–672
 lesions in, 673
 pathways from, 669–670, 670f
 red nucleus and, 670–671, 671f
 prefrontal association area and, 700
 representations of body in, 667, 668f
 role of, 694–695
 sensory pathways to, 670
 somatosensory feedback to, 672
 somatosensory input to, 575, 575f, 577, 670
 specialized areas of, 668–669, 669f
 speech and, 704–705
 spinal cord excitation by, 671–673, 672f
 subareas of, 667–668, 668f
 vasomotor center excitation by, 204
 voluntary movements and, 667, 673, 686
- Motor end plate, 83, 84f. *See also* Neuromuscular junction.
- Motor functions, 543–544, 544f
 basal ganglia in. *See* Basal ganglia.
 brain stem in, 673–674, 673f, 674f
 anencephaly and, 678–679
 gamma efferents in, 659, 660
 stretch reflexes and, 660
 cerebellum in. *See* Cerebellum.
 cerebral cortex in. *See* Motor cortex.
 cognitive control of, 691–692, 695
 integrated control of, 694–695
 spinal cord in, 655
 excitation by cortex for, 671–673, 672f
 organization of, 655–657, 655f, 656f
 pathways from cortex for, 669–671, 670f, 671f
 reflexes and. *See* Spinal cord reflexes.
 sensory receptors and. *See* Golgi tendon organs; Muscle spindles.

- Motor imagery, 686
- Motor nerve fibers, classification of, 563f, 655, 656
- Motor neurons, anterior, 547, 547f, 552, 655, 655f. *See also* Spinal cord reflexes.
- alpha, 655, 656, 656f, 659
 - corticospinal tract and, 669, 672, 672f
 - gamma, 655, 656, 656f, 657, 657f, 658, 659, 660
 - inhibition of, Golgi tendon organ and, 661
 - pathways converging on, 672, 672f
 - pontine reticulospinal tract and, 673–674
 - Renshaw cells and, 656
 - rubrospinal tract and, 671, 672, 672f
- Motor units, 80, 656
- after poliomyelitis, 82
- Mountain sickness
- acute, 530
 - chronic, 530–531
- Movement receptors, 563
- mRNA. *See* Messenger RNA (mRNA).
- Mucin, salivary, 775
- Mucopolysaccharides, in cardiac T tubules, 103
- Mucous cells
- of gastric surface, 777, 779
 - of gastrointestinal tract, 773
 - of pyloric glands, 778
- Mucous glands, 773
- esophageal, 776–777
- Mucous neck cells, gastric, 777, 777f, 778
- Mucus
- gastrointestinal tract, 773, 775
 - in large intestine, 787
 - in saliva, 774f, 775, 776
 - in small intestine, 786
 - in stomach, 777, 778, 779, 780, 799–800
 - in respiratory passages, 473
- Multiple fiber summation, 80
- Mumps orchitis, 977
- Murmurs, cardiac
- with patent ductus arteriosus, 267f, 270
 - in valvular heart disease, 267–268
- Muscarinic receptors, 733
- drugs acting on, 740
 - drugs blocking, 740
- Muscle. *See* Cardiac muscle; Skeletal muscle; Smooth muscle.
- Muscle contraction
- energy of ATP for, 22, 22f, 23, 859
 - heat dissipated in, 862
- Muscle cramps, 665
- Muscle impulse, 64–65
- Muscle spasm
- headache caused by, 591
 - pain caused by, 584
 - spinal cord reflexes causing, 664–665
- Muscle spasticity, stroke leading to, 673
- Muscle spindles, 560f, 656f, 657
- adaptation of, 562, 562f
 - cerebellar input from, 661, 683, 683f
 - feedback to motor cortex, 672
 - joint angulation and, 580
 - nerve fibers from, 564, 656, 656f
 - receptor function of, 657–658, 657f
 - stretch reflex and, 658–659, 658f, 659f, 672
 - clinical applications of, 660, 660f
- Muscle stretch reflex, 658–659, 658f, 659f, 672, 694
- clinical applications of, 660, 660f
- Muscle tone
- central control of, 694
 - of skeletal muscle, 80
- Muscle weakness
- aldosterone excess and, 925–926
 - cortisol excess and, 929
- Muscularis mucosae, contractions of, 769
- Musculoskeletal system, homeostatic functions of, 5
- Mutations, 38
- cancer caused by, 40–41
- Myasthenia gravis, 86–87, 442
- Mydriasis, 632
- Myelin sheath, 67, 67f, 68, 68f. *See also* Demyelination.
- sphingomyelin of, 826
 - thiamine deficiency and, 853
- Myelinated nerve fibers, 67, 67f
- absolute refractory period of, 69
 - classification of, 563, 563f
 - saltatory conduction in, 68, 68f
 - velocity of conduction in, 68, 563
- Myeloblasts, 423–424, 424f
- Myelocytic lineage, 423–424, 424f
- Myelogenous leukemias, 431
- Myenteric plexus, 755, 756, 756f
- of colon, deficient in megacolon, 802
 - of esophagus, 765
 - gastroenteric reflex and, 769
 - parasympathetic neurons in, 757
 - peristalsis and, 759
 - reflexes of, from cecum to ileum, 770
 - of small intestine, 769, 780
- Myenteric reflexes, 759
- defecation and, 771
 - peristaltic rush and, 769
 - stomach emptying and, 767
- Myocardial infarction, 249–250
- acute anterior wall, 140, 140f
 - recovery from, 141, 141f
 - acute posterior wall, 140–141, 140f
 - recovery from, 141, 141f
 - cardiogenic shock secondary to, 259
 - causes of death after, 250–251
 - circulatory effects of. *See* Cardiac failure, circulatory dynamics in.
 - current of injury in, 140–141, 140f, 141f
 - low-voltage ECG after series of, 137, 137f
 - recovery from
 - function of heart after, 252, 256–257, 256f
 - rest during, 251–252
 - stages of, 251–252, 251f
 - subendocardial, 249–250
- Myocardial ischemia. *See also* Angina pectoris.
- ectopic foci caused by, 146
 - electrocardiogram in
 - current of injury and, 138, 140–141, 140f, 141f
 - in mild ischemia, 142, 142f - metabolism of cardiac muscle in, 248
 - pain in, 252
 - vasospastic, 248
- Myofibrils, of skeletal muscle, 71, 72f, 73f, 74f
- T tubules and, 87, 87f, 88
- Myogenic mechanism, 321
- renal blood flow and, 321
- Myoglobin, 79, 1036
- Myopia, 602–603, 602f, 603f
- Myosin
- in amoeboid movement, 23
 - as ATP-degrading enzyme, 859
 - of cardiac muscle, 101, 103
 - Frank-Starling mechanism and, 110
 - ventricular volume and, 108
 - coated pits and, 18–19, 18f
 - in mitosis, 39
 - of platelets, 451, 454
 - of skeletal muscle
 - contraction mechanism and, 74, 74f, 75–76, 76f
 - hypertrophy and, 81
 - muscle tension and, 77, 77f
 - structural features of, 71, 72f, 73f, 74–75, 74f - of smooth muscle, 92–94, 92f
- Myosin light chain kinase, 93–94, 94f
- calmodulin and, 891
- Myosin phosphatase, 94, 94f
- Myxedema, 917–918, 918f
- N**
- NAD⁺. *See* Nicotinamide adenine dinucleotide (NAD⁺).
- Naming objects, cortical area for, 699f, 700
- Nasal cavity, 472f, 474
- Nasal field of vision, 627
- Nasal glands, autonomic control of, 735
- Nasal sinuses, headache associated with, 591–592, 591f
- NASH (nonalcoholic steatohepatitis), 838
- Natriuretic drugs, for essential hypertension, 226
- Natural killer lymphocytes, 433
- Nausea, 804
- Nearsightedness, 602–603, 602f, 603f
- Neck proprioceptors, 678
- Necrosis
- cellular, 40
 - in hypovolemic shock, 277–278, 278f
- Negative feedback, 7–8, 8f, 9
- delayed, 9
 - in hormone systems, 885
- Neglect syndrome, 692, 692f
- Neocortex, 715
- Neonatal respiratory distress syndrome, 468, 519, 1022, 1026
- Neonate. *See also* Infant.
- circulation of
 - readjustments in, 1022–1023
 - special problems in, 1024, 1024f - immunity in, 1025–1026
 - jaundice in, 1024, 1024f
 - liver function in, 1025
 - nutrition of, 1023, 1025, 1026
 - renal function in, 1024
 - respiration in, 1021–1022, 1021f, 1024, 1026
 - special functional problems in, 1023–1026
 - temperature regulation in, 873, 1025, 1025f
 - prematurity and, 1027
 - weight loss in, 1023
- Neospinothalamic tract, 585
- Neostigmine, 86
- for myasthenia gravis, 86–87
- Nephritis, interstitial, 403
- Nephrogenic diabetes insipidus, 295
- Nephron(s), 305–306, 306f, 307f. *See also* Distal tubule; Loop of Henle; Proximal tubule.
- age-related loss of, 403
 - transport and permeability properties of, 348t
- Nephrosclerosis, 403
- benign, 403
 - malignant, 403
- Nephrotic syndrome, 404
- edema in, 298, 377
- Nernst equation, 50, 57–58
- Nernst potential, of neuron membrane, 552–553
- Nerve fibers, physiologic classification of, 563–564, 563f
- Nerve impulse, 64–65. *See also* Action potential(s), nerve.
- Nerve trunks
- myelinated fibers in, 67, 67f
 - saltatory conduction in, 68, 68f
 - velocity of conduction in, 68
 - unmyelinated fibers in, 67, 67f
- Nervous system. *See also* Central nervous system (CNS); Enteric nervous system; Synapses.
- compared with computer, 546, 546f
 - general design of, 543–545, 544f
 - integrative function of, 544–545
 - regulatory functions of, 5

- Net acid excretion, 390
 Net filtration, 185
 Net filtration pressure, 181, 184, 185–186
 abnormal, edema and, 185–186
 glomerular, 314, 314f
 Net reabsorption pressure, 185, 186
 Neuroendocrine hormones, 881
 Neurogenic bladder, 310
 Neurogenic shock, 279–280
 sympathomimetic drugs for, 281
 Neurohormonal systems, in brain, 711, 712–713, 713f
 Neurohypophysis. *See* Pituitary gland, posterior.
 Neuromuscular junction
 of skeletal muscle, 83
 acetylcholine action at, 73, 83–86, 84f
 acetylcholine synthesis at, 83, 86
 drugs acting at, 85, 86
 fatigue of, 85–86
 myasthenia gravis and, 86–87
 structure of, 83, 84f
 of smooth muscle, 94–95, 94f
 Neuron(s). *See also* Axon; Dendrites; Soma of neuron; Synapses.
 central nervous system, 543, 544f
 continuously discharging, 568
 excitation of, 552–555, 552f, 553f, 554f.
 See also Action potential(s), neuronal.
 dendrite functions in, 555–556, 556f
 drug effects on, 557
 rate of firing and, 556–557, 556f
 excitatory state of, 556–557, 556f
 facilitation of, 545, 555
 inhibition of, 553f, 554–555
 inhibitory state of, 556–557
 metabolism of, 749
 morphologic variations in, 547
 motor. *See* Motor neurons, anterior.
 rate of firing of, for different neuron types, 556–557, 556f
 resting membrane potential of soma, 552, 552f
 Neuronal circuits
 inhibitory, 569
 instability and stability of, 569–570, 569f
 Neuronal pools, 564–568
 grossly inhibitory, 569
 prolongation of signal by, 567–568
 relaying of signals through, 565–567, 565f, 566f, 567f
 Neuropeptide Y, 846, 847, 847f, 849, 851
 Neuropeptides, 550, 550b, 551–552
 Neurophysins, 904
 Neurotransmitters, 546, 547, 550–552, 550b, 881
 in basal ganglia, 692–693, 692f
 in enteric nervous system, 756–757
 in hypothalamus, feeding and, 847f, 847t
 neurohormonal control of brain activity by, 712–713, 713f
 release from presynaptic terminal, 548
 of retinal neurons, 617
 Neutral fats. *See* Triglycerides.
 Neutrophilia, 428–429
 Neutrophils, 423, 423t, 424f
 chemotaxis by, 439
 diapedesis by, 424f, 425, 428, 429f
 in infection, 425–426
 in inflammation, 428–430, 429f
 in milk, 1016
 opsonization and, 439
 Niacin, 853–854
 Nicotinamide adenine dinucleotide (NAD⁺), 813, 814
 in deamination, 834
 in fatty acid oxidation, 822f, 823
 glucocorticoids and, 928
 lactic acid formation and, 816
 niacin requirement and, 853–854
 Nicotinamide adenine dinucleotide phosphate (NADP⁺)
 in fatty acid synthesis, 824, 824f
 niacin requirement and, 853–854
 pentose phosphate pathway and, 816f, 817
 Nicotine, 86
 Nicotinic acid. *See* Niacin.
 Nicotinic drugs, 740
 Nicotinic receptors, 733
 Night blindness, 612
 Nitrates, for angina pectoris, 196, 252
 Nitric oxide
 as central nervous system transmitter, 551
 glomerular filtration rate and, 318
 penile erection and, 978–979
 vasodilation by, 195–196, 196f
 Nitric oxide synthase, 195, 196f
 Nitrogen
 dissolved in body fluids, 537, 537t. *See also* Decompression sickness.
 excretion of, 845
 high partial pressures of, 535
 Nitrogen balance, 845
 Nitrogen narcosis, 535, 539
 Nociceptive reflex, 662
 Nociceptors. *See* Pain receptors.
 Nodes of Ranvier, 67, 67f, 68, 68f
 Nonalcoholic steatohepatitis (NASH), 838
 Nondominant hemisphere, 702
 corpus callosum and, 705
 Nonpitting edema, 299
 Nonprotein nitrogen
 chronic renal failure and, 406
 placental diffusion of, 1007
 Nonshivering thermogenesis, 865, 873
 Nonsteroidal antiinflammatory agents, gastric mucosa and, 801
 Nonvolatile acids, 385, 387, 388, 390
 anion gap and, 395
 Norepinephrine
 adrenal medullar secretion of, 736, 884, 921
 basal level of, 737
 of adrenergic nerve endings, 731–732
 adrenergic receptors and, 733
 in basal ganglia, 692–693, 692f
 cardiac effects of, 120
 as central nervous system transmitter, 551
 coronary blood flow and, 247, 248
 depression and, 726–727
 drugs blocking release of, 740
 drugs blocking synthesis of, 740
 drugs causing release of, 740
 fatty acid mobilization caused by, 825
 gastrointestinal smooth muscle and, 755, 756, 757
 glomerular filtration rate and, 318
 metabolic rate and, 867
 molecular structure of, 731
 for shock, 281
 as smooth muscle neurotransmitter, 95, 96, 97
 sweat glands and, 870
 as sympathomimetic drug, 739
 synthesis of, 732, 884
 thermogenesis and, 873
 as vasoconstrictor, 199, 203, 203f, 204
 in skeletal muscle, 244
 Norepinephrine system, in brain, 712–713, 713f
 Nose, 474
 Nuclear bag muscle fibers, 657–658, 657f
 Nuclear chain muscle fibers, 657–658, 657f
 Nuclear membrane, 11, 11f, 13, 17, 17f
 Nuclear pores, 17, 17f
 Nucleolus(i), 12f, 17, 17f, 32
 Nucleotides
 deoxyribose, 27–29, 28f, 29f
 ribose, 29f, 30
 Nucleus, 11, 11f, 17, 17f
 evolution of, 18
 Nucleus accumbens, Parkinson's disease and, 693
 Nucleus ambiguus, 506
 Nucleus parabrachialis, 506
 Nucleus retroambiguus, 506
 Nucleus tractus solitarius. *See also* Tractus solitarius.
 energy expenditure and, 846
 respiration and, 505
 sleep and, 722
 Nystagmus, cerebellar, 689
O
 Oat bran, 829
 Obesity, 850–851
 coronary artery disease and, 829
 cortisol excess causing, 929
 end-stage renal disease associated with, 402
 fat storage in, 825–826
 genetic factors in, 851
 leptin and, 849, 851
 melanocortin system and, 846–847, 851
 in rodents, 826, 847
 hypertension and, 225–226
 left axis deviation in, 135
 sympathetic activation in, 865
 treatment of, 851
 type II diabetes and, 951, 952
 Obstructive jaundice, 841–842
 Occlusion, of teeth, 969
 Oddi, sphincter of, 780–781, 784f, 785
 Odontoblasts, 970
 Odor blindness, 650
 Ohm's law, 159, 160, 230–231
 Oleic acid, 819
 Olfaction. *See also* Smell.
 amygdala and, 719
 hippocampus and, 719
 Olfactory bulb, 649f, 651, 651f
 granule cells in, 650, 652
 Olfactory cells, 649, 649f, 651
 stimulation of, 649–650, 649f
 Olfactory cilia, 649, 649f
 Olfactory membrane, 648–649, 649f, 651
 Olfactory nerve, 649
 Oliguria, 399
 Olivocerebellar tract, 670, 683, 683f
 Oncogenes, 40, 41
 Oncotic pressure. *See* Colloid osmotic pressure.
 Oocyte
 primary, 987, 1003
 secondary, 1003
 Ophthalmoscope, 605–606, 605f
 Opsins, 614
 Opsonization, 19, 425
 phagocytosis and, 439, 439f
 Optic chiasm, 623, 623f
 destruction of, 627
 Optic disc, edematous, 748
 Optic nerves, 623, 623f
 destruction of, 627
 peripheral vs. central retina and, 619
 Optic radiation, 623, 623f
 Optic tracts, 623, 623f
 interruption of, 627
 Opticokinetic movements, 629
 Optics
 of eye, 600–605
 physical principles of, 597–600
 Orexigenic substances, 846, 847, 847t, 851
 Organ of Corti, 634–635, 634f, 636–638, 636f, 637f
 damage to, 642
 retrograde pathways in, 641–642
 Organum vasculosum, 905

- Orgasm
female, 1000
male, 979
- Orlistat, 851
- Oscillatory circuits. *See* Reverberatory circuits.
- Oscilloscope, for recording membrane potentials, 69, 69f
- Osmolality, 52, 291
of stomach contents, 767, 768
- Osmolar clearance, 354
- Osmolarity, 52, 291. *See also* Extracellular fluid osmolality.
of body fluids, 288t, 291
plasma, 288t, 291
estimated from sodium concentration, 294, 355
- Osmoles, 290–291
- Osmoreceptor cells, 355, 356, 356f, 358, 905
- Osmosis, 51, 51f, 290
active transport combined with, 55–56, 55f
renal reabsorption and, 324, 328
sodium-potassium pump and, 53
- Osmotic coefficient, 291
- Osmotic diuresis, 950
- Osmotic diuretics, 397, 398t
- Osmotic equilibrium, of intracellular and extracellular fluids, 291–292, 292f
- Osmotic pressure, 51–52, 51f, 291. *See also* Colloid osmotic pressure.
of cerebrospinal fluid, 747
- Ossicular system, 633–634, 633f
damage to, 642
- Osteitis fibrosa cystica, 968
- Osteoblasts, 900, 958, 959–960, 959f
calcitonin and, 966
of cementum, 971
fracture repair and, 960
parathyroid hormone and, 963–964
- Osteoclasts, 900, 959–960, 959f
calcitonin and, 966
of cementum, 971
estrogen and, 994
parathyroid hormone and, 963, 964–965
- Osteocytes, 958, 959f
parathyroid hormone and, 963, 964
- Osteocytic membrane system, 964
calcitonin and, 966
- Osteoid, 958
- Osteolysis, 963–964
- Osteomalacia, 969
in renal disease, 406–407, 969
- Osteon, 959–960
- Osteoporosis, 969
in postmenopausal women, 969, 994
- Osteoprotegerin, 959, 994
- Osteoprotegerin ligand, 959, 964
- Oval window, 633–634, 633f, 635, 635f, 636
- Ovarian cycle, 988–991. *See also* Female hormones; Menstrual cycle.
follicular phase of, 989–990, 989f, 990f
gonadotropic hormones and, 988–989
hypothalamic-pituitary hormones and, 996–998, 996f, 997f
luteal phase of, 990–991
ovulation in, 990, 990f
plasma levels of hormones in, 988, 988f
summary of, 991
suppression of, during nursing, 1015
- Ovarian follicle(s), 988f
atretic, 990
development of, 989–990, 989f
mature, 989f, 990
primary, 989
primordial, 987, 989, 989f
- Ovarian hormones, 991–996, 992f, 993f.
See also Estrogen(s); Progestins.
abnormalities of, 999–1000
- Ovaries
anatomy of, 987, 987f, 988f
cholesterol used by, 827
- Overdrive suppression, 145
- Overflow incontinence, 310
- Overhydration
hyponatremia causing, 295t, 296
hyponatremia in, 295, 295t
- Ovulation, 989f, 990, 990f, 1003, 1004f
infertility due to failure of, 1001
preovulatory surge and, 885, 988f, 997–998
suppression of, 1001
timing of fertilization and, 1000–1001
- Ovum(a)
development of, 987, 989–990, 989f
entry into fallopian tube, 1003, 1004f
fertilized, 1003–1004, 1004f
mature, 1003
release of. *See* Ovulation.
- Oxalate, as anticoagulant, 456, 460
- Oxaloacetic acid, in citric acid cycle, 813, 813f
deficiency of, 824
starting with fatty acids, 822–823
- Oxidases, of peroxisomes, 15–16
- Oxidative metabolism. *See also* Aerobic energy.
at high altitude, 529
hypoxia caused by defects in, 521
in skeletal muscle, 78, 79
for exercise, 1033, 1033f, 1033t
- Oxidative phosphorylation, 814–815, 814f
pentose phosphate pathway and, 816–817
uncoupled, 865, 873
- Oxygen
brain's special need for, 749
diffusing capacity for, 491, 492f
carbon monoxide method, 492
diffusion coefficient of, 487t
diffusion of. *See also* Diffusion, of gases.
from alveoli to capillaries, 5, 495–496, 496f
from capillaries to cells, 497, 501
from capillaries to interstitial fluid, 496–497, 496f
through capillary membrane, 179, 180
- energy equivalent of, 863
- in extracellular fluid
normal range of, 7t
regulation of, 6
- lipid solubility of, 46
- in local blood flow control
acute, 192, 192f, 193
long-term, 197–198
in skeletal muscle, 243
smooth muscle and, 97
- placental diffusion of, 1006–1007, 1006f
- respiratory control by, 507, 508–510, 509f, 510f
- tissue concentration of, capillary blood flow and, 178–179
- transport of, 495–502
from alveoli to capillaries, 495–496, 496f
in blood, 496, 496f, 501
from capillaries to tissue cells, 497, 501
from capillaries to tissue fluid, 496–497, 496f
in dissolved state, 498, 501, 521, 535–536, 536f
during exercise, 498–499
hemoglobin in, 495, 498–500, 498f, 499f, 500f
- Oxygen consumption
by brain tissue, 744
cardiac output and, 230, 230f
in cellular metabolism, 500–501
ADP concentration and, 500, 501, 501f
blood flow limited, 501
- Oxygen consumption, in cellular metabolism (*Continued*)
diffusion limited, 501
interstitial fluid Po_2 and, 496f, 497
intracellular Po_2 and, 500–501, 501f
coronary blood flow and, 247, 248
during exercise, 510, 510f, 1036, 1036f, 1036t
heat generation and, 1040
maximal, 1037, 1037f, 1039
work output and, 1038, 1038f
by heart, 109, 249
metabolic rate determination from, 863
basal, 863
- Oxygen debt, 861, 1034, 1034f
- Oxygen free radicals, high alveolar Po_2 and, 536–537
- Oxygen lack theory, of local blood flow regulation, 192, 193, 193f
- Oxygen partial pressure (Po_2)
alveolar, 488, 488f
altitude and. *See* High altitude, alveolar Po_2 at.
high levels of, 499, 535–537, 536f
intracellular, 497
with oxygen therapy, 521, 521f
solubility coefficient and, 486
in tissues, hemoglobin buffering of, 499
ventilation-perfusion ratio and, 492–494, 493f
- arterial
chemoreceptors and, 208
during exercise, 1037
measurement of, 515–516
atmospheric, 527, 528t. *See also* High altitude.
in tissues
cerebral blood flow and, 744
with high alveolar Po_2 , 536
- Oxygen saturation, arterial, 530
at different altitudes, 527, 528f, 528t
local blood flow and, 192, 192f
- Oxygen therapy, 520, 521, 521f
in heart failure, with acute pulmonary edema, 261
hyperbaric, 540
in premature infant, 1027
for shock, 281
- Oxygen toxicity, 501
at high pressures, 535–537, 539
- Oxygen-diffusing capacity, 1037, 1037t
- Oxygen-hemoglobin dissociation curve, 498, 498f, 499f
fetal, 1006, 1006f
hemoglobin buffering and, 499
at high pressures, 535–536, 536f
of high-altitude residents, 530, 530f
shift in, factors causing, 499–500, 500f
- Oxyntic cells. *See* Parietal (oxyntic) cells.
- Oxyntic (gastric) glands, 766, 777–778, 777f, 779
hydrogen ion transport in, 54
peptic cells of, 777, 777f, 778, 779
structure of, 777, 777f
- Oxyphil cells, 963, 963f
- Oxytocin, 896, 905–906
chemical structure of, 904
copulation and, 1000
fertilization and, 1003
hypothalamus and, 716, 904
labor and, 905
lactation and, 716, 905–906, 1015–1016
uterine contraction and, 1012, 1013
- P**
- P wave, 121, 121f
atrial contraction and, 122
cardiac cycle and, 105, 105f
normal voltage of, 123
vectorial analysis of, 133f

- Pacemaker
 cardiac, 118–119
 arrhythmias and, 143
 artificial implanted, 145, 153
 ectopic, 119
 in paroxysmal tachycardia, 148
 gastrointestinal smooth muscle, 754
- Pacemaker waves, of smooth muscle, 96
- Pacinian corpuscles, 560*f*, 561–562, 561*f*, 572
 adaptation of, 562, 562*f*, 563
 joint angulation and, 580
 stimulus intensity and, 579
 vibrations detected by, 572, 579
- Packed red cell volume. *See* Hematocrit.
- Paget disease, calcitonin in, 966
- PAH. *See* Para-aminohippuric acid (PAH).
- Pain
 analgesia system of brain and spinal cord, 586–588, 587*f*
 brain stem excitatory area and, 711
 in coronary artery disease, 252. *See also* Angina pectoris.
 dual pathways for transmission of, 584–586, 585*f*
 surgical interruption of, 586
 electrical stimulation for treatment of, 588
 fast vs. slow, 583
 of headache, 590–592, 591*f*
 of herpes zoster, 590
 hyperalgesia and, 583–584, 590
 inhibition by tactile signals, 587–588
 of labor, 1013
 parietal, 589–590, 589*f*
 protective function of, 583
 referred, 588, 588*f*
 headache as, 591
 from visceral organs, 588, 589, 589*f*
 of tic douloureux, 590
 tissue damage and, 583, 584
 visceral, 588–590, 589*f*
- Pain fibers, 564
 fast and slow, 584–585
 spatial summation and, 564, 564*f*
- Pain receptors, 559, 560*b*, 583
 nonadapting nature of, 583–584
 thermal excitation of, 592, 592*f*
 types of stimuli acting on, 583
- Pain reflex, 662
- Pain sense, 571
 anterolateral system and, 573
 localization of, 577
- Paleocortex, 715
- Paleospinothalamic tract, 585, 586
- Palmitic acid, 819
- Pancreas
 acini of, 773, 780–781, 939, 939*f*
 physiologic anatomy of, 939, 939*f*
- Pancreatic duct, 780–781
- Pancreatic polypeptide, 939
- Pancreatic secretions, 780–783, 782*f*, 783*f*
 alkalinity of, 800
 amylase, 781, 790
 in neonate, 1025
 deficiency of, 801
 lipases, 781, 792–793, 792*f*
 proteolytic enzymes, 781, 791, 791*f*
- Pancreatitis, 781, 801
- Panhypopituitarism, 902
 in adult, 903
 with gigantism, 903
 dwarfism in, 902–903
- Panting, 871
- Pantothenic acid, 812–813, 855
- Papilla of Vater, 780–781
 blockage at, 801
- Papillary muscles, 107, 107*f*
- Papilledema, 748
- Para-aminohippuric acid (PAH), 330
 renal plasma flow and, 341–342, 342*f*
- Parachute jumps, deceleratory forces in, 532–533
- Paracrines, 881
- Paradoxical sleep, 722
- Parafollicular cells, thyroid, 966
- Parallax, 605
- Parallel fibers, of cerebellum, 684–685
- Parasitic infections, eosinophils in, 430
- Parasympathetic denervation, 737
- Parasympathetic nervous system. *See also* Autonomic nervous system; Vagus nerves.
 anatomy of, physiologic, 730–731, 731*f*
 in arterial pressure control, 206
 bladder and, 308, 308*f*, 309
 bronchiolar constriction caused by, 473
 cardiac innervation by, 111, 111*f*, 119, 201, 202*f*
 cardiac regulation by, 111, 111*f*, 119–120
 bradycardia and, 144
 cardiac output and, 231
 vasomotor center and, 203
 circulatory control by, 201, 202*f*
 coronary blood flow and, 247
 erection and
 in female, 1000
 penile, 978–979
 eye control by, 601, 631, 632, 730–731
 gastric secretions and, 778
 gastrointestinal regulation by, 755, 756–757
 blood flow and, 762
 defecation and, 738, 757, 771, 771*f*
 large intestine mucus and, 787
 peristalsis and, 759
 psychogenic diarrhea and, 802
 gastrointestinal secretions and, 773–774
 localized activation of, 738
 salivary glands and, 776, 776*f*
 sexual lubrication and, 979
 ureteral peristalsis and, 309
- Parasympathetic tone, 737
- Parasympathomimetic drugs, 740
- Parathyroid glands, 962–963, 963*f*
- Parathyroid hormone (PTH), 962–966
 bone resorption and, 959
 calcium homeostasis and, 367–369, 368*f*
 extracellular fluid concentration in, 963–966, 963*f*, 965*f*, 967
 intestinal absorption in, 796, 964
 renal reabsorption in, 339, 964
 chemistry of, 963
 control of secretion of, 965–966, 965*f*
 deficiency of, 967
 excess of
 in chronic renal failure, 407
 primary, 967–968
 secondary, 968
 phosphate homeostasis and, 369
 extracellular fluid concentration in, 963–965, 963*f*
 renal excretion in, 964
 in pregnancy, 1009
 summary of effects of, 965–966, 965*f*
 vitamin D and, 961–962, 961*f*
- Parathyroid poisoning, 968
- Paraventricular nuclei
 food intake and, 846, 849
 pituitary hormones and, 897, 904, 904*f*, 905, 906
- Parietal (oxyntic) cells, 777, 777*f*
 ghrelin released by, 848
 hydrochloric acid secretion by, 777–778, 777*f*, 778*f*
 stimulation of, 778, 779
 intrinsic factor secretion by, 778
- Parietal lobe, somatosensory signals and, 575
- Parietal pain, 589–590, 589*f*
- Parieto-occipitotemporal association area, 699–700, 699*f*
 in nondominant hemisphere, 702
 prefrontal association area and, 700
- Parkinson's disease, 691, 693–694, 727
- Parotid glands, 775, 790
- Paroxysmal tachycardia, 148–149
 atrial, 148, 148*f*
 ventricular, 148–149, 149*f*
- Partial intraventricular block, 145–146, 145*f*
- Partial pressures. *See also* Carbon dioxide partial pressure (Pco₂); Oxygen partial pressure (Po₂).
 of dissolved gases, 485–486
 in gas mixture, 485
 net diffusion and, 486–487
 of water vapor, 486
- Parturition, 1011–1014, 1012*f*
 involution of uterus after, 1013–1014
- Passive immunity, 442
- Past pointing, 689
- Patch-clamp method, 48, 49*f*
- Patent ductus arteriosus, 269–271, 270*f*, 1023
 aortic pressure pulse associated with, 169, 169*f*
 murmur of, 267*f*, 270
- Pco₂. *See* Carbon dioxide partial pressure (Pco₂).
- Pellagra, 854
- Pelvic nerves
 bladder and, 308, 309
 parasympathetic fibers in, 731
 defecation reflex and, 771, 771*f*
 to intestine, 757, 787
- Pendrin, 908, 908*f*
- Pendular movements, 687–688
- Penetrating arterioles, of brain, 743, 743*f*
- Penile erection, 196, 738, 978–979, 979*f*
- Pentagastrin, 780
- Pentose phosphate pathway, 816–817, 816*f*
- Pepsin, 778, 791, 791*f*
 deficiency of, 800
 excess of, 800
- Pepsinogen, 777, 778
 regulation of secretion of, 779
- Peptic (chief) cells, 777, 777*f*, 778, 779
- Peptic ulcer, 780, 786, 800, 800*f*, 801
 obstruction caused by, 804
 treatment of, 801
- Peptidases
 of enterocytes, 787, 791
 zinc in, 856
- Peptide hormones, 881, 882
 clearance from blood, 886
- Peptide linkages, 789, 790, 831
 energy required for, 859, 862
 formation of, 34, 35
- Peptide YY, 846*f*, 848
- Peptidyl transferase, 34
- Peptones, 783, 783*f*, 791
- Perforins, 441
- Periaqueductal gray, pain signals and, 586–587, 587*f*
- Pericardial effusion, 300
 low-voltage ECG associated with, 137
- Perilymph, 637–638
- Perimetry, 627, 627*f*
- Periodic breathing, 512–513, 512*f*
- Periodontal membrane, 970
- Peripheral chemoreceptor system.
See Chemoreceptor reflexes; Chemoreceptors.
- Peripheral circulation, 157
- Peripheral membrane proteins, 13*f*, 14
- Peripheral resistance unit (PRU), 162–163

- Peripheral vascular resistance. *See* Total peripheral resistance; Vascular resistance.
- Peristalsis, 759, 759f
 of colon, 771
 of esophagus, 764f, 765
 of pharynx, 764, 765
 of rectum, 771
 of small intestine, 769
 of ileum, 769–770, 770f
 of stomach, 766
 emptying and, 766, 767
- Peristaltic reflex, 759
- Peristaltic rush, 769
- Peristaltic waves, in small intestine, 769
- Peritoneointestinal reflex, 772
- Peritonitis
 abdominal muscle spasm in, 665
 intestinal paralysis secondary to, 772
 septic shock secondary to, 280
- Peritubular capillaries, 304–305, 305f, 306, 307f, 311, 311f. *See also* Vasa recta.
 reabsorption and, 323–324, 324f
 physical forces and, 335–337, 335f, 336t, 337f
- Perivascular spaces, of brain, 746, 747, 747f
- Periventricular nuclei, 586–587, 587f
- Pernicious anemia, 417, 420, 778, 800, 854
- Peroxidases, 536–537
 iodide oxidation by, 908, 908f
 deficient, 917
- Peroxide radical, high alveolar Po_2 and, 536–537
- Peroxisomes, 15–16
 of neutrophils and macrophages, 426
- Petit mal epilepsy, 725f, 726
- pH. *See also* Acid-base regulation; Hydrogen ions.
 bicarbonate buffer system and, 382
 blood
 acid-base disorders and, 393, 394–395, 394f
 carbon dioxide transport and, 504
 measurement of, 515–516
 oxygen-hemoglobin dissociation curve and, 499–500, 500f
 respiratory control and, 508, 508f, 510, 510f
 of body fluids, 380, 380t
 definition of, 380
 of gastrointestinal secretions, 775t
- Phagocytes, in spleen, 175
- Phagocytosis, 18, 19, 423, 425–426
 after apoptosis, 40
 aqueous humor cleansed by, 607
 bactericidal agents and, 20, 426
 by eosinophils, 430
 in inflammatory response, 428, 429
 innate immunity and, 433
 monocyte-macrophage system and, 426–428
 opsonization and, 439, 439f
- Phagocytotic vesicle, 19, 19f, 425–426
- Pharyngoesophageal sphincter, 764
- Phasic receptors, 563
- Phenylthiocarbamide, 646
- Phonation, 474–475
- Phonocardiogram, 266, 267f
 cardiac cycle and, 105, 105f
 of valvular murmurs, 267f, 268
- Phosphagen energy system, 1033, 1034b, 1036
- Phosphate, 856. *See also* Hypophosphatemia.
 in bone, 957
 deposition of, 958
 parathyroid hormone and, 963–964
 in extracellular fluid and plasma, 955
 forms of, 955
 level of, 955–956
- Phosphate, in extracellular fluid and plasma (*Continued*)
 parathyroid hormone and, 963–965, 963f
 in rickets, 968
 fecal excretion of, 957
 fetal accumulation of, 1020, 1020f
 intestinal absorption of, 796, 957, 962
 parathyroid hormone and, 964–965
 vitamin D and, 962, 964–965
 phospholipids as donors of, 826
 renal excretion of, 369, 957, 962, 964
 with reduced GFR, 404, 405f
 renal failure and, chronic, 407
- Phosphate buffer system, 383, 388, 388f
- Phosphatidylinositol biphosphate (PIP₂), 890
 aldosterone and, 927
- Phosphocreatine, 78, 861
 depleted in irreversible shock, 278–279
 in strenuous muscle activity, 860, 861, 1032–1034, 1033f
 summary of use of, 861, 861f
- Phosphodiesterase-5 inhibitors, 196, 986
- Phosphofructokinase, inhibition of, 815
- Phosphogluconate pathway, 816–817, 816f
- Phospholipase, pancreatic, 781
- Phospholipase A₂, 792–793
- Phospholipase C, hormonal activity and, 890, 890b, 890f
 parathyroid, 965
 thyroid, 914
- Phospholipids, 12, 13, 819, 826. *See also* Lecithin.
 chemical structures of, 826, 826f
 in chylomicrons, 819
 dietary, 792
 digestion of, 792–793
 insulin and, 944
 in lipoproteins, 821, 821t
 second messenger system using, 890, 890b, 890f
 synthesis of, 826
 in endoplasmic reticulum, 20
 in liver, 822, 839
 thyroid hormones and, 912
 uses of, 826
 structural, 827
- Phosphoric acid, as component of DNA, 27, 28f
- Phosphorus, 856
- Phosphorylase, 811, 811f
 activation of, 36, 812
- Photopsins, 614
- Photoreceptors. *See* Cones; Rods.
- Physiologic dead space, 471–472, 493, 494
- Physiologic shunt, 493, 494
- Physiology, 3
- Physostigmine, 86
- Pia mater, perivascular space and, 747, 747f
- Pial arteries, 743, 743f
- Pigment layer, of retina, 609–611, 610f
- Piloerection, for temperature regulation, 872–873
- Piloerector muscles, nerve fibers to, 729–730, 730f, 731
- Pineal gland, 986
 blood-brain barrier and, 748–749
- Pinocytosis, 18–19, 18f
 in intestinal epithelium, 794, 794f
 of proteins in renal tubule, 326
 in thyroid gland, 908f, 909
- Pinocytotic vesicle, 18–19, 19f
 in intestinal epithelium, 794, 794f
- PIP₂. *See* Phosphatidylinositol biphosphate (PIP₂).
- Pitting edema, 299
- Pituitary gland, 904
- Pituitary gland, 895–906
 adenoma of, 935, 936
 anatomy of, 895, 895f
- Pituitary gland (*Continued*)
 anterior
 cell types in, 896–897, 896f, 896t
 hormone deficiencies of, 902–903
 hormones of, 895, 895f, 896, 896t, 898. *See also specific hormones.*
 hypothalamus and, 716–717, 897–898, 897f, 898t, 901–902
 pregnancy and, 1009
 embryology of, 895
 intermediate lobe of, 934
 posterior
 hormones of, 895, 896, 897. *See also specific hormones.*
 hypothalamus and, 895, 897, 904, 904f, 905, 906
- PKC (protein kinase C), 890, 890f
- Place principle, 638
- Placenta, 1005–1007
 anatomy of, 1005–1007, 1006f
 blood flow through, 1010
 breaks in membrane of, 1005–1006
 carbon dioxide diffusion through, 1007
 diffusion conductance of, 1005–1006, 1005f
 duration in pregnancy and, 1005, 1005f
 hormones secreted by, 1007–1009
 nutrient diffusion through, 1007
 oxygen diffusion through, 1006–1007, 1006f
 preeclampsia and, 1011
 separation and delivery of, 1013
 waste product diffusion through, 1007
- Plaque, dental, 971
- Plaques, atheromatous, 827, 828, 828f
- Plasma. *See also* Extracellular fluid.
 composition of, 287, 288f, 288t
 as fluid compartment, 4–5, 286, 286f, 287
 hypovolemic shock in loss of, 279
 with trauma, 279
 osmolarity of, 288t, 291. *See also* Extracellular fluid osmolarity.
 estimated from sodium concentration, 294, 355
 viscosity of, 165
- Plasma cells, 423, 424, 437, 441f
- Plasma colloid osmotic pressure, 181, 181f, 184, 184t, 185t
 albumin and, 184, 184t, 833
 lymph flow and, 188
- Plasma membrane
 of cell. *See* Cell membrane.
 of skeletal muscle fiber, 71
- Plasma proteins. *See also* Albumin.
 as amino acid source, 833, 834f
 calcium bound to, 367
 capillaries impermeable to, 4–5
 carbon dioxide transport by, 503
 colloid osmotic pressure and, 184, 184t
 of complement system, 438
 cortisol and, 929
 edema caused by decrease in, 297, 298, 300
 in cirrhosis, 377–378, 833
 in nephrotic syndrome, 377
 equilibrium between tissue proteins and, 833–834, 834f
 estrogens bound to, 993
 glomerular filtration of, 312, 313, 313t.
See also Proteinuria.
 glucocorticoids and, 835
 hormone transport by, 885–886
 of adrenocortical steroids, 923–924
 of steroids, 885–886
 of testosterone, 980
 of thyroid hormones, 882, 885–886
 immunoglobulins as, 437–438
 in interstitial fluid, 184, 185, 189
 interstitial fluid cations and, 287
 intestinal obstruction and loss of, 279

- Plasma proteins (*Continued*)
 lymphatic return of, 186
 magnesium bound to, 369
 major types of, 833
 in neonate, 1025, 1027
 nephrotic syndrome and, 377, 404
 in potential spaces, 300
 progesterone bound to, 993
 synthesis of, 833, 840
 thyroid hormones bound to, 909–910
- Plasma substitutes, 281
- Plasma transfusion, 280–281
- Plasma volume, measurement of, 290
- Plasmalemmal vesicles, of capillary endothelial cells, 178, 178f
- Plasmin, 457
- Plasminogen, 457
- Platelet factor 3, 455
- Platelet plug formation, 451–452, 452f
- Platelets, 423, 424, 451–452
 in clot, 452, 452f, 454
 clot retraction and, 454
 concentration of, in blood, 423
 deficiency of, 458
 endothelial surface and, 452, 457
 intrinsic clotting pathway and, 455
 life span of, 425
 prothrombin receptors on, 453
- Pleural effusion, 300, 483
 low-voltage ECG associated with, 137
- Pleural fluid, 465–466, 483, 483f
- Pleural pressure, 466, 466f
- Pleural space, 483
- Pluripotential hematopoietic stem cells, 414–415, 414f, 423–424
- Pneumonia, 518–519, 518f, 519f
- Pneumotaxic center, 505, 506, 506f
- PO₂. *See* Oxygen partial pressure (PO₂).
- Podocytes, 312–313, 313f
- Poiseuille's law, 163–164
- Poison ivy, 443
- Polar body
 first, 1003
 second, 1003
- Polarography, 515
- Poliomyelitis, macromotor units subsequent to, 82
- Polycystic ovary syndrome, 952
- Polycythemia, 421
 hematocrit in, 165, 165f, 287
- Polycythemia vera, 421
 cyanosis in, 521–522
- Polymorphonuclear leukocytes, 423, 423t, 424f. *See also* Basophils; Eosinophils; Neutrophils.
- Polypeptide hormones, 881, 882, 885f
- Polypeptides
 classification into proteins and peptides, 882
 from protein digestion, 791, 791f
- Polyribosomes, 33
- Polysaccharides, 789–790
- Pons. *See also* Brain stem.
 respiratory control by, 505, 506, 506f
 reticular substance of, 711–712
 swallowing and, 764
- Pontine reticular nuclei, 673–674, 673f
- Pontine reticulospinal tract, 673–674, 674f
- Pontocerebellar tracts, 670, 682
- Pores. *See also* Ion channels.
 in capillaries. *See* Capillaries, pores in.
 in cell membrane, 14
 nuclear, 17, 17f
- Portal hypertension, 838
- Portal vein, 759–760, 759f, 837, 837f, 838
 blockage in, 838
 colon bacilli in, 839
- Portal vessels, hypothalamic-hypophysial, 897–898, 897f
- Position senses, 571, 573, 580, 580f
- Positive and supportive reaction, 663
- Positive feedback, 8–9, 8f
 in hormone systems, 885
- Postcentral gyrus, 575f, 576, 577
- Posterior parietal cortex
 lesions of, 692
 spatial coordinates of body and, 692, 699, 699f
- Postganglionic neurons, autonomic
 drugs that block, 740
 drugs that stimulate, 740
 muscarinic receptors of, 733
 parasympathetic, 731
 enteric nervous system and, 757
 sympathetic, 729–730, 730f
 adrenal medulla and, 730
 gastrointestinal tract and, 757
 transmitters of, 731, 732
- Postsynaptic neuron, 546, 548–549. *See also* Neurotransmitters.
 excitatory receptors of, 547, 549–550
 inhibitory receptors of, 547, 549, 550
 second messengers in, 548–549, 549f
- Postsynaptic potentials, 553–555, 553f, 554f
 summation of, 553, 554f, 555
- Postural instability, in Parkinson's disease, 693
- Postural reflexes, 663–664
- Posture, and baroreceptor reflexes, 206–207. *See also* Equilibrium.
- Potassium
 aldosterone secretion and, 921–922
 in bone, 957–958
 cardiac action potential and, 102–103, 115–116
 in cerebrospinal fluid, 747
 dietary, benefit of, 367
 in extracellular fluid
 aldosterone secretion and, 927
 fibrillation tendency and, 250
 heart function and, 112
 normal range of, 7, 7t, 361
 regulation of, 361–362, 362f, 362t
 gastric acid secretion and, 777–778, 778f
 intestinal absorption of, 796
 neuronal somal membrane and, 552–553, 552f
 renal excretion of, 361, 362–363, 363f
 renal reabsorption of, 331, 331f, 332–333, 362, 363f, 364
 renal secretion of, 311–312, 332, 333, 333f, 362–367, 363f
 acidosis and, 364, 367
 aldosterone and, 337–338, 364–366, 364f, 365f, 366f
 concentration in extracellular fluid and, 364, 364f, 365f, 366f
 distal tubular flow rate and, 364, 366, 366f
 in saliva, 774f, 775, 776
 sports-related loss of, 1040
 in sweat, 870
 in skeletal muscle, 243–244
- Potassium ion channels, 47, 47f, 48, 48f
 of cardiac muscle, 66, 115
 in sinus node, 116
 ventricular action potential and, 115–116
 of cochlear hair cells, 637
 memory and, 708
 of pancreatic beta cells, 945, 945f
 in postsynaptic neuron membrane excitation and, 549
 G-protein-activated, 549, 549f
 inhibition and, 550, 554
 of smooth muscle, 97
 voltage-gated
 in cardiac muscle, 66
 of nerve membrane, 61, 62–63, 62f
- Potassium leak channels, 59, 59f, 60, 63
- Potassium-sparing diuretics, 332, 333f, 399
- Potential energy, of ventricular contraction, 108f, 109
- Potential spaces
 fluids in, 300
 pleural, 483
- Power law for stimulus intensity, 579, 580f
- auditory, 638
- P-Q interval, 121f, 123
- P-R interval, 121f, 123
 prolonged, 144–145, 144f
- Pre-capillary sphincters, 177
 in local blood flow control, 193, 193f
 sympathetic innervation of, 201
 vasomotion of, 178–179, 193
- Precordial leads, 126, 126f
- Prednisolone, 924t
- Prednisone, 922
- Preeclampsia, 1011
 hypertension in, 224
- Prefrontal association area, 699f, 700, 702–703
- Prefrontal cortex
 feeding and, 848
 schizophrenia and, 727
- Prefrontal lobotomy, 702, 703
- Preganglionic neurons
 as cholinergic neurons, 731
 parasympathetic, 731
 sympathetic, 729, 730f
- Pregnancy
 circulatory system during, 1010–1011, 1010f
 hormones secreted in, 1007–1009, 1007f
 maternal body's response to, 1009–1011, 1010f
 metabolism in, 1010
 nutrition in, 1010
 parathyroid enlargement in, 965
 toxemia of, 224
 weight gain in, 1010
- Pregnanediol, 993, 1001
- Pregnenolone, 922, 923f, 932
- Prekallikrein, 455
- Preload, 109
- Prelymphatics, 186
- Premature contractions, 146–147
 atrial, 146, 146f
 A-V nodal or A-V bundle, 146, 146f
 causes of, 146
 definition of, 146
 in long QT syndromes, 147, 148f
 ventricular, 146–147, 147f
 refractory period and, 103, 103f
 in ventricular paroxysmal tachycardia, 148–149
- Premature infant, 1026–1027
 retrolental fibroplasia in, 197–198, 1027
- Premotor area, 667–668, 668f, 698, 699f
 basal ganglia and, 690f, 691–692, 691f
 Broca's area and, 668–669, 669f, 700, 702, 704
 cerebellar communication with, 682, 686, 688
 hand skills and, 669
 voluntary eye movement and, 669
- Preprohormones, 882
- Prerenal acute renal failure, 399–400, 400b
- Presbyopia, 601
- Pressure
 fluid. *See* Hydrostatic pressure; Osmotic pressure.
 gas. *See* Partial pressures.
- Pressure buffer system, 207, 207f
- Pressure diuresis, 213–218, 214f, 215f, 319, 337, 371–373
 aldosterone oversecretion and, 375, 925
 antidiuretic hormone and, 375–376

- Pressure gradient, blood flow and, 159, 160
 Pressure natriuresis, 213, 215, 216, 319, 337, 371–373, 371*f*
 aldosterone oversecretion and, 375, 925
 angiotensin II and, 374, 374*f*
 antidiuretic hormone and, 375–376
 obesity and, 225–226
 Pressure sensations, 571. *See also* Tactile receptors; Tactile sensations.
 on footpads, equilibrium and, 678
 pathways into central nervous system, 573
 Pressure-volume curves, of neonatal lungs, 1021, 1021*f*
 Presynaptic facilitation, memory and, 707, 707*f*, 708
 Presynaptic inhibition, 554
 by enkephalin, 587
 memory and, 707
 Presynaptic membrane, calcium channels in, 548
 memory and, 707, 707*f*, 708
 Presynaptic neuron, 546
 Presynaptic terminals, 547–548, 547*f*.
See also Neurotransmitters.
 long-term memory and, 708
 transmitter release from, 548, 550
 transmitter synthesis in, 550–551
 Pretectal nuclei, visual fibers to, 623
 Prevertebral ganglia, 729
 Primary motor cortex, 667, 668*f*
 damage to, 673
 Primordial follicle, 987, 989, 989*f*
 Primordial germ cells, 973, 974*f*
 Principal cells, renal, 332, 332*f*
 aldosterone and, 337
 potassium and, 362–364, 363*f*
 Procaine, 69
 Procarboxypolypeptidase, 781
 Procoagulants, 453
 Proelastase, 791
 Proerythroblasts, 415, 415*f*. *See also* Erythroblasts.
 erythropoietin and, 416–417
 hemoglobin synthesis in, 417
 Progesterone, 987, 988*f*, 991
 adrenal secretion of, 934
 breast development and, 995, 1014
 chemistry of, 992, 992*f*, 993*f*
 in contraceptive drugs, 1001
 degradation of, 993
 endometrial nutrients and, 1005
 excretion of, 993
 fallopian tube relaxation and, 1004
 functions of, 994–995
 gonadotropin inhibition and, 997, 998
 menstrual cycle and, 995–996
 ovarian cycle and, 990, 991
 plasma protein binding of, 993
 in pregnancy, 1007*f*, 1008–1009
 synthesis of, 992, 992*f*, 993*f*
 uterine contractility and, 1011–1012
 Progestins, 991, 992, 992*f*. *See also* Progesterone.
 in contraceptive drugs, 1001
 Prohormone convertase, 933–934, 933*f*
 Prohormones, 882
 Prolactin, 896, 896*t*
 lactation and, 1014–1015, 1015*f*
 pregnancy and, 1009
 Prolactin inhibitory hormone, 898, 898*t*, 1015
 Prometaphase, 38*f*, 39
 Promoter, 30, 35–36, 35*f*
 Pronucleus
 female, 1003–1004, 1004*f*
 male, 1003–1004, 1004*f*
 Proopiomelanocortin, 933–934, 933*f*
 Proopiomelanocortin neurons, 846, 847, 847*f*, 849, 933–934
 obesity and, 865
 Prophase, 38*f*, 39
 Proprioceptive senses, 571. *See also* Position senses.
 equilibrium and, 678
 Propriospinal fibers, 656–657, 672*f*
 Propulsive movements. *See also* Peristalsis.
 of colon, 770–771
 of small intestine, 769
 Propylthiouracil, antithyroid activity of, 915, 917
 Prosopagnosia, 700
 Prostaglandin(s)
 fertilization and, 1003
 fever and, 876
 glomerular filtration rate and, 318, 319
 platelet synthesis of, 451
 in seminal vesicles, 976
 Prostate gland, 307*f*, 973, 973*f*
 cancer of, 985
 function of, 976
 life cycle changes in, 984–985
 testosterone and, 982–983
 Protanope, 616
 Proteases, in thyroid hormone release, 908*f*, 909
 Proteasomes, muscle atrophy and, 82
 Protein(s). *See also* Plasma proteins.
 absorption of, 797
 amino acids stored as, 833
 as bases, 379
 as buffers, 383–384
 hemoglobin as, 383, 413
 in cell, 11
 in cell membrane, 13, 13*f*, 14, 45, 46*f*
 chemical structures of, 790, 831
 deposition of
 estrogens and, 994
 testosterone and, 835–836, 982–983, 1031
 in diabetes mellitus, depletion of, 951
 dietary
 complete vs. partial, 835, 843
 deficiency of, 843, 901, 902*f*
 energy available in, 843–844
 gastrin release stimulated by, 779
 glomerular filtration rate and, 321
 metabolic utilization of, 844–845
 recommended intake of, 835, 843
 digestion of, 789, 790–791, 791*f*
 enterogastric reflexes and, 767, 768
 pancreatic enzymes in, 781, 791
 as energy source, 834–835
 in starvation, 835, 843–844
 equilibrium between plasma and tissues, 833–834, 834*f*
 in feces, 798
 in interstitial fluid, 185, 187, 189
 in lipoproteins, 821, 821*t*
 in lymph, 187
 metabolism of, 834–835, 834*f*
 cortisol and, 928–929, 936
 hormonal regulation of, 835–836
 insulin and, 944–945
 liver's functions in, 839–840
 obligatory loss of, 835
 renal reabsorption of, 326
 specific dynamic action of, 864–865
 starvation-related depletion of, 852, 852*f*
 storage of
 insulin and, 835, 945
 in neonate, 1025
 structural, 27
 synthesis of. *See also* Transcription; Translation.
 chemical steps in, 34, 34*f*
 Protein(s), synthesis of (*Continued*)
 endoplasmic reticulum and, 20, 20*f*, 33–34, 34*f*
 energy of ATP for, 22, 22*f*, 23, 859
 growth hormone and, 899, 902
 insulin and, 835, 944
 in neonate, 1025
 triglycerides synthesized from, 825
 Protein C, 456–457
 Protein channels, 45, 46–48, 46*f*, 48*f*. *See also* Ion channels.
 gating of, 47, 48, 48*f*, 49*f*
 selective permeability of, 47, 47*f*
 Protein hormones, 881, 882, 885*f*
 Protein kinase A, 932
 Protein kinase C (PKC), 890, 890*f*
 Protein kinases
 calmodulin-dependent, 891
 glucagon and, 948
 hormone action and, 882, 891
 Protein spacers, 843–844
 Proteinuria, in minimal change nephropathy, 313–314
 Proteoglycan filaments, 180–181, 180*f*
 fluid flow and, 299
 of glomerular capillary wall, 312, 313
 interstitial fluid pressure and, 299
 as spacer for cells, 299
 Proteoglycans, 14, 20
 of bone, 957, 958
 Proteolytic enzymes
 in acrosome, 975, 977
 of phagocytic cells, 426
 Proteoses, 783, 791
 Prothrombin, 453, 453*f*, 454
 Prothrombin activator, 453, 453*f*, 454–456, 455*f*, 456*f*
 Prothrombin time, 460–461, 460*f*
 Protoplasm, 11
 Proximal tubule, 306, 306*f*
 glomerulotubular balance of, 334–335
 reabsorption in, 329–330, 329*f*, 330*f*
 of amino acids, 325–326
 of calcium, 368, 368*f*, 369
 of glucose, 325–326
 of phosphate, 369
 of potassium, 362, 363*f*
 of sodium, 327–328
 of water, 328
 secretion by, 329*f*, 330
 urine concentration and, 346, 346*f*, 348*t*, 352
 PRU (peripheral resistance unit), 162–163
 Pseudopodium, 23, 23*f*
 Psychomotor seizure, 725*f*, 726
 Psychosis, 726
 manic-depressive, 727
 Pteroylglutamic acid. *See* Folic acid.
 PTH. *See* Parathyroid hormone (PTH).
 Ptyalin, 774*f*, 775, 790
 Puberty
 female, 988, 993, 998–999, 998*f*, 999*f*
 anovulatory cycles at, 998
 gonadotropic hormone levels at, 998–999, 998*f*
 regulation of onset, 984, 999
 Pudendal nerve
 external anal sphincter and, 771
 external bladder sphincter and, 308, 308*f*, 310
 Pulmonary. *See also* Lungs.
 Pulmonary artery(ies), 477
 distensibility of, 167
 Pulmonary artery pressure, 158, 159*f*, 477, 478, 478*f*. *See also* Pulmonary hypertension.
 elevated, in mitral valve disease, 269
 during exercise, 480, 481*f*
 left-sided heart failure and, 481
 Pulmonary artery stretch receptors, 208
 sodium excretion and, 376

- Pulmonary capacities, 469–471, 469*f*, 470*t*
- Pulmonary capillaries, 489, 490, 490*f*
 damage to, causing pulmonary edema, 482
 fluid exchange at, 481–483, 482*f*, 482*t*
 J receptors adjacent to, 512
 length of time blood stays in, 481
 oxygen therapy and, 521*f*
 pressure in, 158, 159*f*; 478, 478*f*, 481
 as sheet of flow, 481, 489
- Pulmonary circulation, 157, 158*f*, 477–484
 anatomy of, physiologic, 477
 blood flow distribution
 alveolar oxygen concentration and, 479
 hydrostatic pressure zones and, 479–481, 479*f*, 480*f*
 ventilation-perfusion ratio and, 492–494
 blood volume in, 157, 478–479
 capillary dynamics in, 481–483, 482*f*
 exercise and, 480, 481*f*
 left-sided heart failure and, 478–479, 481
 pressures in, 158, 159*f*; 477–478, 478*f*
 two components of, 477
- Pulmonary congestion
 in heart failure, left-sided, 259
 patent ductus arteriosus with, 270
- Pulmonary edema, 482–483, 482*f*
 in acute mountain sickness, 530
 common causes of, 482
 in decompression sickness, 538
 in heart failure, 256, 298
 as acute edema, 261
 aortic valve lesions and, 268, 269
 decompensated, 258
 left-sided, 259, 482, 483
 after myocardial infarction, 250, 256
 oxygen therapy in, 521, 521*f*
 in oxygen toxicity, 537
 patent ductus arteriosus with, 270
 in shock, hypovolemic, 277
 in valvular heart disease
 aortic valve, 268, 269
 mitral valve, 269
- Pulmonary embolism, 459
- Pulmonary function, abbreviations and symbols for, 470*t*
- Pulmonary function studies, 469–471, 469*f*
- Pulmonary hypertension. *See also* Pulmonary artery pressure.
 emphysema leading to, 518
 endothelin receptor blockers for, 196
 at high altitude, 530, 531
- Pulmonary membrane. *See* Respiratory membrane.
- Pulmonary valve, 107
 congenital stenosis of, 136, 136*f*, 137
 second heart sound and, 107, 266, 266*f*
- Pulmonary vascular resistance
 alveolar oxygen concentration and, 479
 decrease at birth, 1023
 total, 163
- Pulmonary veins, 477
- Pulmonary venous pressure, 478
- Pulmonary ventilation, 465–475
 acid-base disorders and, 392
 alveolar. *See* Alveolar ventilation.
 definition of, 465
 energy required for, 468
 during exercise, 1037, 1037*t*
 mechanics of, 465–468, 466*f*, 467*f*
 minute respiratory volume in, 471
 respiratory passageways in, 472–475, 472*f*
 volume and capacity measurements of, 469–471, 469*f*, 470*t*
- Pulmonary volumes, 469–471, 469*f*, 470*t*
- Pulmonary wedge pressure, 478
- Pulp
 of spleen, 175, 175*f*
 of teeth, 969, 969*f*, 970
- Pulse deficit, premature contractions and, 146
- Pulse pressure. *See also* Arterial pressure pulses.
 definition of, 168
 determinants of, 168–169
- Punishment centers, 717–718
 memory and, 709
- Pupillary diameter, 601–602, 602*f*
 autonomic control of, 632, 734*t*, 735
 dark adaptation by, 615
- Pupillary light reflex, 623, 631*f*, 632, 735
 in central nervous system disease, 632
- Pupillary reaction to accommodation, 632
- Purines, 27, 37
- Purkinje cells, 684–685, 684*f*, 686
- Purkinje fibers, 115, 117–118
 action potentials in, 102*f*, 103, 117
 blocks in. *See also* Bundle branch block.
 multiple small, 138
 QRS prolongation caused by, 138
 ectopic pacemaker in, 119–120
 intrinsic rhythmicity of, 119
 synchronous ventricular contraction and, 119
- Pursuit movement, 629
- Pus, formation of, 430
- Putamen, 670, 690, 690*f*, 691*f*
 Huntington's disease and, 694
 lesions in, 691
 neurotransmitters in, 692–693, 692*f*
 Parkinson's disease and, 693
- Putamen circuit, 690–691, 690*f*, 691*f*
- PVCs (premature ventricular contractions), 146–147, 147*f*
 refractory period and, 103, 103*f*
- Pyelonephritis, 403–404
- Pyloric glands, 777, 778, 779
- Pyloric pump, 767, 768
- Pyloric sphincter, 756, 767, 768
- Pylorus, 767
- Pyramidal cells, 697, 698*f*
 in motor cortex, 669–670, 671, 672
 somatosensory feedback to, 672
- Pyramidal tract. *See* Corticospinal (pyramidal) tract.
- Pyridoxal phosphate, 854
- Pyridoxine, 854–855
 amino acid synthesis and, 834, 854
- Pyrimidines, 27, 37
- Pyrogens, 875–876
- Pyrophosphate, 958
- Pyruvic acid, 22
 alanine derived from, 834, 834*f*
 conversion back to glucose, 816
 conversion to acetyl-CoA, 812–813
 conversion to lactic acid, 816
 from glycolysis, 812, 812*f*
 production from lactic acid, 816
- Q**
- Q wave, 121, 121*f*, 132
 after myocardial infarction, 141, 141*f*
- QRS complex, 121, 121*f*
 bizarre patterns of, 138, 141
 cardiac cycle and, 105, 105*f*
 current of injury and, 138, 139*f*
 monophasic action potential and, 122, 122*f*
 normal voltage of, 123
 prolonged
 definition of, 138
 after myocardial infarctions, 137, 137*f*, 141
 premature ventricular contractions with, 146
 from Purkinje system blocks, 136*f*, 138
 in ventricular hypertrophy or dilatation, 137–138
 vectorial analysis of, 131–132, 132*f*
- QRS complex (*Continued*)
 ventricular contraction and, 122–123
 voltage abnormalities of, 137, 137*f*
- QRS vectorcardiogram, 134, 134*f*
- Q-T interval, 121*f*, 123
 prolonged, 147, 148*f*
- Quinidine
 for paroxysmal tachycardia, 148
 for ventricular tachycardia, 149
- R**
- R wave, 121, 121*f*, 132
- Radiation, heat loss by, 868–869, 869*f*
- Radioimmunoassay, 891–892, 892*f*
- Rage pattern, 718
 amygdala and, 719
 limbic cortex and, 720
 sympathetic discharge in, 739
- RANK ligand, 959
- Raphe magnus nucleus, 586–587, 587*f*
- Raphe nuclei
 serotonin system and, 713, 713*f*
 sleep and, 722
- Rapid ejection, period of, 106
- Rate of movement sense, 571, 580
- Rate receptors, 563
- Rathke's pouch, 895
- Reabsorption pressure, net, 185, 186
- Reactive hyperemia, 194
- Reading, 700, 702, 704*f*, 705
- Reagents, 443, 444
- Receptor field, of nerve fiber, 564
- Receptor potentials, 560–562, 561*f*
 of cochlear hair cells, 637–638
 of rods, 612–613
 of taste cells, 647
- Receptor proteins
 of olfactory cilium, 649, 649*f*
 postsynaptic, 547*f*, 548–550, 549*f*
 down-regulation or up-regulation of, 569–570
 in taste villus, 647
- Receptors, cell membrane, 14
 carbohydrates as, 14
 phagocytosis and, 19
 pinocytosis and, 18–19
- Reciprocal inhibition, 566–567, 567*f*, 663
 flexor reflex and, 662, 662*f*, 663, 663*f*
- Reciprocal innervation, 663, 672
- Recoil pressure, of lungs, 467
- Red blood cell count, in neonate, 1024, 1024*f*
- Red blood cells (erythrocytes), 413–420
 A and B antigens on, 445–447, 446*f*, 446*t*, 447*t*
 concentration of, in blood, 413
 cortisol and, 931
 destruction of, 840, 841
 fetal, 1019, 1020
 functions of, 413
 hemoglobin concentration in, 413. *See also* Hemoglobin.
 life span of, 419–420, 840
 metabolic systems of, 419
 production of, 414–417, 414*f*, 415*f*
 regulation of, 416–417, 416*f*
 radiolabeled, in blood volume measurement, 290
 shape and size of, 413, 415*f*
 spleen as reservoir for, 175
 splenic removal of, 175
 testosterone and, 982
- Red muscle, 79
- Red nucleus, 670–671, 671*f*, 678*f*
 basal ganglia and, 690*f*
 cerebellar input from, 687, 687*f*
 cerebellar input to, 684, 687
 dynamic neurons in, 672

- Red pulp, of spleen, 175, 427–428
- Reduced eye, 600
- Re-entry, 149–150
- fibrillation and, 150
- Referred pain, 588, 588*f*
- headache as, 591
 - from visceral organs, 588, 589, 589*f*
- Reflexes
- autonomic, 665, 729, 738
 - local, 738
 - spinal. *See* Spinal cord reflexes.
- Reflexive learning, 709
- Refraction of light, 597, 597*f*. *See also* Lenses.
- Refractive errors, 602–604, 602*f*, 603*f*, 604*f*
- Refractive index, 597
- of parts of eye, 600, 600*f*
- Refractive power, 599*f*, 600, 600*f*
- of eye, 600, 600*f*
- Refractory period
- of cardiac muscle, 103, 103*f*
 - of nerve fiber, 69
- Regression of tissues, lysosome role in, 19
- Regulatory T cells, 442
- Regurgitation, valvular, 267
- Reinforcement, 718
- Reissner's membrane, 634–635, 634*f*
- Relative refractory period, of cardiac action potential, 103, 103*f*
- Relaxin, 1009
- Release sites, on presynaptic membrane, 548
- Renal. *See also* Kidney(s).
- Renal artery stenosis, 223–224, 223*f*, 407
- Renal blood flow, 315, 316–317, 317*t*.
- See also* Renal ischemia.
 - age-related decrease in, 403
 - autoregulation of, 317, 319–321, 319*f*, 320*f*
 - estimation of, 340*t*, 341–342, 342*f*
 - filtration fraction calculated from, 342
 - medullary, 317, 351–352
 - physiologic control of, 317–319
 - in pregnancy, 1011
- Renal clearance methods, 340–343, 340*t*, 341*f*, 342*f*, 343*t*
- Renal failure
- acute, 399
 - body fluid effects of, 406, 406*f*
 - causes of, 399–401, 400*b*
 - in hypovolemic shock, 277–278
 - physiologic effects of, 401
 - in transfusion reactions, 448–449
- chronic, 399, 401–407. *See also* End-stage renal disease (ESRD).
- anemia in, 406
 - body fluid effects of, 406–407, 406*f*
 - causes of, 401, 402*b*
 - glomerulonephritis leading to, 403
 - hypertension leading to, 218
 - metabolic acidosis in, 393
 - nephron function in, 404–405, 405*f*, 405*t*, 406*f*
 - osteomalacia in, 406–407
 - progression to end stage, 401–402, 402*f*, 402*t*
 - pyelonephritis leading to, 403–404
 - transplantation for, 409
 - vascular lesions leading to, 403
 - dialysis for, 409–410, 409*f*, 410*t*
 - nephrotic syndrome in, 404
- Renal function curves, sodium-loading, 226, 226*f*. *See also* Renal output curve.
- Renal glycosuria, 408–409
- Renal ischemia
- acute renal failure caused by, 399–400, 400*b*, 401
 - chronic renal failure associated with, 403
 - hypertension caused by, 407
- Renal output curve, 213, 214*f*
- angiotensin II and, 222, 222*f*
 - chronic, 215–216, 215*f*
 - determinants of pressure and, 214–215, 215*f*
 - infinite feedback gain and, 214, 214*f*
- Renal tubular acidosis, 392, 408
- Renal tubules. *See also* Distal tubule; Loop of Henle; Proximal tubule.
- active transport in, 55–56, 55*f*
 - hydrogen ion transport in, 54, 55
- Renin, 220
- decreased, in primary aldosteronism, 936
 - glomerular filtration rate and, 320
 - increased, hypertension caused by, 407
- Renin-angiotensin system
- aldosterone secretion and, 927
 - arterial pressure control and, 220–222, 220*f*, 221*f*, 222*f*
 - in integrated response, 227, 227*f*, 228
 - in cardiac failure, 260
 - hypertension and, 223–224, 223*f*
 - in hypovolemic shock, 275
- Renointestinal reflex, 772
- Renshaw cells, 656–657
- Repolarization, in action potential, 61, 61*f*
- Repolarization waves, 121–123, 122*f*. *See also* T wave.
- long QT syndromes and, 147, 148*f*
- Reproduction, homeostatic function of, 6
- Residual body, of digestive vesicle, 19, 19*f*
- Residual volume, 469, 469*f*
- in asthma, 520
 - determination of, 471
- Resistance, vascular. *See* Vascular resistance.
- Respiration. *See also* Breathing.
- artificial, 522–523, 522*f*
 - in athletes, 1035*f*, 1036–1038, 1037*f*, 1037*t*
 - functions carried out in, 465
 - in neonates, 1021–1022, 1021*f*, 1024, 1026
 - in pregnancy, 1010
 - regulation of. *See* Respiratory control.
 - thyroid hormones and, 913
- Respiratory acidosis. *See* Acidosis, respiratory.
- Respiratory alkalosis. *See* Alkalosis, respiratory.
- Respiratory bronchiole, 472–473, 489, 489*f*
- Respiratory center, 505–507, 506*f*
- brain edema and, 512
 - chemoreceptor transmission to, 507, 508, 508*f*, 509
 - Cheyne-Stokes breathing and, 512
 - direct chemical control of, 507–508, 507*f*, 508*f*
 - exercise-related stimulation of, 510, 511
 - high altitude and, 529
 - panting and, 871
 - sleep apnea and, 513
- Respiratory control, 505–513
- anesthesia and, 512
 - brain edema and, 512
 - in central sleep apnea, 513
 - during exercise, 510–511, 510*f*, 511*f*
 - irritant receptors in, 512
 - J receptors in, 512
 - in periodic breathing, 512–513, 512*f*
 - peripheral chemoreceptors in, 507, 508–510, 508*f*, 509*f*, 510*f*
 - respiratory center in. *See* Respiratory center.
 - voluntary, 512
- Respiratory disorders, 515
- constricted, 516, 516*f*
 - hypoxia in, 520
 - methods for studying, 515
 - blood gases and pH, 515–516
 - forced expiratory vital capacity, 517, 517*f*
 - forced expiratory volume, 517, 517*f*
 - maximum expiratory flow, 516–517, 516*f*
 - pulmonary function studies, 469–471, 469*f*
- Respiratory disorders (*Continued*)
- specific pathophysiology, 517–520
 - asthma, 520
 - atelectasis, 519, 519*f*
 - emphysema, 517–518, 518*f*
 - pneumonia, 518–519, 518*f*, 519*f*
 - tuberculosis, 520
- Respiratory distress syndrome, neonatal, 468, 519, 1022, 1026
- Respiratory exchange ratio, 504, 844–845
- Respiratory membrane, 489–490, 490*f*
- diffusing capacity of, 491–492
 - at high altitude, 529
 - diffusion of gases through, 485, 486, 487, 489–492, 492*f*
 - impaired, hypoxia caused by, 520, 521, 521*f*, 522
- Respiratory muscles, 465, 466*f*
- Respiratory passages, 472–475, 472*f*
- humidification in, 487, 487*t*
- Respiratory quotient, 844–845
- Respiratory rate, minute respiratory volume and, 471
- Respiratory tract, insensible water loss through, 285, 286*t*
- Respiratory unit, 489, 489*f*
- Respiratory waves, 210
- Response element. *See* Hormone response element.
- Resting membrane potential
- of gastrointestinal smooth muscle, 753–754, 754*f*, 755
 - of nerve fiber, 59–60, 59*f*, 60*f*
 - of neuronal soma, 552, 552*f*
 - of skeletal muscle fiber, 87
 - of smooth muscle, 95
- Resuscitators, respiratory, 522–523, 522*f*
- Reticular activating system. *See* Reticular substance, excitatory area in.
- Reticular lamina, hair cells and, 637–638, 637*f*
- Reticular nuclei, 673–674, 673*f*, 678
- alpha waves and, 724
 - limbic system and, 715
- Reticular substance
- autonomic regulation and, 739
 - basal ganglia and, 690*f*
 - cerebellar input to, 684
 - excitatory area in, 711–712, 712*f*
 - acetylcholine system and, 713
 - auditory pathways and, 639
 - sleep and, 722, 723
 - hypothalamus and, 715
 - inhibitory area in, 712, 712*f*
 - limbic system and, 715
 - motor fibers leading to, 670
 - pain perception and, 586
 - vestibular apparatus and, 678*f*
- Reticulocerebellar tracts, 670, 683, 683*f*
- Reticulocytes, 415, 415*f*, 417
- Reticuloendothelial cells
- of liver sinusoids, 759–760, 837
 - of spleen, 175
- Reticuloendothelial system, 426–428. *See also* Macrophages, tissue.
- Reticulospinal tracts, 670, 672*f*, 673–674, 674*f*, 678, 678*f*
- Retina, 609–621
- anatomic and functional elements of, 609–611, 610*f*. *See also* Cones; Ganglion cells, of retina; Rods.
 - blood supply of, 611
 - electrotonic conduction in, 617–618
 - glucose for, 949
 - layers of, 609, 610*f*
 - light and dark adaptation by, 614–615, 614*f*
 - neural function of, 616–621, 617*f*, 618*f*, 620*f*

- Retina (*Continued*)
 peripheral vs. central, 619. *See also* Fovea.
 photochemistry of, 611–615, 611f, 612f, 613f.
See also Color vision.
- Retinal, 611–612, 611f, 613
 identical in rods and cones, 614
- Retinal artery, central, 611
- Retinal detachment, 611
- Retinal isomerase, 611f, 612
- Retinitis pigmentosa, 627
- Retinoid X receptor, 910, 911f, 962
- Retinol, 853
- Retrograde amnesia, 709
- Retrolental fibroplasia, 197–198, 1027
- Reverberatory circuits, 567–568, 567f, 568f
 continuous output from, 568, 568f
 in focal epilepsy, 726
 rhythmical output from, 568
- Reverse enterogastric reflex, 780
- Reverse T₃ (RT₃), 908f, 909, 909f
- Reverse transcriptase, 41
- Reward centers, 717, 718
 memory and, 709
- Reynolds' number, 161–162
- Rh blood types, 447–449
 erythroblastosis fetalis and, 420, 447–448, 1024
- Rh immunoglobulin globin, 448
- Rheumatic fever, 442
 valvular lesions caused by, 266–267
- Rhodopsin, 609, 611–614, 611f, 613f
 absorption curve for, 614, 614f
- Rhodopsin kinase, 614
- Rhythm method of contraception, 1001
- Riboflavin (vitamin B₂), 854
- Ribonucleic acid. *See* RNA (ribonucleic acid).
- Ribose, 30
- Ribosomal RNA, 31, 32
- Ribosomes
 endoplasmic reticulum and, 14, 20, 20f,
 33–34, 34f
 formation of, 32
 insulin and, 944
 nucleoli and, 17, 32
 protein synthesis on, 32f, 33–35, 34f
 structure of, 32
- Rickets, 968–969
 in hypophosphatemia, 408
 parathyroid enlargement in, 965
 vitamin D-resistant, 969
- Rickettsia, 17–18, 18f
- Right atrial pressure, 172
 cardiac output and, 172. *See also* Cardiac
 output curves.
 exercise and, 245
 in heart failure
 compensated, 257
 decompensated, 258
 measurement of, 174–175, 174f
 peripheral venous pressure and, 172
 venous return and. *See* Venous return curves.
- Right atrium, stretch of, heart rate increase
 and, 110
- Right bundle branch block, right axis deviation
 in, 136–137, 137f
- Right ventricle
 external work output of, 108
 maximum systolic pressure, 108
- Right ventricular dilatation, QRS prolongation
 in, 137–138
- Right ventricular hypertrophy
 electrocardiogram with, 136, 136f, 137
 QRS prolongation in, 137–138
 in mitral valve disease, 269
- Right ventricular pressure curve, 477, 478f
- Right-handedness, 702
- Righting reflex, 664
- Right-sided heart failure, emphysema leading
 to, 518
- Right-to-left shunt, 269
 in tetralogy of Fallot, 271, 271f
- Rigor mortis, 82
- RISC (RNA-induced silencing complex), 32–33
- RNA (ribonucleic acid), 27, 27f
 building blocks of, 30
 noncoding, 32–33
 in nucleolus, 17
 synthesis of, 29f, 30–31
 types of, 31. *See also specific types.*
 viral, 18
- RNA codons, 29f, 30, 31–32, 31t, 32f
- RNA polymerase, 29f, 30, 35
- RNA-induced silencing complex (RISC), 32–33
- Rods, 609
 absorption curve for, 614, 614f
 dark adaptation by, 614–615
 electrotonic conduction in, 617–618
 ganglion cells excited by, 619
 neural circuitry and, 616–617, 617f
 pathway to ganglion cells, 617, 617f
 neurotransmitter released by, 617
 number of, 619
 of peripheral retina, 619
 photochemistry of, 611–614, 611f, 612f, 613f
 structure of, 609, 610f
- Rods of Corti, 637, 637f
- Root, of tooth, 969, 969f
- Round window, 635, 635f
- RT₃ (reverse T₃), 908f, 909, 909f
- Rubrospinal tract, 670–671, 671f, 687, 687f
- Ruffini's corpuscles, 572
 joint angulation and, 580
- Ruffini's endings, 560f, 572
- Rugae, of bladder mucosa, 308
- Ryanodine receptor channels
 in cardiac muscle, 103
 in skeletal muscle, 88
- S**
- S cells, intestinal, 782
- S wave, 121, 121f, 132
- Saccades, 629, 688
- Saccule, 674–675, 675f, 676–677
- Safety factor
 for nerve impulse propagation, 65
 local anesthetics and, 69
 of neuromuscular junction, 85–86
- Sagittal sinus, negative pressure in, 173
- Saline solutions
 fluid shifts and osmolarities caused by,
 293–294, 293f
 isotonic, 291–292, 293, 293f
- Saliva, 775–776
 daily volume of, 775
 ions in, 775–776
 lingual lipase in, 792
 oral hygiene and, 776
 proteins in, 775
 ptyalin in, 774f, 775, 790
- Salivary glands, 773, 774f, 775
 aldosterone and, 926
 blood supply to, 776
 nervous regulation of, 730–731, 731f, 734t,
 735, 776, 776f
 taste signals and, 648, 776
- Salpingitis, infertility secondary to, 1002
- Salt appetite, 360
- Salt intake. *See also* Sodium; Sodium chloride.
 pressure diuresis and, 217–218. *See also*
 Pressure natriuresis.
 renin-angiotensin system and, 222, 222f, 228
- Salt sensitivity, 216, 372
 essential hypertension and, 226, 226f
- Saltatory conduction, 68, 68f
- Salty taste, 645, 646, 646t
- Sarcolemma, of skeletal muscle, 71, 87f
- Sarcomere(s), of skeletal muscle, 71, 72f, 73f, 74
 addition or subtraction of, 82
 length of, tension and, 77, 77f
- Sarcoplasm, 73
- Sarcoplasmic reticulum
 of cardiac muscle, 103–104, 104f
 of skeletal muscle, 73, 73f
 in fast fibers, 79
 release of calcium by, 74, 88–89, 88f
 T tubules and, 87f, 88, 88f
 uptake of calcium by, 74, 78, 88–89, 88f
 of smooth muscle, 97–98, 98f
- Satiety, 845
- Satiety center, 716, 845, 849
- Saturated fat, blood cholesterol and, 827
- Saturation diving, 539
- Scala media, 634–635, 634f, 635f, 637
- Scala tympani, 634–635, 634f, 635f, 636, 637
- Scala vestibuli, 634–635, 634f, 635f, 636, 637
- Schistosomiasis, 430
- Schizophrenia, 727
- Schlemm, canal of, 607, 607f, 608
- Schwann cells, 67, 67f
 at neuromuscular junction, 83
 at smooth muscle nerve endings, 95
- Scotomata, 627
- Scotopsin, 611–612, 611f
- Scratch reflex, 664
- SCUBA diving, 539, 539f
- Scurvy, 855
- Second heart sound, 265–266, 267f
- Second messengers, 14. *See also* Cyclic
 adenosine monophosphate (cAMP);
 Cyclic guanosine monophosphate
 (cGMP).
 adrenergic or cholinergic receptors and, 733
 hormonal functions and, 888, 889–891
 adenylyl cyclase-cAMP and, 889–890,
 889b, 890f
 aldosterone and, 927
 calcium-calmodulin and, 891
 phospholipase C and, 890, 890b, 890f
 thyroid hormones and, 910, 914
 in postsynaptic neurons, 548–549, 549f
 in smooth muscle, 97
 in taste cells, 647
- Second-degree heart block, 145, 145f
- Secretin, 758, 758t
 bile secretion and, 784, 784f, 785
 duodenal mucous glands and, 786
 gastric secretion and, 780
 molecular structure of, 780
 pancreatic secretions and, 782–783, 800
 small intestine motility and, 769
 stomach emptying and, 768
- Secretory granules. *See* Secretory vesicles.
- Secretory vesicles, 16, 16f, 21
 of gastrointestinal glands, 774
 of polypeptide and protein hormones, 882
- Segmentation contractions
 of colon, 770
 of small intestine, 768–769, 768f
- Seizures. *See also* Epilepsy.
 hippocampal, 719
 in oxygen poisoning, 536
- Self-antigens, 434–435
- Semen, 976–977
 ejaculation of, 979
- Semicircular ducts, 674, 675f, 676, 676f,
 677, 677f
 flocculonodular lobes and, 678, 689
- Semilunar valves, 106–107, 107f. *See also*
 Aortic valve; Pulmonary valve.
 second heart sound and, 107, 265–266
- Seminal vesicles, 973, 973f, 976

- Seminiferous tubules, 973–974, 973*f*, 974*f*
 estrogen in, 980
 injury to, 977
 negative feedback control of, 984
- Sensitization, memory and, 706
- Sensory areas, of cerebral cortex, 698, 698*f*, 699*f*
- Sensory nerve fibers
 classification of, 563–564, 563*f*
 in spinal cord, 655, 655*f*, 656–657, 656*f*
 summation in, 564, 564*f*, 565*f*
- Sensory pathways. *See also* Anterolateral system; Dorsal column–medial lemniscal system.
 into central nervous system, 569
 corticofugal, 581–582
 inhibitory feedback in, 569
- Sensory receptors, 543, 544*f*. *See also* Tactile receptors.
 adaptation of, 562–563, 562*f*
 differential sensitivity of, 559
 receptor potentials of, 560–562, 561*f*
 types of, 559, 560*b*, 560*f*
- Sensory signals
 brain stem excitatory area and, 711–712
 hippocampal activation by, 718–719
- Sensory stimulus intensity
 enormous range of, 579
 judgment of, 579, 580*f*
- Septic shock, 280
 disseminated intravascular coagulation in, 459
- Serotonin
 in basal ganglia, 692–693, 692*f*
 as central nervous system transmitter, 551
 depression and, 726–727
 endogenous analgesia system and, 587
 from mast cells and basophils, 431
 memory and, 707–708
 reticular inhibitory area and, 712
 sleep and, 722
 small intestine peristalsis and, 769
- Serotonin system, in brain, 712, 713, 713*f*
- Sertoli cells, 974, 974*f*, 975, 976
 estrogen formed by, 980
 follicle-stimulating hormone and, 984
 inhibin secreted by, 984
- Serum, 454
- Sex chromosomes, 974–975, 981, 1003, 1004
- Sex determination, 1004
- Sex hormone–binding globulin, 980
- Sexual act
 female, 1000
 lubrication for
 by female glands, 1000
 by male glands, 979
 male, 978–979
- Sexual behavior
 amygdala and, 720
 hypothalamus and, 717
- Sexual function, thyroid hormones and, 914
- Sexual reflexes, 738, 978, 1000
- Sexual sensation
 anterolateral system and, 573
 male structures associated with, 978
- Shaken baby syndrome, 746
- Shingles, 590
- Shivering, 867
 fever and, 876, 876*f*
 hypothalamic stimulation of, 873
 set-point and, 874, 874*f*
 primary motor center for, 873
 skin receptors and, 872
- Shock. *See* Anaphylactic shock; Cardiogenic shock; Circulatory shock; Hypovolemic shock; Septic shock
- Shock lung syndrome, 277–278
- Short interfering RNA (siRNA), 33
- Shunt
 congenital, 269. *See also* Patent ductus arteriosus.
 physiologic, 493, 494
 oxygen therapy and, 521
- Shunt flow, 496
- Sibutramine, for weight loss, 851
- Sickle cell anemia, 415*f*, 420
 hemoglobin structure in, 418
- Signal transducer and activator of transcription (STAT) proteins, 888
- Silencing RNA (siRNA), 33
- Siliconized containers, 460
- Simple cells, of visual cortex, 626, 627
- Simple spike, 685
- Sinoatrial block, 144, 144*f*
- Sinoatrial node. *See* Sinus node.
- Sinus arrhythmia, 144, 144*f*
- Sinus bradycardia, 143–144, 143*f*
- Sinus node, 115–116, 116*f*
 action potentials in, 115–116, 116*f*
 atrial stretch and, 229–230
 as pacemaker, 118–119
 parasympathetic stimulation and, 119, 120
 sympathetic stimulation and, 120
- Sinus tachycardia, 143, 143*f*
- Sinuses, nasal, headache associated with, 591–592, 591*f*
- siRNA (silencing RNA), 33
- Size principle, 80
- Skeletal motor nerve axis, 543–544, 544*f*
- Skeletal muscle, 71–82. *See also* Motor functions; Neuromuscular junction.
 action potentials in. *See* Action potential(s), skeletal muscle.
 agonist-antagonist coactivation of, 81
 neuronal circuits and, 566
 in arterial pressure control, 209–210
 in athletes. *See* Sports physiology, muscles in
 atrophy of, 81, 82
 blood flow in, 191, 192*t*, 243
 control of, 191, 195, 196–197, 198, 243–244
 during exercise, 1038, 1038*f*, 1038*t*
 during rhythmical contractions, 243, 244*f*, 1038*f*
 total body circulation and, 244–245
 capillary pores in, permeability of, 179, 180*t*
 vs. cardiac muscle, 102–104
 central nervous system control of, 543–544, 544*f*
 contraction mechanism of, 74–78, 74*f*, 75*f*, 76*f*
 sequential steps of, 73–74
 contracture of, 82
 decreased mass of, cardiac output and, 234
 denervation of, 82
 different functional types of, 79, 79*f*, 81
 efficiency of, 78–79
 energy sources for, 73, 74, 75, 76, 78–79
 in athletes, 1032, 1033*f*, 1033*t*, 1034*b*, 1035, 1035*f*
 excitation-contraction coupling in, 87, 88–89, 88*f*, 89*f*
 fast and slow fibers in, 79, 1036, 1036*t*
 fatigue in, 80–81
 fatty acid diffusion into, 820
 force of
 vs. length, 77, 77*f*
 vs. velocity of contraction, 77–78, 77*f*
 glucose in, insulin and, 941–942, 946*f*
 glycogen in, 78, 80–81, 811, 941
 during exercise, 1032, 1032*t*, 1035
 recovery of, 1034, 1035*f*
 hyperplasia of, 82
- Skeletal muscle (*Continued*)
 hypertrophy of, 81–82
 exercise training and, 1035–1036
 innervation of, 80, 83
 insulin and, 941–942, 946*f*
 isometric vs. isotonic contraction of, 79, 79*f*
 length of
 vs. force, 77, 77*f*
 remodeling of, 82
 lever systems using, 81, 81*f*
 maximum strength of, 80
 motor units of, 80
 after poliomyelitis, 82
 remodeling of, to match function, 81–82
 respiratory, 465, 466*f*
 dyspnea associated with, 522
 sensory receptors in. *See* Golgi tendon organs; Muscle spindles.
 vs. smooth muscle, 91, 92–93, 94
 staircase effect of, 80
 strenuous bursts of activity with, 860–861
 structural organization of, 71–73, 72*f*, 73*f*
 summation in, 80, 80*f*
 sympathetic vasodilator system and, 204
 tension developed in, 77, 77*f*
 testosterone and, 835–836, 982
 tetanization in, 80, 80*f*
 thyroid hormones and, 913
 tone of, 80
 velocity of contraction vs. load on, 77–78, 77*f*
 work output of, 78
- Skill learning, 709
- Skill memory, 706–707
- Skin
 blood flow control in, 195
 cholesterol in, 827
 in defense against infection, 433
 estrogens and, 994
 heat loss through
 blood flow and, 868, 868*f*
 mechanisms of, 868–870, 869*f*
 homeostatic functions of, 6
 insensible water loss through, 285, 286*t*
 testosterone and, 982
 tissue macrophages in, 426
 vitamin D synthesis in, 960
- Skin graft, interstitial fluid pressure and, 183
- Skin temperature, 867
 local reflexes regulating, 875
 set-point and, 874, 874*f*
- Sleep, 721–725
 basic theories of, 722–723
 brain waves in, 723, 724, 725, 725*f*
 cycle between wakefulness and, 722–723
 growth hormone secretion and, 901, 901*f*
 metabolic rate and, 864
 physiologic functions of, 723–724
 rapid eye movement (REM), 712–713, 721–722
 brain waves in, 725, 725*f*
 deprivation of, 723
 possible cause of, 722
 slow-wave, 721–725
 brain waves in, 725, 725*f*
 thyroid hormones and, 913
- Sleep apnea, 513
- Slit pores, of glomerular capillaries, 312–313, 313*f*
- Slow calcium channels, 64
 in cardiac muscle, 102–103
- Slow ejection, period of, 106
- Slow muscle fibers, 79
- Slow pain, 583
- Slow sodium-calcium channels, in cardiac muscle, 66, 115
 sinus nodal action potential and, 116
 ventricular action potential and, 115–116

- Slow waves, of gastrointestinal smooth muscle, 753–754, 754f, 755
 in small intestine, 769
 in stomach, 766
- Slow-chronic pain pathway, 584–585, 585f, 586
- Slow-reacting substance of anaphylaxis, 443, 444
 in asthma, 520
 bronchiolar constriction caused by, 473
- Slow-twitch muscle fibers, 1036, 1036t
- Sludged blood
 in circulatory shock, 277
 in septic shock, 280
- Small interfering RNA (siRNA), 33
- Small intestine. *See also* Duodenum.
 absorption in
 active transport in, 55–56, 55f
 anatomical basis of, 793–794, 793f, 794f
 of ions, 794–796, 795f
 of nutrients, 796–797
 total area of, 794
 total capacity of, 794
 total volume of, 793
 of water, 794
 carbohydrate digestion in, 790
 digestive enzymes of, 787, 790
 disorders of, 801–802
 fat digestion in. *See* Fats, digestion of.
 malabsorption by, 801–802
 movements of, 768–770, 768f, 770f
 obstruction of, 804, 804f
 peptic ulcer of, 800, 801
 secretions of, 786–787
 secretory cells of, 773, 774f
- Smell, 648–652. *See also* Olfaction.
 adaptation of, 650
 affective nature of, 650
 intensities detectable by, 650
 olfactory cell stimulation in, 649–650, 649f
 olfactory membrane in, 648–649, 649f
 primary sensations of, 650
 signal transmission into central nervous system, 651–652, 651f
 taste and, 645
 threshold for, 650
- Smoking
 atherosclerosis and, 829
 peptic ulcer and, 801
 pulmonary ventilation in exercise and, 1037–1038
- Smooth endoplasmic reticulum, 14, 15f, 20, 20f
- Smooth muscle, 91–98
 action potentials in. *See* Action potential(s), smooth muscle.
 autonomic innervation and control of, 94–95, 94f
 contractile mechanism in, 92–93, 92f
 calcium ions and, 93–94, 94f, 97–98
 contraction without action potentials, 96, 97
 energy requirement of, 93
 of gut, stretch-induced excitation of, 96
 hormonal effects on, 97
 junctional potential of, 96
 latch mechanism of, 93, 94
 latent period of, 97–98
 of lymphatic vessels, 188
 maximum force of contraction, 93
 of metarterioles, 177, 193
 multi-unit, 91, 91f, 95, 96
 neuromuscular junctions of, 94–95, 94f
 pacemaker waves of, 96
 peristalsis in, 759
 of precapillary sphincter, 177, 193
 resting membrane potential of, 95
 vs. skeletal muscle, 91, 92–93, 94
 slow wave rhythm of, 95f, 96
 stimulatory factors for, 94, 97
- Smooth muscle (*Continued*)
 stress-relaxation of, 93
 reverse, 93
 structural organization of, 91, 91f, 92, 92f
 of trachea, bronchi, and bronchioles, 472–473
 types of, 91, 91f. *See also specific types.*
 vascular. *See also* Blood flow control.
 autoregulation of blood flow and, 194–195
 intrinsic tone of, 737
 local factors controlling, 97
 nitric oxide and, 195, 196f
- Sneeze reflex, 473, 512
- Sodium. *See also* Hyponatremia;
 Hyponatremia; Salt intake; Sodium chloride.
 in bone, 957–958
 in cerebrospinal fluid, 747
 dietary intake of
 arterial pressure and, 376
 integrated responses to, 376
 potassium intake and, 367
 recommendations for, 367
 diffusion through capillary pores, 179, 180t
 extracellular fluid, regulation of, 345, 355
 angiotensin II and aldosterone in, 359–360, 359f, 927, 928
 by osmoreceptor-ADH system, 345, 355–357, 358–359, 360
 salt appetite and, 360
 by thirst, 357–360, 358t, 359f
 extracellular fluid volume and, 370–371, 375–376
 intestinal absorption of, 794–795, 795f, 797
 in colon, 795, 797
 intestinal secretion of, 787
 neuronal somal membrane and, 552, 552f
 plasma concentration of
 aldosterone and, 925
 with reduced GFR, 404, 405, 405f
 postsynaptic potentials and, 553, 553f
 renal adaptation to intake of, 303, 304f
 renal excretion of. *See also* Pressure natriuresis.
 angiotensin II and, 374–375, 374f
 balance of intake and, 370
 diuretics and, 397, 398f
 regulation of, 370–371
 renal reabsorption of, 324, 325, 325f
 aldosterone and, 328, 337–338, 375
 angiotensin II and, 338–339, 338f
 arterial pressure and, 337
 atrial natriuretic peptide and, 339
 chloride ions and, 328, 328f
 diuretics and, 397
 estrogen and, 994
 with gradient-time transport, 327–328
 hydrogen ions and, 326, 331, 331f, 390
 oxygen consumption and, 316, 317f
 in pregnancy, 1009, 1011
 by principal cells, 332
 sympathetic activation and, 339
 with transport maximum, 328
 urine concentration and, 353
 water reabsorption and, 328
 in saliva, 774f, 775, 776
 salty taste of ions of, 645
 in sweat gland secretions, 870–871
- Sodium bicarbonate. *See also* Bicarbonate.
 for acidosis, 393
 metabolic alkalosis caused by, 393
- Sodium channel blockers, 332, 333f, 398t, 399
- Sodium chloride. *See also* Chloride; Salt intake; Sodium.
 diarrheal loss of, 796
 mineralocorticoid deficiency and, 924
- Sodium chloride (*Continued*)
 renal retention of, angiotensin II and, 221–222, 222f
 renal transport of
 in distal tubule, 331–332, 332f
 urine concentration and, 348–349, 348t, 353
 replacement of, in athletes, 1040
 tubuloglomerular feedback and, 319–320, 320f, 321
- Sodium co-transport, 54–55, 55f
 of amino acids and peptides, 54–55, 794–795, 795f, 797
 of glucose, 325–326, 326f, 794–795, 795f, 796, 811
- Sodium counter-transport, 55, 55f
- Sodium gluconate, for acidosis, 393
- Sodium ion channels, 47, 48, 48f. *See also* Calcium-sodium channels.
 acetylcholine-gated, 73–74, 84, 84f, 85, 85f
 epithelial, aldosterone and, 926–927, 926f
 in olfactory cilium, 649, 649f
 of photoreceptors, 612–613, 612f, 613–614, 613f
 of postsynaptic neuronal membrane, 548, 549
 of smooth muscle, 97
 voltage-gated, of muscle fiber, 73–74
 voltage-gated, of nerve membrane, 48, 49f, 61–63, 61f, 62f, 64
 calcium ion concentration and, 64
 local anesthetics and, 69
 propagation of impulse and, 64–65
 refractory period and, 69
- Sodium lactate, for acidosis, 393
- Sodium space, 289
- Sodium-calcium counter-transporter, renal, 368–369, 368f
- Sodium-calcium exchanger, in cardiac muscle, 104, 104f
 digitalis activity and, 258
- Sodium-chloride co-transport, thiazide diuretics and, 398
- Sodium-chloride-potassium co-transport, loop diuretics and, 397–398
- Sodium-hydrogen counter-transport, renal, 386–387, 386f
- Sodium-iodide symporter, 908, 908f
- Sodium-loading renal function curves, 226, 226f
- Sodium-potassium ATPase pump, 53–54, 53f
 in cardiac muscle, 104, 104f
 digitalis activity and, 258
 gastric acid secretion and, 777, 778f
 intestinal absorption and, 794–795
 iodide trapping and, 908, 908f
 potassium secretion and, 362, 363–364, 363f, 367
 in re-establishing ionic gradients, 65
 renal reabsorption and, 324, 325, 325f, 327–328
 of bicarbonate, 386–387, 386f
 in collecting tubule, 332, 333f, 337
 in distal tubule, 331–332, 332f, 333f
 in loop of Henle, 331, 331f
 resting membrane potential and, 59, 59f, 60, 60f
 synthesis of, 926–927, 926f
 thyroid hormones and, 912
- Solubility coefficients, of gases, 485–486, 486t
- Solvent drag, 328
- Soma of neuron, 547, 547f
 ion concentration differences and, 552–553, 552f
 resting membrane potential of, 552, 552f
 uniform electrical potential in, 553
- Somatic senses. *See also* Sensory pathways.
 classification of, 571
 definition of, 571

- Somatomedin C, 900–901
 Somatomedins, 900–901
 Somatosensory association areas, 577
 Somatosensory cortex, 574–577, 575f, 576f
 basal ganglia and, 691, 691f
 cerebellar communication with, 682, 686, 688
 corticospinal tract and, 669
 motor cortex and, 667, 668f
 thermal signals to, 593
 Somatostatin, 898, 898t, 901–902, 949
 gastric secretion and, 780
 pancreatic secretion of, 939
 Somatotropes, 896, 896t, 897
 Somatotropin. *See* Growth hormone (GH; somatotropin).
 Sound. *See* Hearing.
 Sour taste, 645, 646, 646t
 salivation and, 776
 Spacecraft
 acceleratory forces in, 531, 532, 532f
 atmosphere in, 533
 motion sickness in, 533
 weightlessness in, 533–534
 Spaces of Disse, 837, 837f, 838
 Spasticity, stroke leading to, 673
 Spatial coordinates of body
 posterior parietal cortex and, 692, 699, 699f
 prefrontal cortex and, 700
 Spatial summation
 in neurons, 555
 in sensory fibers, 564, 564f
 auditory, 638
 thermal, 593
 Special senses, definition of, 571
 Speech, 474–475, 703–704. *See also* Language.
 articulation in, 704
 Broca's area and, 668–669, 669f, 702, 704, 704f
 cerebellar lesions and, 689
 Sperm count, 978
 Spermatids, 974, 974f, 975
 Spermatocytes, 974, 974f
 Spermatogenesis, 973–976, 974f
 abnormal, 977–978
 estrogen in, 980
 follicle-stimulating hormone and, 975, 983, 983f, 984
 temperature and, 977, 978
 Spermatogonia, 973–976, 974f
 Spermatozoa, 974, 974f, 975, 975f. *See also* Fertilization.
 abnormal, 978, 978f
 capacitation of, 976–977
 in fallopian tube, 1000, 1003
 maturation of, 975, 976
 mature, physiology of, 976
 in semen, 976–977
 storage of, in testes, 975–976
 Spherocytosis, hereditary, 420
 Sphincter of Oddi, 780–781, 784f, 785
 Sphingolipids, of capillary membrane, 178, 178f
 Sphingomyelin, 67
 chemical structure of, 826, 826f
 function of, 826
 Spike potentials
 of gastrointestinal smooth muscle, 753–755, 754f
 of visceral smooth muscle, 95–96, 95f
 Spinal anesthesia. *See* Anesthesia, spinal.
 Spinal cord
 ascending tracts of, 590f
 cerebellar functions and, 686–687
 cerebellar input from, 683, 683f
 descending tracts of, 590f
 lateral motor system of, 671
 medial motor system of, 671
 Spinal cord (*Continued*)
 motor functions of, 655
 excitation by cortex for, 671–673, 672f
 in integrated control system, 694
 organization for, 655–657, 655f, 656f
 pathways from cortex for, 669–671, 670f, 671f
 reflexes in. *See* Spinal cord reflexes.
 sensory receptors and. *See* Golgi tendon organs.
 temperature receptors in, 872
 transection of, 665
 Spinal cord injury
 defecation abnormalities in, 803
 micturition abnormalities in, 310
 Spinal cord level, 545
 Spinal cord reflexes, 694
 autonomic, 665
 defecation reflex, 771, 771f, 803
 cortical input and, 672
 crossed extensor reflex, 663, 663f
 in fetus, 1020
 flexor reflex, 661–663, 662f, 663f
 gastrointestinal, 757
 memory and, 706
 muscle spasm caused by, 664–665
 muscle stretch reflex, 658–659, 658f, 659f
 neural organization for, 655–657, 655f, 656f
 postural and locomotive, 663–664
 scratch reflex, 664
 sexual act and, 978, 1000
 spinal shock and, 665
 in temperature regulation, 875
 tendon reflex, 661
 Spinal nerves
 dermatomes associated with, 582, 582f
 parasympathetic fibers and, 730–731, 731f
 skeletal motor function and. *See* Motor neurons, anterior.
 sympathetic chains and, 729, 730f
 Spinal shock, 665
 Spindle, mitotic, 17, 38–39
 Spinocerebellar tracts, 683, 683f, 687, 687f
 lesions in, 683, 683f, 689
 Spinocerebellum, 686, 687–688, 687f
 Spino-olivary pathway, 683
 Spinoreticular pathway, 683
 Spinothalamic tracts, 573f, 575f, 580, 581
 Spiral ganglion of Corti, 634f, 636–637, 636f, 639
 Spirometry, 469, 469f, 470–471
 forced vital capacity in, 517, 517f
 Spironolactone, 332, 333f, 399
 Splanchnic circulation, 759–760, 760f
 vasoconstriction in, in exercise or shock, 762
 Spleen
 as blood reservoir, 175, 175f
 macrophages of, 427–428
 Sports physiology, 1031–1041. *See also* Exercise.
 body fluids and salt in, 1040
 body heat in, 1039–1040
 cardiovascular system in, 1038–1039, 1038f, 1038t, 1039f, 1039t
 drugs in, 1040
 energy for specific sports in, 1033, 1034b
 female and male athletes in, 1031
 muscles in, 1031–1036
 endurance of, 1032, 1032t, 1033
 metabolic systems in, 1032, 1033f, 1033t, 1034b
 nutrients used in, 1035, 1035f
 power of, 1032, 1032t, 1033
 strength of, 1031, 1032
 training effect on, 1035–1036, 1035f
 respiration in, 1035f, 1036–1038, 1037f, 1037t
 Sprue, 801–802, 854
 anemia in, 420, 802
 Staircase effect, 80
 Stapedius muscle, 634
 Stapes, 633–634, 633f, 635, 635f, 636
 conduction deafness and, 642
 Staphylococcal infection, inflammatory response to, 428
 Starches
 dietary, 789–790
 digestion of, 790, 790f
 in neonate, 1025
 Starling equilibrium, for capillary exchange, 185–186, 185t
 Starling forces, 181
 Starvation, 852, 852f. *See also* Malnutrition, and metabolic rate.
 fatty acids in blood in, 821
 growth hormone secretion in, 901
 ketosis in, 823
 protein degradation in, 835
 triglycerides in liver in, 822
 STAT (signal transducer and activator of transcription) proteins, 888
 Static position sense, 571, 580
 Statins, 829
 Statoconia, 675–676, 675f
 Stearic acid, 819
 ATP from oxidation of, 823
 Steatohepatitis, nonalcoholic (NASH), 838
 Steatorrhea
 calcium and vitamin D deficiency in, 969
 in sprue, 802
 Stellate cells
 of cerebellum, 685
 of cerebral cortex. *See* Granular cells.
 Stem cells
 bone, 960
 pluripotential hematopoietic, 414–415, 414f, 423–424
 Stent, coronary artery, 253
 Stepping movements, 664
 Stercobilin, 840–841, 841f, 842
 Stereocilia
 of cochlea, 637–638
 of vestibular apparatus, 675–676, 675f
 Stereopsis, 605, 605f, 625, 630
 Sterility. *See* Infertility.
 Steroid hormones, 882. *See also* Adrenocortical hormones; Androgens; Ovarian hormones.
 cholesterol used for, 827, 882
 mechanism of action, 891
 nongenomic actions of, 927
 receptors for, 891
 structures of, 885f
 Stimulatory field, 565
 Stokes-Adams syndrome, 119, 145
 Stomach. *See also* Gastric entries.
 absorption in, 793
 anatomy of, 766, 766f
 emptying of. *See* Stomach emptying.
 fat digestion in, 792
 gastrin secretion by, 758, 758t
 mixing function of, 765, 766
 motilin secretion by, 758–759
 peristalsis of, 766
 emptying and, 766, 767
 protein digestion in, 791, 791f
 secretions of. *See* Gastric secretion.
 starch digestion in, 790
 storage function of, 765, 766
 ulcers of. *See* Peptic ulcer.
 Stomach emptying, 765, 766–767
 regulation of, 767–768, 780
 peptic ulcer and, 800
 Storage colon, 797

- Strabismus, 630–631, 630f
- Streamline flow, 161
- Streptococcal infection
glomerulonephritis secondary to, 400
inflammatory response to, 428
- Streptococcus mutans*, 971
- Streptokinase, 259
- Stress
ACTH secretion and, 932–933
arterial pressure increase in, 205
cortisol and, 929, 930, 930f; 932–933
fat utilization in, 825
- Stress response, of sympathetic nervous system, 738–739
- Stress-relaxation of blood vessels, 227, 227f
increased blood volume and, 238
intravascular pressure and, 168, 168f
reverse, in hypovolemic shock, 275
- Stress-relaxation of smooth muscle, 93
reverse, 93
- Stretch receptors
atrial. *See* Atrial stretch receptors.
of bronchi and bronchioles, 506
- Stretch reflex. *See* Muscle stretch reflex.
- Stria vascularis, 637
- Striate cortex, 624
- Striated muscle. *See also* Skeletal muscle.
band structure of, 71
cardiac muscle as, 101
- Stroke
cerebral circulation and, 745–746
hypertension and, 218
motor control system and, 673
- Stroke volume output, 106, 109f
aortic valve lesions and, 268
athletic training and, 1039, 1039f
pulse pressure and, 168–169
- Stroke work output, 107–108
- Stroke work output curve, 110, 110f
- Strychnine, 557
- Stumble reflex, 664
- Subarachnoid space, 747, 747f
- Subcortical level of nervous system, 545
- Subcutaneous tissues, macrophages in, 426
- Subendocardial infarction, 249–250
- Subliminal zone, 565–566
- Sublingual glands, 775
- Submandibular glands, 774f, 775
- Submarines, 540
- Submucosal plexus, 755, 756, 756f
parasympathetic neurons in, 757
of small intestine, 769
- Subneural clefts, 83, 84f
- Substance P, 586
- Substantia gelatinosa, 585, 585f
- Substantia nigra, 690, 690f, 691, 691f
dopamine system and, 713, 713f
Huntington's disease and, 694
neurotransmitters in, 692–693, 692f
Parkinson's disease and, 691, 693–694
- Subthalamus, 690, 690f, 691, 691f
lesions in, 691, 693–694
- Subthreshold stimulus, 565
- Subthreshold zone, 565–566
- Sucrase, 787, 790
- Sucrose, 789–790
- Sulfonyleurea drugs, 945
- Summation
in neuronal pools, 566
of postsynaptic potentials, 553, 554f, 555, 556–557
in sensory fibers, 564, 564f, 565f
thermal, 593
of skeletal muscle contractions, 80, 80f
- Superior cervical ganglion, 631, 631f
- Superior colliculus
involuntary visual fixation and, 629
- Superior colliculus (*Continued*)
turning to visual disturbance and, 630
visual fibers to, 623
- Superior olivary nuclei, 639, 639f; 641–642
- Superior salivatory nucleus, 648
- Superoxide
high alveolar P_{O_2} and, 536–537
of neutrophils and macrophages, 426
- Superoxide dismutases, 536–537
- Supplementary motor area, 668, 668f, 669, 698, 699f
basal ganglia and, 690f; 691–692, 691f
- Suppressor T cells, 441, 441f, 442
- Suprachiasmatic nucleus, visual fibers to, 623
- Supraoptic nucleus, pituitary hormones and, 897, 904, 904f; 905, 906
- Suprathreshold stimulus, 565
- Supraventricular tachycardias, 148
- Surface tension, in alveoli, 467–468
of premature babies, 468
- Surfactant, 468, 490
neonatal respiratory distress and, 468, 519, 1022
- Surround inhibition, 578–579, 578f
- Sustentacular cells
of olfactory membrane, 649, 649f
of taste bud, 646
- Swallowing, 763–765, 764f
disorders of, 799
esophageal secretions and, 776–777
- Swallowing center, 764, 764f, 765
- Swallowing reflex, 764, 765
- Sweat
composition of, 870–871
water loss in, 285, 286t
- Sweat glands, 870, 870f
aldosterone and, 926
autonomic control of, 729–730, 730f, 731, 734t, 735, 870–871
- Sweating, 870–871. *See also* Evaporative heat loss.
acclimatization to heat and, 871, 877
hypothalamic control of, 870, 872, 872f
set-point and, 874, 874f
local, 875
skin receptors and, 872
- Sweet taste, 645, 646, 646t, 647
- Sympathetic chains, 729, 730f
- Sympathetic denervation, 737
- Sympathetic nervous system. *See also* Autonomic nervous system.
adrenal function and. *See* Adrenal medulla.
alarm response of, 738–739
anatomy of, physiologic, 729–730, 730f
bladder and, 308, 308f
blood reservoirs and, 175
bronchiolar dilation and, 473
in cardiac failure
acute stage, 255–256, 256f; 257, 262
decline to normal, 257
decompensated, 262–263
fluid retention and, 260
cardiac innervation by, 111, 111f, 119, 201, 202f
cardiac regulation by, 111, 111f, 120
cardiac output and, 231, 238–239, 239f
after myocardial infarction, 251
tachycardia and, 143
vasomotor center and, 203
cerebral blood flow and, 745
circulatory control by, 201–204, 202f
mean circulatory filling pressure and, 236, 236f
volume-pressure curves and, 168, 168f
coronary blood flow and, 247, 248
energy expenditure and, 849
exercise-related discharge of, 244–245
- Sympathetic nervous system (*Continued*)
eye control by, 631, 632
Horner's syndrome and, 632
fatty acid mobilization caused by, 825
gastrointestinal regulation by, 755, 757
duodenal mucus and, 786
glandular secretions and, 774
ileocecal sphincter and, 770
reflexes in, 757
stomach emptying and, 767
vasoconstriction in, 762
glomerular filtration rate and, 317–318
glucose availability and, 812
heat conduction to skin and, 868
in hypovolemic shock, 274–275
vasomotor failure and, 277
localized activation of, 738
male sexual act and, 979
mass discharge of, 738
metabolic rate and, 867
nonshivering thermogenesis and, 865
obesity and, 225
renal function and, 373–374
sodium reabsorption in, 339
salivary glands and, 776
segmental distribution of fibers in, 730
sweat glands and, 729–730, 730f, 731, 734t, 735, 870–871
temperature regulation by, 872–873
ureteral peristalsis and, 309
vasoconstriction caused by, 165f, 166, 166f
norepinephrine and epinephrine in, 199, 204
in skeletal muscle, 244
- Sympathetic tone, 737
- Sympathetic vasoconstrictor tone, 203, 203f
- Sympathetic vasodilator system, 204, 204f
- Symphomimetic drugs, 739–740
for shock, 281
- Synapses, 543, 544f; 546–557. *See also* Dendrites; Neurotransmitters; Postsynaptic neuron; Postsynaptic potentials; Presynaptic terminals.
acid-base abnormalities and, 557
drug effects on, 557
facilitation of, 545
fatigue of, 557
in reverberatory circuit, 567–568
stabilizing effect of, 569–570, 569f
hypoxia and, 557
information processing role of, 545
memory and, 706, 707, 707f
long-term, 708
one-way conduction at, 546, 547
physiologic anatomy of, 547–550, 547f
types of, 546–547
- Synaptic afterdischarge, 567
- Synaptic body, of rod or cone, 609, 610f
- Synaptic cleft, 547, 547f; 550
of neuromuscular junction, 83
- Synaptic delay, 557
- Synaptic space, 83
- Synaptic trough, 83, 84f
- Synaptic vesicles, of neuromuscular junction, 83, 84f, 86
- Syncytium
of cardiac muscle, 101–102, 102f
of gastrointestinal smooth muscle, 753
of unitary smooth muscle, 91
- Synovial spaces, negative pressure in, 183
- Systemic circulation, 157. *See also* Circulation.
blood volume distribution in, 157, 158f
pressures in different portions of, 158, 159f
- Systole, 105, 105f
duration of, heart rate and, 105
emptying of ventricles during, 105f, 106

- Systolic blood pressure, 158, 168
 age-related increase in, 171, 171*f*
 measurement of, 170–171, 170*f*
 Systolic pressure curve, 108, 108*f*
 Systolic stretch, 250, 250*f*, 251
- T**
- T₃. *See* Triiodothyronine (T₃).
 T₄. *See* Thyroxine (T₄).
 T lymphocytes, 433, 434. *See also* Lymphocytes.
 activation of, 439–440, 440*f*
 delayed-reaction allergy associated with, 443
 memory cells of, 440
 preprocessing of, 434–435, 435*f*, 442
 specificity of, 435–436
 transfusion of, 442
 types of, 440–442, 441*f*. *See also specific types.*
- T tubules. *See* Transverse (T) tubules.
- T wave, 121, 121*f*, 122–123
 abnormalities in, 141–142, 142*f*
 atrial, 122, 133–134, 133*f*
 cardiac cycle and, 105, 105*f*
 monophasic action potential and, 122, 122*f*
 normal voltage of, 123
 vectorial analysis of, 133, 133*f*
- Tabes dorsalis, 310
- Tabetic bladder, 310
- Tachycardia(s)
 incomplete intraventricular block
 caused by, 145–146
 paroxysmal, 148–149
 atrial, 148, 148*f*
 ventricular, 148–149, 149*f*
 sinus, 143, 143*f*
- Tactile receptors, 560*b*, 560*f*, 571–572, 572*f*
 feedback to motor cortex, 672
 flexor reflex and, 662
 nerve fibers from, 564, 572
 position senses and, 580
- Tactile sensations, 571–573
 pain inhibition associated with, 587–588
- Tactile stimuli, salivation and, 776
- Tamponade, cardiac, cardiac output curve and, 234, 234*f*
- Tandem pore domain potassium channel, 59, 59*f*
- Tank respirator, 522*f*, 523
- Taste, 645–648
 adaptation of, 648
 factors affecting experience of, 645
 preference in, 648
 primary sensations of, 645–648
 thresholds for, 646, 646*t*
 salivation and, 648, 776
 signal transmission into central nervous system, 647–648, 648*f*
 taste buds and, 646–647, 647*f*
- Taste blindness, 646
- Taste cells, 646, 647, 647*f*
- Taste hairs, 646
- Taste pore, 646, 647*f*
- TATA box, 35, 35*f*
- Tectorial membrane, 636*f*, 637, 637*f*
- Tectospinal tracts, 670, 672*f*
- Teeth, 969–972
 abnormalities of, 971–972
 development of, 970–971, 970*f*
 functions of, 969
 mineral exchange in, 971
 parts of, 969, 969*f*
- Telophase, 38*f*, 39
- Temperature, body, 867–877. *See also* Heat loss; Thermogenesis (heat production); Thermoreceptors.
 abnormalities of, 875–877, 875*f*, 876*f*.
See also Fever.
 behavioral control of, 875
- Temperature, body (*Continued*)
 core temperature, 867
 range of, 867, 867*f*
 set-point of, 872*f*, 873–874, 874*f*
 food intake and regulation of, 849, 873
 gain of control system for, 8
 heart function and, 112
 heart rate and, 143
 hypothalamic regulation of, 715, 871–875
 anterior hypothalamic-preoptic area in, 871, 873
 atmospheric temperature range and, 871, 871*f*
 deep body receptors and, 872, 874
 fever and, 875–876, 876*f*
 low temperatures and, 877
 neuronal effectors in, 872–873, 872*f*
 posterior hypothalamus in, 872
 set-point in, 872*f*, 873–874, 874*f*, 876, 876*f*
 skin receptors and, 872, 874
 spinal reflexes and, 875
 neonatal regulation of, 873, 1025, 1025*f*
 prematurity and, 1027
 normal range of, 7, 7*t*, 867, 867*f*
 ovulation and, 1001, 1002*f*
 rectal, 867*f*
 skin temperature, 867
 local reflexes regulating, 875
 set-point and, 874, 874*f*
 sympathetic regulation of, 738
- Temporal field of vision, 627
- Temporal summation
 in neurons, 555
 in sensory fibers, 564, 565*f*
- Tendon fibers, muscle fibers and, 71
- Tendon receptors. *See* Golgi tendon organs.
- Tendon reflex, 661
- Teniae coli, 770
- Tension-time index, 109
- Tensor tympani muscle, 633, 634
- Teratoma, 985
- Testicular tumors, Leydig cell, 985
- Testis(es)
 anatomy of, 973, 973*f*
 cholesterol used by, 827
 descent of, 981
 fetal, human chorionic gonadotropin and, 984, 1008
 storage of sperm in, 975–976
 temperature of, 977, 978
- Testis determining factor, 981
- Testosterone
 chemical structure of, 980*f*
 degradation and excretion of, 980
 in fetal development, 980, 981, 981*f*, 984, 1008
 functions of, 980–982
 luteinizing hormone and, 983, 984
 mechanism of action of, 982–983
 metabolic rate and, 864
 metabolism of, 980
 nongenomic effects of, 983
 ovarian synthesis of, 991, 992, 992*f*
 plasma level of, over life cycle, 980, 981*f*
 protein deposition in tissues and, 835–836, 982–983, 1031
 secretion of, 979–980, 980*f*
 spermatogenesis and, 975
- Tetany, hypocalcemic, 64, 367, 956, 956*f*
 in hypoparathyroidism, 967
 in premature infant, 1027
 in rickets, 968–969
- Tetracaine, 69
- Tetraethylammonium ion, 63
- Tetralogy of Fallot, 271, 271*f*
- Tetrodotoxin, 63
- Thalamocortical system, 697–698
 alpha waves and, 724
 petit mal epilepsy and, 726
- Thalamus. *See also* Ventrobasal complex of thalamus.
 alpha waves and, 724
 basal ganglia and, 690, 690*f*, 691–692, 691*f*
 in Parkinson's disease, 693–694
 cerebellar input to, 684
 cerebral cortex and, 697–698, 698*f*, 712
 memory and, 709
 motor cortex input from, 670, 687, 687*f*
 olfactory signals and, 651
 pain pathways to, 585–586, 585*f*
 surgical interruption of, 586
 pain perception and, 586
 reticular excitatory signals and, 711, 712*f*
 sleep and, 722
 somatosensory association areas and, 577
 somatosensory pathways to anterolateral, 573, 581, 581*f*
 dorsal column–medial lemniscal, 573, 574, 574*f*, 576
 joint rotation and, 580, 580*f*
 thermal signals in, 593
 somatosensory role of, 581
 taste signals and, 647–648, 648*f*
 visual pathways in, 623–624, 623*f*
- Theca cells, 989, 989*f*, 990
 androgen synthesis in, 992, 993*f*
 of corpus luteum, 990–991
- Theobromine, 557
- Theophylline, 557
- Thermal pain stimuli, 583, 584, 584*f*
- Thermode, 871
- Thermogenesis (heat production), 867, 873
 during exercise, 1039–1040
 hypothalamic inhibition of, 872, 872*f*
 at low temperatures, 877
 nonshivering, 865, 873
- Thermogenic effect of food, 864–865, 867
- Thermogenin, 873
- Thermoreceptive senses, 571
 anterolateral system and, 573
 localization of, 577
- Thermoreceptors, 559, 560*b*, 592–593, 592*f*
 nerve fibers from, 564
 transmission pathways from, 593
- Theta waves, 723*f*, 724–725, 725*f*
- Thiamine. *See* Vitamin B₁ (thiamine).
- Thiazide diuretics, 332, 332*f*, 398, 398*t*
- Thiocyanate ions
 antithyroid activity of, 915
 in saliva, 776
- Third heart sound, 266
- Thirst
 extracellular fluid osmolarity and, 357–360, 358*t*, 359*f*
 hypothalamic control of, 716
- Thirst center, 358, 716
- Thoracic duct, 186, 186*f*, 819
 rate of flow through, 187
- Thoracic duct lymph
 fat in, 187, 760
 protein concentration of, 187
- Thought, 705–706
 communication of, 703–704
 elaboration of, 703
 holistic theory of, 706
 prefrontal association area and, 700, 703
 Wernicke area and, 701, 704–705
- Threshold for drinking, 358
- Thrill, in aortic stenosis, 267
- Thrombin, 453, 453*f*, 454
 adsorbed to fibrin fibers, 457
 thrombomodulin binding of, 456–457
- Thrombocytes. *See* Platelets.

- Thrombocytopenia, 458
 Thrombocytopenic purpura, 458
 Thromboembolic conditions, 459
 Thrombomodulin, 456–457
 Thromboplastin, chemical structure of, 826
 Thrombosthenin, 451, 454
 Thromboxane A₂
 platelet aggregation and, 452
 vasoconstriction caused by, 451
 Thrombus, 459. *See also* Coronary thrombosis.
 Thymine, 27, 28, 28f, 31t
 Thymus, T lymphocyte processing in, 434–435, 435f, 442
 Thyroglobulin, 882, 907, 908–909, 908f
 cleaving of hormones from, 909, 914
 hypothyroidism and, 917
 organification of, 908–909
 storage of, 909
 Thyroid adenoma, 916
 Thyroid gland
 anatomy of, 907, 907f
 blood flow in, 907
 calcitonin secretion in, 966
 diseases of, 916–918, 916f, 918f
 histology of, 907, 907f
 inhibitors of, 915
 Thyroid hormones, 907–919. *See also*
 Reverse T₃ (RT₃); Thyroxine (T₄);
 Triiodothyronine (T₃).
 cold climate and, 873
 daily rate of secretion, 909
 functions of, 910–914
 basal metabolic rate and, 907, 911, 912, 913f
 blood cholesterol and, 827
 body weight and, 912
 carbohydrate metabolism and, 912
 cardiovascular system and, 913
 central nervous system and, 913
 fat metabolism and, 825, 912
 gastrointestinal motility and, 913
 gene transcription and, 910, 911f
 growth and, 912
 liver fats and, 912
 metabolic activity and, 911–912
 muscles and, 913
 nongenomic effects in, 910
 other endocrine glands and, 913–914
 plasma lipids and, 912
 respiration and, 913
 sexual function and, 914
 sleep and, 913
 vitamin requirements and, 912
 long duration of action, 910, 910f
 mechanism of action, 891
 protein binding of, 882, 909–910
 protein metabolism and, 836, 911
 protein synthesis and, 910, 911f
 receptors for, 891, 910, 911f
 regulation of secretion of, 914–915, 915f
 release of
 from thyroid, 909
 to tissues from plasma, 910
 slow onset of, 910, 910f
 structures of, 909f
 synthesis of, 882, 907, 908–909, 908f, 909f
 inhibitors of, 915
 transport of, to tissues, 909–910
 Thyroiditis
 autoimmune, 917
 idiopathic goiter and, 917
 Thyroid-stimulating hormone (TSH;
 thyrotropin), 896, 896t, 914–915, 915f
 antithyroid substances and, 915
 in foods, 917
 diagnostic measurement of, 916
 endemic goiter and, 917
 hyperthyroidism and, 916
 Thyroid-stimulating hormone (TSH;
 thyrotropin) (Continued)
 iodide trapping and, 908, 914
 pregnancy and, 1009
 thermogenesis and, 873
 Thyroid-stimulating immunoglobulins, 916
 Thyrotoxicosis. *See* Hyperthyroidism.
 Thyrotropes, 896, 896t
 Thyrotropin. *See* Thyroid-stimulating hormone
 (TSH; thyrotropin).
 Thyrotropin-releasing hormone (TRH), 898,
 898t, 914–915
 test dose of, 918
 thermogenesis and, 873, 915
 Thyroxine (T₄), 907. *See also* Thyroid hormones.
 compared to triiodothyronine, 907
 converted to triiodothyronine, 910
 diagnostic measurement of, 916, 918
 heat production and, 873
 mechanism of action, 891
 metabolic rate and, 864, 867
 in pregnancy, 1009
 protein metabolism and, 836
 Thyroxine-binding globulin, 882, 909–910
 Thyroxine-binding prealbumin, 909–910
 Tic douloureux, 590
 Tickle sense, 571, 572. *See also* Tactile sensations.
 anterolateral system and, 573
 scratch reflex and, 664
 Tidal volume, 469, 469f
 minute respiratory volume and, 471
 Tight junctions
 of brain capillaries, 749
 of gastric mucosa, 799–800
 renal tubular, 324, 325f, 327–328
 Tissue capillarity, high altitude and, 529
 Tissue factor, 455, 455f, 456
 prothrombin time and, 461
 Tissue gel, 180–181
 Tissue plasminogen activator (t-PA)
 for cardiogenic shock, 259
 clot lysis and, 457
 for pulmonary embolism, 459
 for thrombotic occlusion, 459
 Tissue thromboplastin. *See* Tissue factor.
 Tissue typing, 449
 Titin, 73, 73f
 Titratable acid, 389–390
 TNF (tumor necrosis factor), in inflammation,
 430, 430f
 Tolerance, immune, 442
 Tone
 muscle. *See* Muscle tone.
 sympathetic and parasympathetic, 737
 Tonic contraction, of gastrointestinal smooth
 muscle, 755, 756
 Tonic receptors, 562
 Tonic seizures, 725
 Tonic-clonic seizures, 725
 Tonometry, 607, 607f
 Tonotopic maps, 640
 Torsades de pointes, 147, 148f
 Total body water
 measurement of, 289
 regulation of, 345
 Total lung capacity, 469, 469f
 determination of, 471
 Total peripheral resistance, 163. *See also*
 Vascular resistance.
 cardiac output and, 230–231, 230f
 elevated, 232–233
 in hypovolemic shock, 274
 renal–body fluid system and, 216–217, 216f,
 217f
 renin-angiotensin system and, 223
 volume-loading hypertension and, 219,
 220, 220f
 Touch, 571. *See also* Tactile receptors; Tactile
 sensations.
 pathways into central nervous system, 573
 Toxic substances
 acute tubular necrosis caused by, 401
 bitter taste of, 646
 t-PA. *See* Tissue plasminogen activator (t-PA).
 Trace elements, 856–857
 Trachea, 472, 472f
 Tractus solitarius, 203. *See also* Nucleus tractus
 solitarius.
 autonomic control by, 739
 baroreceptors and, 205, 206
 swallowing and, 764
 taste signals and, 647–648, 648f
 Tranquilizers, reward or punishment centers
 and, 718
 Transamination
 in amino acid synthesis, 834, 834f, 840
 in deamination, 834–835
 Transcellular fluid, 286
 Transcortin, 923
 Transcription, 27, 27f, 29f, 30–31
 hormonal action and, 888, 889f, 891
 by cortisol, 931
 by growth hormone, 899
 by insulin, 944
 by thyroid hormones, 910, 911f
 in postsynaptic neuron, 549, 549f
 regulation of, 35–36, 35f
 Transcription factors, 35–36, 35f
 thyroid hormone receptors as, 891
 Transcytosis, in capillary endothelium, 178
 Transducin, 613, 613f
 Transfer RNA (tRNA), 31, 32, 32f, 34, 34f
 Transferrin, 418, 418f, 419–420, 840
 Transfusion, for shock, 280–281
 irreversible, 278, 278f
 Transfusion reactions, 445, 446, 448–449
 acute renal failure in, 448–449
 Rh blood types and, 447
 Translation, 27, 27f, 33–35, 34f. *See also*
 Protein(s), synthesis of.
 growth hormone and, 899
 Transmitter substances. *See* Neurotransmitters.
 Transmitter vesicles, 547–548, 550
 memory and, 708
 of neuropeptides, 551
 recycling of, 550–551
 Transplantation of tissues and organs, 449–450
 kidney transplantation, 409
 Transport. *See* Active transport; Diffusion;
 Membrane transport.
 Transport maximum, renal tubular, 326–327,
 327f, 327t
 Transport proteins, 45, 46f. *See also* Carrier
 proteins; Protein channels.
 Transport vesicles, 20–21, 20f
 Transpulmonary pressure, 466f, 467
 Transverse (T) tubules
 of cardiac muscle, 103–104, 104f
 of skeletal muscle, 73f, 87, 87f, 88–89, 88f
 Trauma
 growth hormone secretion in, 901, 902
 hypovolemic shock in, 279
 Tremor
 intention tremor, 687–688, 689
 in Parkinson's disease, 693
 thyroid hormones and, 913
 Treppe, 80
 TRH. *See* Thyrotropin-releasing hormone
 (TRH).
 Triamterene, 332, 333f, 399
 Trichinosis, 430
 Tricuspid valve, 106–107
 first heart sound and, 265, 266, 266f
 as reference level for pressure, 174–175, 174f

- Tricyclic antidepressants, 727
 Trigeminal nerve, sensory nuclei of, 574
 Trigeminal neuralgia, 590
 Triglycerides. *See also* Fatty acids.
 in cell, 12
 as neutral fat globules, 14
 chemical structure of, 819
 in chylomicrons, 819–820
 dietary, 791–792, 791*f*
 digestion of, 789, 791*f*
 bile salts and, 792
 emulsification for, 792
 by pancreatic lipase, 792, 792*f*
 in stomach, 792
 energy production from, 822–825. *See also*
 Fats, as energy source.
 regulation of, 825–826
 functions of, 819
 hydrolysis of, 820, 822
 in lipoproteins, 821, 821*t*
 in liver, 821–822
 resynthesis of, in intestinal epithelium,
 797, 819
 storage of, 821–822. *See also* Adipose tissue.
 synthesis of, 821–822
 from carbohydrates, 824–825, 824*f*
 from proteins, 825
 thyroid hormones and, 912
 Trigone, 307*f*, 308, 308*f*, 309
 Triiodothyronine (T₃), 907. *See also* Reverse T₃
 (RT₃); Thyroid hormones.
 compared to thyroxine, 907
 mechanism of action, 891
 thyroxine converted to, 910
 tRNA. *See* Transfer RNA (tRNA).
 Trophoblast cells, 1004, 1004*f*, 1005, 1005*f*
 estrogen and progesterone secreted by, 1008
 glucose for fetus and, 1007
 human chorionic gonadotropin secreted by,
 1007–1008, 1007*f*
 nutrition of embryo and, 1005, 1005*f*
 placenta and, 1005, 1006*f*
 Tropical sprue, 801
 Tropomyosin, in skeletal muscle, 75–76, 75*f*
 Troponin
 calmodulin and, 891
 in cardiac muscle, 103
 in skeletal muscle, 75–76, 75*f*
 Trypsin, 781, 791
 Trypsin inhibitor, 781
 Trypsinogen, 781
 Tryptophan deficiency, 854
 TSH. *See* Thyroid-stimulating hormone (TSH;
 thyrotropin).
 Tuber cinereum, 897
 Tuberculosis, 520
 bacterial defenses in, 426
 Tubular glands, 773, 777*f*. *See also* Oxyntic
 (gastric) glands; Pyloric glands.
 Tubulin, 16
 Tubuloglomerular feedback, 195, 319–321, 320*f*
 Tufted cells, 651, 652
 Tumor necrosis factor (TNF), in inflammation,
 430, 430*f*
 Turbulent blood flow, 161–162, 161*f*
 Twitches, skeletal muscle, 79
 Two-point discrimination, 578, 578*f*
 Tympanic membrane, 633–634, 633*f*
 damage to, 642
 Tyrosine
 hormones derived from, 882–884
 in norepinephrine synthesis, 732
 in thyroid hormone synthesis, 908–909,
 909*f*, 914
 Tyrosine kinases
 insulin receptor and, 940–941, 941*f*
 leptin receptor and, 888
- U**
 Ubiquinone, 814
 Ubiquitin, muscle atrophy and, 82
 Ulcerative colitis, 771, 802–803
 Ultimobranchial glands, 966
 Ultrafiltration, into peritubular capillary,
 323–324, 325
 Ultrasonic flowmeter, 160–161, 161*f*
 for cardiac output measurement, 240
 Umami taste, 646
 Umbilical arteries, 1005, 1006*f*, 1022, 1022*f*
 Umbilical vein, 1005, 1006*f*
 Unipolar limb leads, augmented, 126–127, 127*f*
 axes of, 130, 130*f*
 vectorial analysis of potentials in, 131
 Unitary (visceral) smooth muscle, 91, 91*f*, 94*f*
 action potentials in, 95, 96
 excited by stretch, 96
 number of fibers in, 96
 spontaneous, 95*f*, 96
 Unmyelinated nerve fibers, 67, 67*f*
 classification of, 563, 563*f*, 564
 Unsaturated fats
 atherosclerosis prevention and, 829
 blood cholesterol and, 827
 formed in liver, 822
 vitamin E and, 855
 Uracil, 30, 31*t*
 Urea
 artificial kidney and, 410
 chronic renal failure and, 406
 diffusion through membrane channels, 47
 formation by liver, 835, 839–840
 ATP expended for, 859
 placental diffusion of, 1007
 reabsorption of, in kidney, 328–329, 328*f*,
 333–334
 in sweat, 870
 urine concentration and, 348*t*, 350–351,
 351*f*, 353
 Urea recycling, 353
 Urea transporters, 328–329, 333–334,
 350, 353
 Uremia, 406
 plasma composition in, 410*t*
 Ureterorenal reflex, 309
 Ureters, 307*f*, 308–309, 308*f*
 pain sensation in, 309
 Urethra, 306, 307*f*
 posterior, 307*f*, 308, 308*f*
 micturition reflex and, 309
 voluntary urination and, 310
 Urethral glands, 973, 979
 Urinary tract infection, septic shock secondary
 to, 280
 Urinary tract obstruction
 acute renal failure in, 399, 401
 infection secondary to, 403–404
 Urine
 concentration of, 345, 346–353
 basic requirements for, 347–348
 in chronic renal failure, 405, 406*f*
 countercurrent mechanism and, 348–349,
 349*f*; 351–352, 352*f*, 353
 disorders of, 354–355
 distal tubule and collecting ducts and,
 350, 350*f*
 maximal level of, 347
 obligatory volume and, 347, 353
 quantification of, 354
 specific gravity and, 347, 347*f*
 summary of, 352–353, 352*f*
 urea and, 350–351, 351*f*
 dilution of, 345–346, 346*f*
 in chronic renal failure, 405
 disorders of, 354–355
 quantification of, 354
- Urine (*Continued*)
 formation of, 310–312, 311*f*. *See also*
 Kidney(s), reabsorption by; Kidney(s),
 secretion by.
 osmolarity of, specific gravity and, 347, 347*f*
 pH of, 380, 380*t*
 minimal, 388
 specific gravity of, 347, 347*f*
 transport from kidney to bladder, 308–309
 volume of
 obligatory, 347, 353
 in pregnancy, 1010
 water loss in, 286, 286*t*
 Urine output, arterial blood pressure and, 337
 Urobilin, 840–841
 Urobilinogen, 840–841, 841*f*, 842
 Urogenital diaphragm, 307*f*, 308
 Urticaria, 443
 Uterine milk, 995, 1004
 Uterus, 987, 987*f*, 988*f*. *See also* Implantation;
 Labor.
 contractility of, 1011–1012
 hypothalamus and, 716
 contraction of, oxytocin and, 905
 estrogenic effects on, 993
 involution of, after parturition, 1013–1014
 parturition and, 1011–1013, 1012*f*
 progesterone and, 994
 Utilization coefficient, 499
 Utricle, 674–675, 675*f*, 676–677
 Uvula, of cerebellum, 678
- V**
 Vagal reflex, to stop paroxysmal tachycardia,
 148
 Vagina, 987, 987*f*, 988*f*
 estrogenic effects on, 993
 Vagovagal reflexes
 gastric muscular tone and, 766
 gastric secretion and, 779
 Vagus nerves
 aortic baroreceptors and, 205
 aortic bodies and, 508*f*, 509
 arterial pressure and, 206, 736
 bronchoconstriction and, 473
 cardiac effects of
 atrioventricular block as, 144
 bradycardia as, 144
 cardiac regulation by, 111, 111*f*, 119–120,
 201, 202*f*
 atrial stretch and, 208–209
 sensory signals and, 203
 vasomotor center and, 203, 208
 coronary blood flow and, 247
 duodenal mucous glands and, 786
 food intake and, 846*f*, 848
 gallbladder emptying and, 785
 gastric secretions and, 779, 780, 780*f*
 pepsinogen in, 779
 ulcers and, 801
 gastrointestinal innervation by, 756–757
 reflexes and, 757
 gastrointestinal regulation by, stomach
 emptying and, 767
 pancreatic secretions and, 782
 parasympathetic fibers in, 730, 731*f*
 respiratory control and, 506
 swallowing and, 764*f*, 765
 taste signals and, 647
 in vasovagal syncope, 204
 Valvulae conniventes, 793, 793*f*
 Valvular heart disease
 cardiac hypertrophy in, 272
 circulatory dynamics in, 268–269
 congenital, 267
 exercise and, 269
 murmurs caused by, 267–268

- Valvular heart disease (*Continued*)
 regurgitation in, 267
 rheumatic, 266–267
 stenosis in, 267
- van den Bergh reaction, 841–842
- van't Hoff's law, 291
- Varicose veins, 174
- Varicosities
 of postganglionic nerve endings, 732
 of smooth muscle nerve endings, 94f, 95
- Vas deferens, 973, 973f, 975–976
- Vasa recta, 306, 307f
 blood flow in, 317
 countercurrent exchange in, 348, 351–352, 352f
- Vascular capacitance, 167. *See also* Vascular compliance.
 sympathetic control of, 168
- Vascular compliance, 167. *See also* Vascular capacitance.
 arterial, 167
 pressure pulse reduction by, 168, 170
 pressure pulse velocity and, 169–170
 pulse pressure and, 168–169
 venous, 167
- Vascular distensibility, 167–168, 168f
- Vascular endothelial growth factor (VEGF), 198
- Vascular resistance, 162–165. *See also* Total peripheral resistance.
 arterial pressure and, 165, 166
 arterial pressure pulses and, 170
 conductance and, 163, 164
 diameter of vessel and, 164
 hematocrit and, 164–165, 165f
 pressure difference and, 159, 160
 pulmonary. *See* Pulmonary vascular resistance.
 in series and parallel circuits, 164, 164f
 units of, 162–163
 venous pressure and, 172
- Vascular smooth muscle. *See also* Blood flow control.
 aldosterone and, 927
 autoregulation of blood flow and, 194–195
 local factors controlling, 97
 nitric oxide and, 195, 196f
- Vasculature of tissues, blood flow regulation and, 197–198, 197f
- Vasoactive intestinal peptide
 gastric secretion and, 780
 penile erection and, 978–979
- Vasoconstriction
 cutaneous, for temperature regulation, 872, 875, 876
 of injured vessel, 451
 ions with effect of, 200
 tissue blood flow and, 165f, 166, 166f
- Vasoconstrictor agent(s), 199
 angiotensin II as, 199, 221
 nitric oxide and, 196
 antidiuretic hormone as, 199, 905
 endothelin as, 196
 limited long-term effect of, 200
- Vasoconstrictor area, of medulla, 202, 202f, 203
 baroreceptor signals and, 206
- Vasoconstrictor system, sympathetic, 201–204, 202f
 adrenal medullae and, 204
 cerebral ischemia and, 209
 hypothalamus and, 204
- Vasoconstrictor tone, sympathetic, 203, 203f
- Vasodilation
 by carbon dioxide increase, 200
 cutaneous, for temperature regulation, 872, 875, 877
- Vasodilation (*Continued*)
 ions with effect of, 200
 in local blood flow control, 191, 192–193, 194, 196–197
 nitric oxide and, 195–196, 196f
 tissue factors and, 97
 in septic shock, 280
- Vasodilator agents, 199–200
 for angina pectoris, 252
 in cardiac muscle, 247
 for essential hypertension, 226
 in gastrointestinal tract, 761
 limited long-term effect of, 200
 in skeletal muscle, 243–244
- Vasodilator area, of medulla, 202f, 203
- Vasodilator system, sympathetic, 204, 204f
- Vasodilator theory, of local blood flow regulation, 192–193
- Vasomotion, of precapillary vessels, 178–179, 193
- Vasomotor center of brain stem, 202–204, 204f
 baroreceptors and, 6
 chemoreceptors and, 208
 CNS ischemic response and, 209
 exercise and, 244
 progressive shock and, 277
 respiratory waves and, 210
- Vasomotor waves, 210–211, 210f
- Vasopressin. *See* Antidiuretic hormone (ADH; vasopressin).
- Vasovagal syncope, 204
- Vectorcardiogram, 134, 134f
- Vegetative functions, of brain, 714
- VEGF (vascular endothelial growth factor), 198
- Veins
 as blood reservoir, 175
 blood volume in, 157, 158
 distensibility of, 167–168, 168f
 exercise-related contraction of, 244–245
 functions of, 157, 171, 173–174, 175
 in nervous control of arterial pressure, 205
 in hypovolemic shock, 274
 sympathetic innervation of, 201, 202f
 temperature receptors in, 872
- Venous admixture, 496, 496f
- Venous dilation, acute, cardiac output and, 233
- Venous plexus, cutaneous, 868, 868f
 as blood reservoir, 175
 heat conduction and, 868
- Venous pooling of blood, 279
- Venous pressures, 172–175. *See also* Blood pressure.
 compression points and, 172, 172f
 gravity and, 172–173, 173f, 174–175, 174f
 measurement of, 174–175, 174f
 reference level for, 174–175, 174f
- Venous pump, 171, 173–174
- Venous return
 artificial respiration and, 523
 calculation of, 237
 in cardiac failure, 256, 257
 cardiac output and, 110, 112, 229–230
 in pathological conditions, 232–234, 233f
 mean filling pressure and, 236–237, 236f
 pressure gradient for, 237
 resistance to, 237, 237f, 238f
 exercise and, 245
 increased blood volume and, 238
 sympathetic stimulation and, 238–239
 shock caused by decrease in, 273, 279, 280
- Venous return curves, 234, 235–237
 combinations of patterns of, 237, 238f
 exercise and, 245, 245f
 in heart failure. *See* Cardiac failure, quantitative graphical analysis of.
 mean systemic filling pressure and, 235, 235f, 236–237, 236f, 238f
- Venous return curves (*Continued*)
 normal, 235–236, 235f
 resistance to venous return and, 237, 237f, 238f
 with simultaneous cardiac output curves, 238–240, 238f
- Venous sinuses, of spleen, 175, 175f, 427–428, 427f
- Venous system
 damming of blood in, after myocardial infarction, 250, 255
 lymph emptying into, 186, 186f
 volume-pressure curve of, 167–168, 168f
- Venous thrombosis, femoral, 459
- Venous valves, 173–174, 174f
 incompetent, 174
- Ventilation. *See* Alveolar ventilation; Mechanical ventilation; Pulmonary ventilation.
- Ventilation-perfusion ratio, 492–494
 abnormalities of, 493–494
 atelectasis and, 519
 in emphysema, 494, 518
 in pneumonia, 518–519, 519f
 in tuberculosis, 520
 hypoxia and, 520
- Ventral lateral geniculate nucleus, 623
- Ventral posterior medial nucleus of thalamus, 647–648, 648f
- Ventral respiratory group, 505, 506, 506f
- Ventricles, cardiac
 as pumps, 106
 synchronous contraction of, 119
 transmission of impulse in, 118, 118f
- Ventricular dilatation
 chemical energy expended and, 109
 circus movement secondary to, 251
 QRS prolongation in, 137–138
- Ventricular escape, 119–120, 145
- Ventricular fibrillation, 149–151, 150f, 151f
 circulatory arrest in, 281
 in long QT syndromes, 147
 after myocardial infarction, 250–251
 paroxysmal tachycardia leading to, 149
- Ventricular function curves, 110–111, 110f
- Ventricular hypertrophy. *See also* Cardiac hypertrophy; Left ventricular hypertrophy.
 axis deviation in, 135–136, 135f, 136f
 high voltage in, 136f, 137
 QRS prolongation in, 137–138
- Ventricular paroxysmal tachycardia, 148–149, 149f
- Ventricular pressure, cardiac cycle and, 105, 105f, 106
- Ventricular rupture, 251
- Ventricular syncytium, 102
- Ventricular tachycardia, paroxysmal, 148–149, 149f
- Ventricular volume, cardiac cycle and, 105, 105f, 106
- Ventricular volume output curve, 110, 110f
- Ventrobasal complex of thalamus, 574, 574f, 575f
 anterolateral pathway and, 581, 581f
 joint rotation and, 580f
 pain fibers terminating in, 585
 signals to motor cortex from, 670
 thermal signals terminating in, 593
- Venules, 177, 178f
 function of, 157
- Vermis, cerebellar, 681–682, 682f, 684, 686
- Vertebral fracture, acceleratory forces causing, 531, 532–533
- Very low-density lipoproteins (VLDLs), 820f, 821

- Vesicointestinal reflex, 772
 Vesicoureteral reflux, 309, 403–404
 Vesicular channels, in capillary endothelium, 178
 Vesicular follicles, 989
 Vestibular apparatus, 674–676, 675*f*, 676*f*.
See also Equilibrium.
 connections with central nervous system, 678, 678*f*, 694
 head rotation and, 676, 677, 677*f*
 linear acceleration and, 676–677
 motion sickness and, 804
 static equilibrium and, 676, 678
 Vestibular membrane, 634–635
 Vestibular nerve, 676, 678, 678*f*
 Vestibular nuclei, 673*f*, 674, 678, 678*f*
 cerebellar input to, 683, 684
 motor fibers leading to, 670
 vomiting and, 804
 Vestibulocerebellar tracts, 670, 683, 683*f*
 Vestibulocerebellum, 686–687
 Vestibulospinal tracts, 670, 672*f*, 674, 674*f*, 678, 678*f*
 Vibration sense, 571, 572. *See also* Tactile sensations.
 pathways into central nervous system, 573, 579
 Villi, intestinal. *See also* Enterocytes.
 absorption by, of water and electrolytes, 786–787
 central lacteal of, 793*f*, 794
 contractions of, 769
 epithelium of, 786
 gluten enteropathy and, 801
 pits between. *See* Crypts of Lieberkühn.
 structure of, 793–794, 793*f*
 vasculature of, 761, 761*f*
 countercurrent flow in, 761–762
 Villi, placental, 1005, 1006*f*
 glucose diffusion and, 1007
 Virchow-Robin space, 743, 743*f*
 Viruses, 17–18, 18*f*
 neutralization of, by complement, 439
 Viscera
 control of. *See* Autonomic nervous system.
 insensitive to pain, 589
 temperature receptors in, 872
 Visceral pain, 588–590, 589*f*
 Visceral reflexes, 729
 Visceral sensations, 571
 Visceral smooth muscle, 91. *See also* Unitary (visceral) smooth muscle.
 Viscosity. *See* Blood, viscosity of.
 Visual acuity, 604–605, 604*f*
 accommodation and, 631
 in central retina, 619
 Visual association areas, 624–625
 Visual contrast, 618, 626
 Visual cortex, 623, 624–626, 624*f*, 625*f*
 fusion of two images and, 630
 reading and, 704*f*, 705
 Visual fields, 627, 627*f*
 Visual image(s)
 analysis of
 neuronal patterns in, 626–627, 626*f*
 two pathways for, 626
 fusion of, 625, 630–631
 lack of, 630–631, 630*f*
 Visual information, interpretation of, 701, 701*f*
 Visual pathways, 623–624, 623*f*
 Visual purple. *See* Rhodopsin.
 Visual receptive aphasia, 703
 Vital capacity, 469, 469*f*
 Vitamin(s), 852–855. *See also specific vitamins.*
 daily requirements of, 852, 853*t*
 Vitamin(s) (*Continued*)
 deficiencies of
 of B vitamins, vasodilation in, 194
 combined, 854
 in starvation, 852
 in fetus, 1020
 storage in body, 852–853
 thyroid hormones and, 912
 Vitamin A, 853
 in retina, 611, 611*f*, 612
 stored in liver, 840, 852
 Vitamin B₁ (thiamine)
 colon bacteria and, 798
 deficiency of, 853. *See also* Beriberi.
 metabolic function of, 853
 Vitamin B₂ (riboflavin), 854
 Vitamin B₆ (pyridoxine), 854–855
 amino acid synthesis and, 834, 854
 Vitamin B₁₂, 854
 colon bacteria and, 798
 in fetus, 1020
 intrinsic factor and, 778, 800, 854. *See also* Pernicious anemia.
 red blood cell production and, 417, 420
 stored in liver, 840
 Vitamin C, 855
 in fetus, 1020
 neonatal need for, 1025
 osteoporosis secondary to, 969
 Vitamin D, 855, 960–962, 961*f*
 actions of, 962
 calcium absorption and, 796, 855, 962, 964–965
 calcium excretion and, 962
 deficiency of
 hyperparathyroidism secondary to, 968
 rickets in, 968–969
 in fetus, 1020
 for hypoparathyroidism, 967
 neonatal need for, 1025, 1026
 parathyroid hormone and, 961–962, 961*f*
 phosphate absorption and, 962, 964–965
 phosphate excretion and, 962
 in pregnancy, 1010
 receptors for, 962
 renal calcium reabsorption and, 368–369
 renal hydroxylation of, 304, 961
 impaired in renal failure, 406–407
 parathyroid hormone and, 964–965
 stored in liver, 840, 852
 Vitamin D-resistant rickets, 969
 Vitamin E, 855
 in fetus, 1020
 Vitamin K, 855
 clotting factor deficiencies and, 458, 855
 colon bacteria and, 798, 855
 in fetus, 1020
 hepatic requirement for, 840
 impaired absorption of, 458, 802
 in pregnancy, 1010
 prothrombin activation and, 453
 for surgical patients, 458
 warfarin and, 459–460
 Vitreous humor, 606, 606*f*
 VLDLs (very low-density lipoproteins), 820*f*, 821
 Vocal folds, 474–475, 474*f*
 Vocalization, 474–475
 Volley principle, 638
 Voltage clamp, 62–63, 62*f*
 Voltage-gated channels, 47, 48, 49*f*.
See also Calcium ion channels, voltage-gated; Potassium ion channels, voltage-gated; Sodium ion channels, voltage-gated.
 of nerve membrane, 61–63, 61*f*, 62*f*
 Volume reflex, atrial, 208
 Volume-loading hypertension, 218–219, 218*f*, 220*f*
 Volume-pressure curves, of arterial and venous systems, 167–168, 168*f*
 Volume-pressure diagram, of cardiac cycle, 108–109, 108*f*, 109*f*
 Volume-pressure work, cardiac, 108
 Vomiting, 803–804, 803*f*
 aversion to foods causing, 651
 hyponatremia caused by, 294–295
 metabolic acidosis caused by, 393
 metabolic alkalosis caused by, 393, 804
 obstruction as cause of, 804, 804*f*
 Vomiting center, 803, 803*f*, 804
 nausea and, 804
 von Willebrand factor, platelets and, 452
 von Willebrand's disease, 458
W
 W ganglion cells, 619, 630
 Walking movements, 664
 Warfarin, 459–460
 Warmth receptors, 592–593, 592*f*. *See also* Thermoreceptive senses.
 Waste products, renal excretion of, 303, 311–312, 330
 Water
 in cell, 11
 diffusion through capillary pores, 179–180, 180*t*
 diffusion through cell membrane, 46, 47, 51–52, 51*f*, 290
 in feces, 798
 in gastrointestinal secretions, 774–775
 intake of, daily, 285, 286*t*
 intestinal absorption of
 in colon, 797–798
 in small intestine, 794, 795
 intestinal secretion of, 786–787
 loss of, daily, 285–286, 286*t*
 in pancreatic secretions, 781, 782, 783*f*
 reabsorption by kidneys, 324, 328, 328*f*
 angiotensin II and, 338–339, 338*f*
 antidiuretic hormone and, 339, 339*f*, 345, 716
 atrial natriuretic peptide and, 339
 estrogen and, 994
 inulin concentration and, 334, 334*f*
 in loop of Henle, 330–331, 330*f*
 in pregnancy, 1011
 renal excretion of, hypothalamus and, 716
 renal regulation of, 303
 total body
 measurement of, 289
 regulation of, 345
 vapor pressure of, 486, 487
 altitude and, 527
 in alveoli, 527
 Weber-Fechner principle, 579
 Weight, body. *See also* Obesity.
 hypertension and, 225
 thyroid hormones and, 912
 Weight loss
 abnormal, 851–852
 in obese patients, 851
 Weightlessness, 533–534
 Wernicke aphasia, 703, 704
 Wernicke area, 699–700, 699*f*, 701, 701*f*
 aphasia related to, 703, 704
 auditory areas and, 702, 704–705, 704*f*
 hemispheric dominance and, 701, 702, 705
 meaning of sounds and, 641
 visual information and, 701, 702, 704*f*, 705

- White blood cell count, in neonate, 1024
- White blood cells. *See* Leukocytes (white blood cells).
- White muscle, 79
- White pulp, of spleen, 175
- White ramus(i), 729, 730*f*
- Withdrawal reflexes, 662–663
- Word blindness, 701, 703
- Word deafness, 703
- Work, of breathing, 468
- Work output
- of heart, 107–109, 108*f*, 109*f*, 110
 - of skeletal muscle, 78
- Working memory, 703, 706
- X**
- X ganglion cells, 619, 624, 625
- Xenograft, 449
- Y**
- Y ganglion cells, 619, 624, 625, 626, 630
- Z**
- Z disc, of skeletal muscle, 71, 72*f*, 73, 73*f*
- contraction mechanism and, 74, 74*f*, 75, 76
- Zinc, 856
- Zona fasciculata, 921*f*, 922
- Zona glomerulosa, 921–922, 921*f*
- Zona pellucida, fertilization and, 977, 1003
- Zona reticularis, 921*f*, 922